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Heroin has always been the most commonly abused drug in Hong Kong. To be free 
from heroin addiction requires tremendous effort from the addicts and the society, 
and often with little success. Relapse is common among ex-addicts even after 
long-term abstinence. In order to augment the efficacy of heroin treatment, 
predictors of relapse risk are necessary to provide information for clinicians and 
service providers to design better and perhaps a more personal treatment programme 
for these users. 
It has been snown that methadone-maintained patients were hyperalgesic as 
demonstrated in their performance of cold-pressor tests, suggesting that chronic 
opioid administration may induce hyperalgesia that encourages repeated drug use to 
prevent the elevation of pain sensitivity under opioid analgesic tolerance. Therefore, 
individual's hyperalgesic potential may be a predictor for relapse. Gene 
polymorphisms in various neurotransmitter receptors have been shown to be 
associated with heroin dependence, this includes /x-opioid receptor (MOR), 6-opioid 
receptor (DOR), catechol-O-methyltransferase (COMT), dopamine receptor D2 
(DRD2) and D4 (DRD4), and serotonin receptor IB (5HT1B). Some of them also 
play substantial roles in pain control, thus some of these receptor polymorphisms 
together with pain response may be good predictors of relapse risk. 
Other potential relapse predictors include personality traits and stress response. 
Personality traits such as neuroticism, extraversion and sensation seeking have been 
related to substance abuse as well as pain perception and response. Stress hormonal 
response has been shown to change radically after opioid abstinence, hence opioid 
abstainers with poor stress coping strategies may be more likely to relapse when 
encountering life stresses. 
The present study aims at exploring the association between gene polymorphisms 
and cold-pain response with heroin dependence and relapse in Hong Kong Chinese 
males heroin-dependent subjects. In addition, the associations between personality 
traits (neuroticism, extraversion, harm avoidance and sensation seeking) and 
pain-induced salivary Cortisol change with cold-pain response at different relapse 
status are also explored. 
iii 
We have recruited 50 current heroin/methadone users with a relapse history (relapse 
group; fulfilled DSM-IV criteria), 35 ex-heroin addicts who had abstained from 
opioid for at least 1 year (no-relapse group; fulfilled DSM-IV criteria), and 170 
healthy age-matched male as controls. A structured interview was conducted, this 
includes the Addiction Severity Index (ASI) which was used for demographics 
collection and information in drug use history and detoxification experience were 
also collected. Cold-pressor test (CPT) was used to measure the pain threshold and 
tolerance of the subjects. DNA samples from all subjects were obtained for 
genotyping of MOR A118G, DOR T921C, COMT Val'^ ^^^^^Met, ProDYN 
68bp-VNTR, DRD2 TaqlA, DRD4 -521C/T and 5HT1B G861C. Personality traits 
of subjects were studied using the NEO PI-R neuroticism and extraversion facets, 
behavioral inhibition system/behavioral approach system (BIS/BAS) and the 
Zuckerman sensation seeking scale-V (SSS-V). Salivary Cortisol baseline levels and 
changes induced by CPT were also measured. 
From the detoxification and relapse history of heroin-dependent subjects, we 
observed that the chance of maintaining opioid abstinence for at least 1 year was 
significantly higher in subjects who opted for voluntary detoxification (organized by 
hospitals, substance use treatment organizations or by the addicts themselves) than 
those that participated in legally-enforced compulsory detoxification (OR = 3.113; P 
=0.010). Moreover, reasons of relapse depend on the modes of detoxification and 
the period of abstinence. Craving is the most common reason of relapse in 
short-term abstainers in all modes of detoxification, while peer influence and life 
stresses were the most common reasons of relapse in long-term abstainers in the 
compulsory and voluntary detoxification respectively. 
Cold-pain response of 'relapse' subjects were distinct from that of 'no-relapse' and 
control subjects by demonstrating significantly lower tolerance-to-threshold (tol/thr) 
ratio (P < 0.001)，indicating that these subjects were less pain sensitive but at the 
same, time less pain tolerant. The similarity in cold-pain response in relapse and 
“ control groups suggested that such response could be restored as opioid abstinence 
continued. 
In personality assessment, 'relapse' subjects scored significantly higher in 
neuroticism (P < 0.001)，particularly in depression (P < 0.001) and vulnerability (P < 
0.001)，and lower in extraversion (P = 0.077). Relapse group also scored 
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significantly higher in SSS disinhibition (P = 0.025) and boredom susceptibility (P = 
0.041) than the other groups. 
Salivary Cortisol baseline level of the 'relapse' subjects was significantly higher than 
that of the ‘no-relapse’ and control subjects (10 am P < 0.0001; 12 am P = 0.003; 3 
pm P = 0.004; 5 pm P = 0.042). However, the CPT-induced salivary Cortisol change 
was not significantly different amongst the groups. 
Genotype and allele frequencies between controls and heroin-dependent subjects 
('no-relapse' and relapse' subjects) were not significantly different in all gene 
markers studied, apart from DRD4 -521C/T. The difference in T allele frequency 
between controls and heroin-dependent subjects was marginally significant (P = 
0.052). However, the distribution of genotypes in both groups was not in 
Hardy-Weinberg equilibrium. When genotype and allele frequencies between 
no-relapse and relapse groups were compared, there were no significant differences 
observed in all gene polymorphisms studied. 
Further analysis by multiple regression revealed that DRD4 -521C/T and COMT 
Valio8"58Met were predictors for the pain thresholds of control and relapse groups 
respectively. In the control group, C carriers displayed a significantly higher 
threshold than non-C carriers (P = 0.016); while in the relapse group, val carriers 
displayed a significantly lower threshold than non-val carriers (P = 0.033). 
Moreover, the pain tol/thr ratio of relapse group correlated positively with 
neuroticism and SSS total scores but negatively with extraversion. 
To conclude, the present study showed that the cold-pain responses, personality 
traits and basal Cortisol level of the 'relapse' subjects were distinct from the controls 
and 'no-relapse' subjects. Moreover, some of the gene markers studied and 
personality traits were associated with cold-pain response in controls and 'relapse' 
subjects, confirming the roles of genetic and personality factors in pain control and 
• this phenomenon is observed when subjects are grouped under their different relapse 
statuses. In the future, more gene markers and phenotypes related to opioid 
dependence (e.g. craving behaviours) should be examined in order to further explore 





研究方法：兩組海洛英依賴者（附合D S M - I V標準），包括 5 0位正在服用海洛英/美 
沙酮及有重服經驗的男性吸毒者（重吸組）及 3 5位已停止服用鸦片類藥物最少一年 
的前海洛英男性服用者（沒重吸組），在訪問中完成成痛嚴重量表（Addiction Severity 
Index)及提供吸毒和戒毒歷史。此外，1 7 0位年齡相配的健康男性亦被招募作為對 
照組。所有參加者均為中國人。參加者的冷痛反應（感受性（threshold)及忍耐力 
(tolerance))由冷痛測試（cold-pressor test)量度’而性格分析則由三份性格量表（NEO 
PI-R 中的「神經質」（neuroticism)及「外向性」extraversion ； BIS/BAS ； S S S - V )測 
量。所有參加者提供6毫升血液樣本作基因分析，以下是本實驗所研究的基因多態性： 




天早上1 0時、中午1 2時、下午1 2時2 0分（冷痛測試2 0分鐘後）、下午3時及 
下午 5時抽取作皮質醇水平測量。 




組的沒有顯著分別。基因分析結果顯示在所有被研究的基因多態性中’只有 D R D 4 
-521C/T與海洛英依賴有關，可情其基因型分佈並不符合Hardy-Weinberg平衡。多變 
量回歸分析顯示DRD4 -521C/T及COMT 分別與對照組和重吸組的冷痛感 
受性有關。性格特徵「神經質」、「外向性」及「刺激尋求度」亦被揭示與重吸組的冷 
痛忍耐力/感受性比例有關。 
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CHAPTER 1 INTRODUCTION 
1.1. Heroin 
Heroin (O^,0^-diacetylmorphine) is a highly addictive narcotic. First synthesized in 
1874 by Charles Alder Wright, an American chemist, the powerful addictive property 
of heroin was hidden until 1911，when physicians reported that their patients who 
used heroin as antitussive became addicted to the drug (1998). In spite of active law 
enforcement, heroin remains a worldwide concern for the last 130 years. In Hong 
Kong, heroin use became more prevalent since World War II and has steadily 
replaced opium smoking (World Health Organization, 2002). In 2004，70.2% of all 
reported drug abuse cases were attributed to heroin (Central Registry of Drug Abuse 
54th Report, 2005) In China, among the 1.14 million drug use population reported in 
2004，heroin users dominate by 81.1% (Liu et al.，2006). In the United States, an 
estimated 398,000 Americans had used heroin between 2003 and 2004 (Results from 
the 2004 National Survey on Drug Use and Health: Detailed Tables, 2005). 
Heroin appears as a white crystalline powder in its pure form. However, street heroin 
is adulterated and takes the forms of white or brown powder. Street names of heroin 
include "smack", ‘H，，and "junk". In Hong Kong, heroin is called bai fan (“white 
powder") and sei zai ("No. 4"). In Central America, heroin is also supplied in black 
viscous liquid-termed "black tar". 
1.1.1. Manufacture 
Heroin is derived from morphine, which is extracted from the seed capsule of opium 
poppy {Papaver Somniferumi). A cut is made on the seed capsule to exude a white 
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latex that contains morphine and other alkaloids, including codeine, noscapine, 
papaverine and thebaine (Paul et al., 1996). After morphine is extracted, it is boiled 
with acetate anhydride to produce heroin base. This primary product is refined by 
hydrochloric acid to increase water solubility. These chemical procedures are simple 
enough to be carried out in clandestine laboratories by chemical amateur. Before 
selling on streets, heroin is "cut" with adulterants such as starch, lactose, mannitol, 
talc, powdered quinine, and even the poison strychnine (Wijesekera et a l , 
1988). This uncertainty of composition and poor production hygiene threaten the 
lives of heroin users by poisoning and bacterial infection. 
In Hong Kong, purity of street heroin decreased dramatically in 1999 due to active 
seizure by police and customs (International Narcotics Control Strategy Report 1999, 
2000)，and gradually increased in the following years. In 2004，the reported average 
retailed heroin purity is 62% (Central Registry of Drug Abuse 54th Report, 2005). 
1.1.2. Administration 
Heroin can be administered through injection (intravenous, intramuscular or 
subcutaneous) and inhalation (snorting, smoking or "chasing dragon"). In Hong 
Kong, the most common route of heroin administration is injection, followed by 
"chasing the dragon" and then smoking (Hong Kong Narcotics Report, 2005). 
Heroin used for injection is usually with 80-90% purity and is termed "injectible 
heroin" or "No. 4 heroin". Intravenous injection (IV injection) is the most prevalent 
means of administration due to its high efficiency. Before injection, heroin powder is 
dissolved in water and a small amount of citric acid. The onset of euphoria through 
IV injection requires only 7 - 8 seconds (sec) while through intramuscular and 
2 
subcutaneous injections require 5 - 8 minutes (min; National Institute on Drug 
Abuse, 2005). Apart from the infection of blood-bome diseases such as AIDS and 
Hepatitis B and C through sharing of needle, users are also exposed to risks of 
bacterial infection, overdose and blood vessel problems such as endocarditis. 
The other route of heroin intake is inhalation, which includes inhaling heroin vapour 
("chasing the dragon"), snorting heroin powder and smoking "heroin joints". Heroin 
for "chasing dragon" and smoking is termed "No. 3 heroin" with purity of 20-30%. 
"Chasing the dragon" refers to the practice of heating powdered heroin on a tin foil 
with daaifan, which contains barbiturates, and inhaling the fume evaporated orally. 
This method, originated in or near Hong Kong in 1950s, has once been widely 
applied in Hong Kong, Southeast Asia and Europe (Strang et al.’ 1997). Powder 
heroin can be inserted into a "joint" of tobacco or marijuana for smoking. Snorting 
heroin is becoming more popular in the young population as the purity of street 
heroin increases with decreasing price. From 1991 to 1995, percentage of heroin 
users aged between 12 to 17 administered heroin by snorting has increased from 15% 
to 41% in United States (Schwartz, 1998). The time to get a "rush" through 
inhalation is slower than injection but less invasive, which is the major attraction to 
both experienced drug users and teenagers. 
Different route of administration demonstrates different pharmacological properties 
and subjective effect sensation. Peak plasma levels of heroin and its metabolites were 
shown to be a lot higher after IV injection than after intranasal or inhalation with 
faster peak time (Comer et al., 1999; Rook et al., 2006). Rating of "high" was also 
higher in IV injectors than intranasal users. 
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1.1.3. Physical and Psychological Effects 
Heroin exerts both acute and chronic effects. The most pronounced acute 
psychological effect is a sense of comfort, peacefulness and even euphoria. After a 
short period of "high", a phase of increasing anxiety follows. Acute physiological 
effects of heroin include drowsiness ("nodding"), respiratory depression and 
analgesia. For r;ov, 1 users, nausea and vomiting are often experienced as the "vomit 
centre" is stimulated by opioids. Such unpleasantness will soon disappear as 
tolerance is established rapidly at this centre. 
Chronic effect of heroin is tolerance and dependence. Development of tolerance is 
demonstrated when a certain amount of heroin cannot produce the same effects as the 
initial use. This mechanism is established by the body to counteract with the prolong 
presence of a drug, during which a new equilibrium is set and a higher dosage is 
required to break through the effective threshold. Physical dependence is shown by 
the appearance of "withdrawal symptoms" when heroin use is abruptly terminated. 
Examples of opiaU withdrawal symptoms include: lacrimation, rhinorrhea, fever and 
chills, hot flashes, nausea, vomiting, diarrhoea, general body aches and irritability. 
These symptoms peak at 24 - 48 hours (h) and diminish gradually during the week. 
However, certain physiological alterations may still persist for months such as 
suppression of rapid-eye-movement (REM) sleeping pattern (Pinger et al.’ 1998). 
Psychological dependence is also experienced by users during abstinence. Craving, 
an intense desire of drug use, can be triggered by seeing or hearing drug related 
objects (e.g. spoons and syringes) or scenes (Camwath and Smith, 2002). It is a 
powerful inducement to drive heroin abstainers back to habitual heroin use, i.e. 
relapse. 
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1.1.4. Heroin Metabolism 
The high lipid solubility of heroin assists it to penetrate biological membranes with a 
higher efficiency than morphine (Oldendorf et al.， 1972). Through the 
blood-brain-barrier, heroin molecules diffuse rapidly into the brain and undergo 
subsequent enzymatic hydrolyses, forming O^-monoacetylmorphine (6-MAM) and 
morphine (FIG 1). Due to the fast blood clearance and lower binding affinity to 
/x-opioid receptor (MOR), heroin is suggested to be a pro-drug for its metabolites 
rather than being the major effector (Inturrisi et a l , 1983). 
After dissociating from MOR, heroin metabolites diffuse back to the blood 
circulation. The half-life of heroin in blood in vivo is about 3 min but its half-life in 
blood in vitro is 9 - 22 min, implying additional organ metabolism is involved in 
blood clearance (Inturrisi et al., 1984; Sawynok, 1986). There are three enzymes 
responsible for this action: human carbxoylesterase-1 (hCE-1; in liver), human 
carbxoylesterase-2 (hCE-2; in liver) and pseudocholinesterase (in serum), only 
hCE-2 is capable of carrying out the catalysis of 6-MAM to morphine efficiently 
(Kamendulis et al., 1996). Thus, liver is the centre for heroin metabolism. Morphine 
is metabolised primarily into morphine-6-glucuronide and morphine-3-glucuronide 
by uridine diphosphate (UDP)-glucuronosyltransferase, which is present in liver, 
brain and kidneys (Yue et a l , 1988; Wahlstrom et al., 1988; Wahlstrom et al., 1989). 
These glucuronides are excreted in urine. FIG 1 shows the metabolism of heroin. 
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FIG 1. Metabolism of heroin. 
1.1.5. Treatments for Heroin Dependence 
Treating heroin dependence is a lasting combat that requires immense determination. 
There are two different strategies in medication therapy: detoxification and 
maintenance. Detoxification brings a patient from opioid-dependent to opioid-free 
state. During this period, medications are applied to alleviate the withdrawal 
symptoms. Maintenance therapy uses opioid substitutes to replace heroin. In addition, 
other counselling services are combined to maintain heroin abstinence. 
The most prevalent heroin substitute is methadone, a synthetic opioid that has been 
used for heroin dependence treatment since the mid-1960s. Its cross-tolerance to 
other opiates allows it to ameliorate narcotic withdrawal symptoms and reduce 
craving under medical guidance (Dole et al.，1966). Although its metabolites are 
inactive, the level of methadone in plasma can sustain for approximately 24 h 
(Inturrisi - and Verebely, 1972)，i.e. longer acting than heroin. This property is > 
attributed to the rapid binding of methadone (>90%) to plasma proteins (Olsen, 1972) 
and gradual release of free methadone from the proteins in liver (Kreek et al., 1978). 
Methadone is a strong MOR agonist, but it occupies only 67-81% of MOR in brain, 
suggesting that there are unoccupied receptors for normal physiological functions 
6 
(Kling et al.，2000). Despite suppressing withdrawal, methadone lacks the capability 
to produce euphoria and sedation contrast to heroin, and hence it is an ideal heroin 
substitute which enables patients to carry on ordinary activities in a heroin-free 
environment while the physical discomforts are alleviated. It should be noted that 
methadone is also addictive. Withdrawal symptoms of methadone are similar to those 
of heroin, but occur about 24-36 h after intake and will last for a few weeks to 
months. 
In Hong Kong, methadone maintenance programme was offered since 1972. At 
present, there 2“e 20 methadone clinics located in various districts providing both 
maintenance and detoxification services in outpatient mode. More than half of the 
reported heroin users in Hong Kong have already registered for the methadone 
maintenance programme (Hong Kong Narcotics Report, 2005). Patients only have to 
pay HKD$ 1 for each daily dose. If a patient is determined to detoxify, his methadone 
dosage will be reduced gradually under medical guidance. 
Other medications used for heroin-dependent treatment and their properties are 
described in TABLE 1. 
Medication Formulation Active Duration Receptor function 
Methadone Oral solution or tablet Daily MOR agonist 
Levomethadyl acetate (LAAM) Oral solution Every 2 - 3 days Full MOR agonist 
Buprenorphine ^ Sublingual tablet Daily Partial MOR agonist 
» 
. Naloxone and naltrexone Oral tablet � Daily MOR antagonists 
TABLE 1. Principle medications used in treating heroin dependence. 
Besides medication therapy, behavioural therapies also play important roles in opioid 
dependence treatment. Drug counselling assists patients to reflect the problems 
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caused by drug dependence, motivate them to take part in drug dependence treatment 
and retain them in opioid abstinence through support and encouragement. Family 
therapy (e.g. significant other involvement and behavioural family counselling) 
educates and encourages family and friends to support the patient in order to 
reinforce his abstinence behaviours, was also shown to improve treatment retention 
and maintaining opioid abstinence (Carroll et a l , 2001; Fals-Stewart and O'Farrell, 
2003). 
Post-detoxification follow-up programmes are important for ex-heroin users to 
consolidate their drug-free status and to prevent relapse. Such programmes provide a 
discrimination-free space for ex-heroin users to prepare themselves back into society 
by establishing the sense of responsibility, discipline, cooperation, and even gaining 
practical working experiences. In Hong Kong, there are 5 public hospitals and 16 
rehabilitation centres organized by non-profit-making or religious organizations 
offering either outpatient or residential services. 
1.2. Opioids and Analgesia 
Pain alerts us from potential danger and exhorts us to rest an injured body part. It is 
triggered by noxious stimuli (e.g. extreme temperature, pressure, irritants), but may 
also be experienced in the absence of such stimuli. Psychological factors such as 
anxiety, depression, attention and anticipation can also modulate pain intensity 
(Brooks and Tracey，2005). � 
1.2.1. Pain Transmission 
Nociceptors are unspecialized free nerve endings that transduce physiological 
noxious stimuli into action potentials. They are present in most tissues, include skin, 
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bone, muscles, most internal organs and blood vessels. The pain signals are 
transmitted either through small-diameter Ad (myelinated) and C (unmyelinated; 
relatively slower conducting) fibres to the dorsal horn of spinal cord, where their 
terminals synapse with the spinothalamic tract (STT) neurones directly or through 
inhibitory intemeurones. Through the anterolateral spinothalamic tract, the impulse 
continues ascending to the medial lemniscus in the brainstem and then to the 
thalamus where the impulse is in turn relayed to the somatosensory cortex. 
1.2.2. Pain Modulation and Endogenous Opioid System 
Modulation of pain signals can be exerted at the spinal and supraspinal levels, and 
opioid system plays a significant role in this pain modulation. Endogenous opioids 
including /3-endorphin, enkephalins and dynorphin, are primary endogenous ligands 
for fi-, 5-，and /c-opioid receptors respectively. Opioids act via these receptors to 
result in a general inhibition of neuronal activity. In the human spinal cord, 
endorphins, enkephalins, and dynorphin are more concentrated in the dorsal horns 
than the ventral horns, particularly in the substantia geletinosa (lamina II) 
(Przewlocki et al., 1983). fi- and /c-opioid receptors are densely populated in laminae 
I and II，while S-ooioid receptors spread throughout the dorsal horn and even on to 
the ventral horn (Holden et al., 2005). Opioid receptors are also present in the 
brainstem (Maurer et a l , 1983) while the two main brainstem areas for pain 
modulation are the periaqueductal gray (PAG) in pons and the rostral ventral medulla 
(RVM) which include raphe nucleus (Pert and Yaksh, 1975) and other nuclei. 
Morphine-induced analgesia can be abolished by applying an opioid antagonist to 
either the spinal cord (Yaksh and Rudy, 1977) or brainstem (Azami et a l , 1982). 
At the spinal level, pain modulation begins with the arrival of a pain signal from a 
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primary afferent neurone, which in turn activates a STT neurone in the dorsal horn. 
However, the STT neurone is under constant inhibition from an inhibitory 
intemeurone. neii this intemeurone is activated, inhibition is released from the STT 
neurone, allowing pain signal transmission. Opioid peptides are released in the dorsal 
horn upon the arrival of a pain signal and may either inhibit nociceptive transmission 
between primary afferent and STT neurones, or enhance such transmission by 
inhibiting other inhibitory neurones (Holden et a l , 2005). At the supraspinal level, 
PAG and RVM are the most well-defined areas for analgesia. The excitatory 
connection between these two areas is crucial as well (Behbehani and Fields, 1979). 
A descending pathway is sent from these brainstem areas to the dorsal hom spinal 
cord to modulate the ascending pain transmission. The optimal analgesia is a 
synergistic result of the modulations from multiple sites (Heinricher and Morgan, 
1999; Holden et al., 2005). 
The net signal transmission is determined by receptor type, location and neurone 
involved (Satoh et al., 1983; Hope et al., 1990). Most reports suggest that the /x- and 
5-opioid systems are more active in producing analgesia than the K-opioid system in 
the spinal cord (Tung and Yaksh, 1982; Satoh et a l , 1983; Porreca et a l , 1984; 
Hirota et al., 1985). Nevertheless, substrate non-specificity of these receptors implies 
a certain opioid, well known for being the primary agonist of a certain type of opioid 
receptor, may concurrently act through multiple opioid receptors (Smith et al., 1988; 
Qi et al., 1990; He and Lee, 1998). Furthermore, interactions between these opioid 
receptors should also be taken into consideration (Riba et al., 2002; Stevenson et a l , 
2003; Yamada et al.，2006). 
10 
1.2.3. Clinical Application of Opiates in Pain Management 
Opiate analgesics (e.g. morphine) are generally effective for nociceptive pain, which 
comes from somatic and visceral origins, but ineffective for neuropathic pain, which 
originates from nervous system damage. They can be administered orally, 
intravenously, subcutaneously and rectally. Side effects of opiates include sedation, 
respiratory depression, nausea, vomiting, constipation, mood swings and papillary 
constriction. Tolerance of analgesic effects develops rapidly if the pain stimulus is 
constant, a higher dosage of opiates is required to attain the same level of analgesia. 
Routine opiate users will experience withdrawal symptoms such as rhinorrhea, 
abdominal pain and diarrhea, with the recurrence of pain if opiate use discontinues 
abruptly. These symptoms can be prevented by tapering opiate doses (Holden et al., 
2005). 
1.2.4. Narcotics and Pain 
Similar to clinically used opioid analgesics, narcotics act through the opioid receptor 
system to produce an analgesic effect, tolerance to narcotics is developed rapidly. 
One would expect that a methadone patient would be less responsive to pain than a 
control subject due to chronic opioid exposure. At his lowest plasma methadone 
concentration, the methadone patient would exhibit a slightly different pain response 
from a control; while at his highest concentration, the difference would be more 
significant (White, 2004). This model is in accordance with the results from studies 
using mechanical pressure and electrical stimulation for pain induction (Schall et al., 
1996; Doverty et al., 2001b). However, in contrast, cold-pressor pain demonstrates a 
very different pattern. Ho and Dole (1979) found that drug-free ex-addicts were more 
cold-pain sensitive than methadone-maintained patients (White, 2004). Doverty et al 
(2001b) observed that methadone-maintained patients displayed significantly lower 
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cold-pressor pain tolerance than controls at their trough plasma methadone 
concentration, and the restoration of plasma methadone level only elevated the 
parameters to a limited extent, which was still far lower than that of controls. This 
finding is in contrast to the results from the electrical stimulation test carried out in 
the same study. A recent study conducted by Pud et al (2006) reported chronic opioid 
users demonstrated a prolonged latency of pain onset and a longer tolerance of 
cold-pressor pain than controls, and there were no differences in these parameters 
before and after the detoxification of the drug users. In addition to methadone users, 
hyperalgesia was also observed in patients maintained on buprenophine (Compton et 
al., 2001), or receiving morphine for pain treatment (Chu et al., 2006). These 
results imply that chronic opioid administration can produce cold-pressor 
hyperalgesia. 
1.3. Biological Basis of Drug Addiction 
Defined by the Diagnostic and Statistical Manual of Mental Disorders /F(DSM-IV), 
"drug addiction" is the repeated use of a psychoactive substance to the extent of 
periodic or chronic intoxication, finally displaying a compulsive pattern of 
drug-seeking and drug-taking behaviour that continues despite adverse consequences. 
"Substance dependence" refers to the impaired control of substance use due to the 
occurrence of drug-induced symptoms, which can only be avoided or eased by 
repeated doses of the substance, despite adverse consequences. "Withdrawal 
symptoms" that arise after the cessation of drug administration vary with the 
substance used, but emotional unsteadiness and somatic discomfort are generally 
involved. "Tolerance" is the drug-induced adaptations, in particular, in the central 
nervous system, which results in declining effects of a constant drug dose. 
"Sensitization", or reverse tolerance, refers to the drug-induced adaptations which 
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enhances somatic sensitivity to the drug with repeated use (Chao and Nestler, 2004). 
Drug addiction :s raused by complex medical, behavioural and sociological factors. 
From the medical point of view, the biological mechanism of addiction is crucial to 
our survival but when we exploit this mechanism by abusing drugs, our cognitive, 
behavioural and physiological normality will be disturbed. Our central nervous 
system (CNS) controls a cycle of pleasure (a "reward" offered by the body as an 
encouragement for performing certain activity) and pain (a "punishment" given by 
the body as a warning for the lack of certain activity) to remind us of the repetitive 
pursuance of natural survival needs such as food, water and sex. Acute drug use 
instantly affects the CNS by altering neurotransmissions of, for example, dopamine, 
7-aminobutyric acid (GABA) and serotonin (5-HT). However, chronic drug 
administration can cause adaptive changes in the CNS, such as gene expression, 
protein synthesis and internalization of surface receptors. Although these changes 
may be reversible, the time for recovery is much longer than that which the pleasure 
lasts, thus addiction is regarded as a brain disease as the brain structure and function 
have been changed by the substance taken (Leshner, 1997). 
1.3.1. Mesocorticolimbic Reward System 
The mesocorticolimbic reward system was pioneered in the early 50，s when James 
Olds and his postgraduate student Peter Milner were using electrical stimulation to 
examine the learning behaviour of rats. An electrode was inserted in the rat's 
hypothalamus by r/istake and landed quite far away from the intended target. Despite 
this error, the rat seemed to enjoy the electrical stimulation and voluntarily continued 
the experiment. Olds and Milner modified the experiment by applying a lever in the 
cage, which the rat could press to receive electrical stimulation (Kometsky, 1979). 
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Since that time, the exploration of the brain in the search for regions responsible for 
this reward system has entered a new era. Discrete areas of the brain were 
demonstrated to be preferred by the rodents for electrical stimulation, the nucleus 
accumbens in particular, and the lesion of these regions disrupted the 
self-administration of drugs of abuse behaviour of rodents (Olds and Milner, 1954; 
Mogenson et al., 1979; Spyraki et al.，1983; Zito et al., 1985)，cats (Marczynski and 
Hackett, 1976; Patkina and Lapin, 1976) and monkeys (Seeger and Gardner, 1979; 
Rolls et al., 1980) were also used to demonstrate the existence of such a rewarding 
mechanism in the brains of vertebrates. 
All basic behaviours are connected to this reward system, including the search for 
food and water, sexual activity and aggression (Vetulani, 2001). This connection 
ensures the animal would seek for natural rewards which are essential to their 
survival, and the continuity of their species and well-being. Centres responding to 
each reward are different and are responsible for generating different feelings (e.g. 
hunger and thirst) and animals can choose the stimulation site according to their 
relevant needs. Nevertheless, the reward stimulation would be suppressed by other 
systems when the amount of reward gained is enough to attain the goal. For example, 
the satiety centre suppresses the reward system for food when an animal has 
consumed enough food. Neurotransmitters control this reward system. Therefore, 
substances that can alter the level of these neurotransmitters are likely to cause 
disturbances to the reward system and provide the user with pleasure even in the 
absence of natural rewards. 
Despite the complexity of the nervous system, there is a common pathway in the 
brain on which virtually all natural rewards are acting: the mesolimbic reward system. 
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(FIG 2) This system comprises of dopaminergic neurones with their cell bodies in the 
ventral tegmental area (VTA) and their projections in the limbic forebrain, the 
nucleus accumbens (NAc) in particular, as well as amygdala and hippocampus. The 
core of NAc may be related to the control of goal-directed behaviour and acquisition 
of drug seeking behaviour, and the shell of NAc may be involved in the 
psychostimulant effects of drugs of abuse (Przewlocki, 2004). Amygdala is important 
for drug exposure conditioning, i.e. establishing connections between environmental 
cues, rewarding actions of acute drug use and aversive withdrawal symptoms. The 
hippocampus is a crucial element in memorizing drug exposure or withdrawal 
experiences. The hypothalamus implements the physiological effects of drugs. 
Another related system operates in parallel and interacts with the mesolimbic system 
is the mesocortical system, which comprises of the dopaminergic network of 
prefrontal cortex, orbitofrontal cortex and anterior cingulated gyrus. It participates in 
conscious drug experience, drug incentive salience, drug cravings and compulsive 
drug use behaviour (Chao and Nestler, 2004). It was observed that in many drug 
addicts, the neurotransmission in these regions are abnormal which explains why 
they are less capable of controlling their drug administration (Goldstein and Volkow, 
2002; Chao and Nestler, 2004). 
The principal neural effect of drugs of abuse is to stimulate the dopaminergic 
neurones in the VTA, subsequently increasing DA release in the NAc and eventually 
leading to a rewarH response (Mogenson et al., 1979; Di Chiara and Imperato, 1988; 
Piepponen et a l , 1999; Przewlocki, 2004). This effect appears to be common after 
the intake of any drug of abuse, including opiates, cocaine, amphetamine, ethanol, 
nicotine and cannabinoids，though they are acting on different targets initially. 
Cocaine, for example, can form a ligand with dopamine transporters and inhibit DA 
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reuptake, and opiates can inhibit 7-aminobutyric acid (GABA) release in neurones 
that interact with VTA dopaminergic neurones, so that DA release of these neurones 
is disinhibited. Other neurotransmitters, for example, glutamate, 5-HT and opioid 
peptides are also involved in the indirect regulation of DA concentrations in the 
system. FIG 2 demonstrates the neuronal network of the reward system involving 
various neurotransmitters. 
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FIG 2. Mesocorticolimbic reward system in rat brain and sites of action of varies drugs of abuse. The 
mesocorticolimbic DA system is originated from the cell bodies located in VTA and projects to NAc, 
amygdala, hippocampus (not shown here) and prefrontal cortex. Different drugs of abuse affect 
distinct parts of the brain which in turn signal the mesocorticolimbic reward system with various 
neurotransmitters. Adapted from Cami and Farre (2003). 
1.3.2. Molecular Neurobiology of Drug Addiction 
1.3.2.1 .Cyclic Adenosine-3',5'-Monophosphate and Protein Kinase A 
Phosphorylation is required for the transmission of extracellular signals into a cell. 
Phosphorylation cascade begins from the activation of primary membrane receptors 
(by either the presence or absence of a ligand, depending on the receptor properties), 
to secondary messengers, enzymes, and other molecules. Cyclic 
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adenosine-3 ‘ ,5 ‘ -monophosphate (cAMP) is a secondary messenger that is produced 
by adenylate cyclase through phosphorylation and in turn phosphorylates other 
molecules such as cAMP-dependent protein kinase A (PKA), which phosphorylates 
other molecules down the cascade. cAMP and PKA were implicated in the regulation 
of synaptic transmission. In 1975, Sharma et al (1975a) discovered different amounts 
of morphine exposure could affect cellular concentrations of cAMP in neuroblastoma 
X glioma cells in culture differently. Later, the same group reported acute opiate 
exposure inhibited adenylate cyclase and caused initial decrease of intracellular 
cAMP level, whereas chronic opiate exposure led to a compensatory increase in 
adenylate cyclase activity and resulted in a gradual recovery of cAMP level. 
Moreover, in the presence of an opioid antagonist, cAMP concentrations became 
elevated to above normal levels (Sharma et al., 1975b). These observations 
demonstrated the down-regulated cAMP pathway induced by acute opioid exposure 
would be overturned by continued opiate exposure, and thus providing insight into 
the biological mechanism of tolerance development. After the drug is removed, the 
cAMP pathway is free of inhibition and is brought to an even higher level, this 
contributes to the characteristics of dependence and withdrawal (Sharma et a l , 1975b 
Nestler and Aghajanian, 1997). 
This cAMP regulation mechanism was later applied on neurones in locus coeruleus 
(LC), the major noradrenergic nucleus in the brain that mediates the control of 
attention, vigilance, and the sympathetic nervous system (Aston-Jones et al., 1999b). 
Chronic opiate administration inhibits LC activity, and opiate abstinence 
dramatically disinhibits LC resulting in hyperactivity and opiate withdrawal 
symptoms (Aghajanian, 1978; Gold et al., 1979). In vivo studies of rats' LC showed 
that down-regulation and up-regulation of cAMP-dependent protein kinase activity 
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correlates with acute and chronic opiate treatment respectively (Duman et al., 1988; 
Nestler and Tallman, 1988; Guitart and Nestler, 1989). 
1.3.2.2.Transcription Factors: cAMP-Response Element Binding Protein and Delta-Fos B 
Another downstream protein involved in the cAMP pathway called cAMP-response 
element binding protein (CREB) is a transcription factor that is activated upon 
phosphorylatior bv PKA. It is suggested that CREB is involved in the gene 
expression responsible for opiate dependence and withdrawal. The level of activated 
(i.e. phosphorylated) CREB decreases after acute opiate treatment but increases as 
the treatment continued, and continued to increase when treatment is withdrawn 
(Guitart et a l , 1992; Widnell et al., 1994). The participation of CREB in 
opiate-induced intracellular signal transduction is supported by antisense 
oligonucleotides blockage of CREB expression, which prevents morphine-induced 
up-regulation of components along the cAMP pathway such as type VIII adenylate 
cyclase and tyrosine hydroxylase (FIG 3). Elevation induced by spontaneous firing 
of LC neurones was prevented completely in CREB gene knockout models 
(Lane-Ladd et ‘ 997). More evidence for CREB participation in the control of the 
cAMP pathway is the finding that mutation of CREB into its a and 6 isoforms causes 
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FIG 3. Action of opiates in locus coeruleus (LC). Opiates acutely decrease the intrinsic firing of LC 
neurones, which is achieved by series of intramolecular events. Opiates bind to opioid receptors and 
trigger the Gj/�associated, in turn increasing the conductance of an inwardly rectifying K+ channel 
(altering cell excitability) and inhibiting adenylate cyclase (AC) (modulating gene expression). 
Inhibition of AC reduces the intracellular cAMP and subsequently hinders the protein kinase A 
(PKA) cascade, which responsible for the phosphorylation of ion channels/pumps (Na+-dependent 
inward current is decreased possibly), and decreases other phosphorylation cascade that further 
affects numerous neuronal activities. For example, the reduction of phosphorylation state of 
cAMP-response element binding protein (CREB), a transcription factor which can initiate prominent 
alteration in LC by activating certain genes expression, e.g. ACVIII and tyrosine hydroxylase (TH). 
These changes accumulate and alter the phenotype gradually to drug-addicted state. Upon the 
removal of opiates, the disinhibition is released and all previously affected pathways revive, which 
contribute to deperderce and withdrawal effects. Adapted from Neslter (2004). 
Behavioural studies have shown the link between the increase in CREB activity and 
cAMP pathway in NAc to their functions in addiction. Bilateral intra-NAc infusion 
of PKA activator in rats, which ultimately enhances CREB expression, increases the 
‘ cocaine self-administration baseline with reduced cocaine reward and increased 
cocaine-seeking behaviour after cocaine abstinence; in contrast, infusion of PKA 
activator imposes opposite effects (Self et al., 1998; Chao and Nestler, 2004). Rats 
with their CREB expression altered by viral-mediated gene transfer, either 
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overexpressed or suppressed, results in opposite phenotypes. Overexpression of 
CREB in NAc produces a depressant-like effect which is demonstrated by reduced 
cocaine, morphine and sucrose reward and lower mobility in a forced swim test, 
while suppression of CREB results in the opposite phenotype (Pliakas et al., 2001; 
Barrot et al., 2002; Newton et al” 2002). Moreover, in the NAc shell of mice, local 
increase in CREB activity decreases response to emotional stimuli, and vice versa, 
this implicates the potential relationship between this brain region and 
mood/behaviour changes due to addiction (Barrot et al., 2002). These findings 
provide evidence to the 'motivational tolerance and dependence' mechanism, which 
is represented by the up-regulation of cAMP pathway and CREB level in NAc: the 
molecular adaptations reduce the sensitivity of the individual towards the rewarding 
effects follower: b / subsequent drug exposure (tolerance) and attenuate the reward 
system (dependence), leaving the individual in a state of amotivation and depression 
after drug removal (Nestler, 2004). 
In addition to type VIII adenylate cyclase and tyrosine hydroxylase, another target 
gene mediated by CREB is dynorphin, an endogenous opioid peptide whose 
expression in NAc shell spiny neurones is induced by chronic drug exposure 
(Svingos et al., 1999). This induction is mediated by CREB (Carlezon, Jr. et a l , 
1998). As dynorphin forms ligands with the /c-opioid receptor located on the 
dopaminergic neurons in the VTA, DA release is blocked (Funada et al., 1993; 
DePaoli et a l , \9?4; Spanagel and Shoaib, 1994) which results in depression-like 
behaviour similar to that induced by overexpression of CREB (Newton et a l , 2002; 
Mague et al., 2003; Todtenkopfet a l , 2004) (FIG 4). 
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FIG 4. Regulation of dynorphin under the effect of drugs of abuse. This figure shows a 
dopaminergic (DA) neurone in ventral tegmental area (VTA) innervates a GABAergic neurone in 
nucleus accumbens (NAc) that expresses dynorphin (DNY). DYN serves as a negative feedback 
signal from NAc, which binds on kappa opioid receptors on the cell body and nerve terminal of DA 
neurones in VTA and then hinders DA release from these neurones. Chronic drug use (e.g. opiates 
and cocaine) triggers DYN production and secretion through the up-regulation of the cAMP pathway, 
followed by activation of CREB and induction of DYN gene expression, thus the negative feedback 
loop is increased and the drug-induced effects are reduced. Adapted from Nestler (2004). 
Another transcription factor that mediates the chronic action of drugs of abuse in the 
NAc is delta-fosB (AfosB), which is the truncated form of FosB as a result of 
alternative splicing (Nestler et a l , 1999). The heterodimerization of Fos family 
members (c-Fos, FosB, Fos-related antigens (Fras)) with Jun family transcription 
factors (c-Jun, JunB, JunD) forms activator protein-1 (AP-1), which binds to specific 
AP-1 binding sites to commence transcription. While FosB protein induces 
behaviour alteration under cocaine treatment (Hiroi et al., 1997), its spliced form, 
AfosB, also has an important role as a regulator. Despite belonging to the Fos family, 
AfosB per se lacks the domain for transcription activation, thus it does not promote 
AP-1-mediated transcriptions (Hope et al., 1992). Fos family members are induced 
transiently after acute drug exposure, but AfosB accumulates in NAc and the striatum 
region of mice after chronic exposure to drugs of abuse, including morphine, cocaine, 
amphetamine, nicotine and phencyclidine, as well as to natural stimuli (Kelz et al., 
1999; Werme et al., 2002). It possesses extraordinary stability and persists in the 
brain even after the drug is withdrawn. In behavioural studies, expression of AfosB, 
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which mimic chronic drug exposure, increases cocaine reward behaviour and risk of 
relapse after withdrawal (Kelz et a l , 1999; Colby et al., 2003; McClung and Nestler, 
2003). These evidence further support that AfosB can mediate some persistent neural 
and behavioural piasticity that is induced by chronic drug exposure (Nestler et al., 
1999). 
Interestingly, coordination between transcription factors is observed although they 
are targeting different genes. One such coordination was observed by McClung and 
Nestler (2003) through a microarray study in NAc of inducible transgenic mice. 
AfosB and CREB, under acute exposure to cocaine, express genes that cause 
reduction of cocaine reward, but only prolonged AfosB expression can induce 
cocaine reward. The group concluded that gene expression after short cocaine 
exposure depends more on CREB but becomes increasingly more dependent on 
AfosB as the cocaine exposure lengthened. This implies that the gene expression is 
regulated sequentially through the interaction between transcription factors during 
the development of addiction, and the gene clusters account for corresponding stages 
of addiction development should be able to elucidate the intercellular changes caused 
by chronic drug use. 
In recent years, studies of dopamine receptors have provided more information on 
the regulation of gene expression during acute and chronic drug administration. 
Dopamine D1 receptor was found to induce AfosB after chronic cocaine exposure in 
NAc and caudate putamen (Zhang et al., 2002). Zhang et al (2004) observed that 
dopamine D1 and D3 receptors were eliciting opposite effects on extracellular 
signal-regulated kinase (ERK) activation and Fos protein induction after acute and 
chronic cocaine treatment. D1 receptor activates ERK and c-Fos while D3 eliminates 
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them after acute cocaine exposure. ERK is an enzyme that can be activated via 
phosphorylation by PKA, and activates the transcription of various transcription 
factors including CREB and Fos proteins. The group also observed that the 
expression of genes of dynorphin, neogenin and synaptogenin in NAc and caudate 
putamen is increased in D3 mutant mice when compared to wild type mice after 
repeated cocaine administration, which implies that Dl receptor is responsible for the 
activation. These three neuropeptides are involved in neuroadaptation, neurone 
morphology altcrauon and neurotransmitter release control respectively. These data 
suggest that Dl receptor might be one of the activation sites for the development of 
chronic drug-induced behaviours through serial activation of cAMP pathway, ERK, 
gene transcription of transcription factors and neuropeptides. 
1.3.2.3.Neurotrophic Factors 
Neurotrophic factors are responsible for neuronal morphology. They participate in 
the development of the nervous system as well as mediating neuroplasticity of the 
adult nervous system via regulating synaptic transmission, maintaining growth, 
survival and differentiation of neurones (Chao and Nestler, 2004). The characteristics 
of neurotrophic factors make them prime candidates for neuronal morphology during 
addiction development. 
An example of neurotrophic factors that relates to the mesocorticolimbic system is 
brain丄derived neurotrophic factor (BDNF). It can be taken up at nerve terminals and 
transported retrogradely to the cell body, as well as being transported anterogradely 
towards nerve terminal and released to promote rapid intraneuronal signalling. 
BDNF affects the reinforcement and locomotor activity induced by psychostimulants. 
In early studies, infusion of BDNF was shown to oppose the morphological alteration 
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of VTA and LC DA neurones induced by chronic morphine exposure (Sklair-Tavron 
and Nestler, 1995; Sklair-Tavron et a l , 1996; Numan et al., 1998). Later, knockout 
mice studies showed that BDNF is responsible for normal expression of dopamine 
D3 receptor in NAc and striatum, and such expression is important for behavioural 
sensitization (Guillin et al., 2001). D3 receptor can modulate reactivity towards 
cocaine (Le Foil et al., 2002) and its blockade can lead to the attenuation of cocaine 
rewards and cocaine seeking behaviour (Vorel et al., 2002). Involvement of BDNF in 
withdrawal characteristics became more apparent when a BDNF-knockout mice 
study showed a three-fold reduction of withdrawal symptoms induced by chronic 
morphine treatment (Akbarian et a l , 2002). Moreover, BDNF levels increases 
progressively in VTA, NAc, and amygdala after prolonged cocaine withdrawal and 
enhances the responsiveness to cocaine cues (Grimm et al” 2003). A recent study 
demonstrated that BDNF infusion, but not nerve growth factor (NGF), into VTA can 
enhance and contribute to the persistent cocaine-seeking behaviour after withdrawal. 
The study also showed that BDNF imposes its effect through the mitogen-activated 
protein kinase (MAPK) pathway (Lu et a l , 2004). 
Another neurotrophic factor associated with chronic drug abuse is cyclin-dependent 
kinase 5 (CdkS). It is a member of the Ser/Thr cyclin-dependent kinases, and is well 
known for its roles in organizing neuronal cytoarchitecture. CdkS is not activated in 
dividing cells although Cdks are proteins that regulate cell cycle phase transition. 
Regulation of Cdk5 activity is controlled by its activators, p35 (expressed in 
postmitotic neurones only) and p39, transcriptional and post-translational effects. In 
drug addiction, Cdk5 suppresses the neuronal alteration induced by chronic cocaine 
exposure in CNS (Gupta and Tsai, 2001). Inter-related with many drug-induced 
intracellular responses, including the PKA pathway and AfosB, Cdk5 is also involved 
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in drug-induced adaptive responses. DARPP-32, a protein which can be an inhibitor 
of either kinase and phosphatase depending on the site of phosphorylation, is 
converted into a strong PKA inhibitor when it is phosphorylated at Thr-75 by Cdk5 
(Bibb et al., 1999). This in turn down-regulates the dopamine-dependent PKA 
pathway and influences other important reactions down the cascade. DNA 
microarray analysis showed that Cdk5 is up-regulated by the overexpression of 
AfosB in striatum, which mimics the effect of chronic cocaine treatment (Bibb et al., 
2001). Acute and chronic stimulant exposures impose different effects on dendritic 
morphology: acute exposure enhances branching and spine growth, but chronic 
exposure to cocaine and opiates has the opposite effect. Infusion of Cdk5 inhibitor 
into NAc attenuates cocaine-induced dendritic spine outgrowth in NAc core and shell 
(Norrholm et a l , 2003). In opioid-addicted rat brains, it was found that there were 
less Cdk5 and p35 in the prefrontal cortex and p35, but not Cdk5, was significantly 
associated with the hyperphosphorylation of neurofilament in these brains 
(Ferrer-Alcon et al., 2003), which is also a feature observed in the post-mortem 
brains of opioid addicts. 
1.4. Biological Basis of Relapse 
Relapse, the recurrence of drug intake habit, is common in drug users after a period 
of drug abstinence. This poses an obstacle to effective drug abuse treatment. The 
underlying factors that reinitiate drug-seeking and craving behaviours were 
investigated through an animal model of relapse. In this model, animals were first 
trained to press one of the two levers provided to self-administer a drug. This was 
followed by a period of drug withdrawal. Though no drug was provided, the animals 
were still free to seek the drug by pressing the lever. This process is termed 
"extinction training". As soon as this behaviour ceased, the test for drug-seeking 
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behaviour reinitiation began. Three events were observed to be highly effective in 
evoking relapse and drug-related behaviours after abstinence in laboratory animals as 
well as in humans: environmental stimuli relate to previous drug-intake experience, 
exposure to the drug, and acute exposure to stressful circumstances (Stewart, 2000). 
1.4.1. Environmental Stimuli 
Drug-associated environmental cues contribute to drug relapse and craving even after 
long periods of abstinence, and are associated with learning and memory. One of the 
areas responsible for these functions is the amygdala. Rats trained to associate 
discriminative stimulus with intravenous cocaine injection demonstrated strong 
recovery of drug-seeking response and increased Fos protein expression in the 
basolateral amygdala and medial prefrontal cortex when re-exposed to the 
cocaine-related discriminative stimulus after four months of abstinence (Ciccocioppo 
et al., 2001). Lesions of the basolateral amygdala significantly reduce the ability of 
this area to elicit drug-seeking behaviour in the presence of environmental cues, but 
did not alter the response capability or the unconditioned effect of cocaine (Kalivas 
and McFarland, 2003; Hayes and Gardner, 2004). Furthermore, in amygdala of rats, 
the inhibition of calcium/calmodulin protein kinase II (CaMKII), an enzyme that 
participates in learning and memory, could attenuate the development and 
maintenance of morphine conditioned place preference (Lu et al” 2000). 
1.4.2. Drug Re-exposure/Priming 
"Priming" injections of abused drugs or other drugs in the same class are effective in 
reinitiating the drug-taking behaviour, such an effect is dose-dependent (de Wit and 
Stewart, 1981; de Wit and Stewart, 1983). Both heroin and cocaine reinstatements 
are dependent on the mesocorticolimbic dopaminergic pathway. This was proven by 
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the reinstatement of drug self-administration behaviour after intra-VTA injection of 
morphine in both heroin- and cocaine-trained animals as well as enhancing 
dopaminergic neurotransmission (Stewart, 1983; Stewart, 1984; Stewart and Vezina, 
1988). Interestingly, glutamate release in VTA, which is triggered by intra-VTA 
injection of glutamate release enhancer, attenuates such behaviour, implicating that 
the balance between certain neurotransmitters is important for preventing the relapse 
behaviour stimulated by drug exposure (Bossert et al., 2004). 
1.4.3. Acute Stress Exposure 
Acute exposure to stress can initiate drug-seeking behaviour and its effect is 
comparable to heroin priming. Stress-induced emotional states, particularly anxiety, 
are closely related to the risk of relapse. In clinical studies, anxiety, neuroticism and 
nervousness were found to be positively related to the latency of opiate relapse 
(Powell et al., 1993; Liebmann et al., 1998). Other factors including withdrawal 
symptoms, depression, insomnia and uncontrolled pain also contribute to the relapse 
risk of chemical dependence (Jones et al” 2003). Clinical studies showed that 
imagining or describing of craving experiences could provoke acute stressful events 
to the body, which can subsequently trigger stress-induced relapse mechanisms 
(Weinstein et al., 1997; Sinha et al., 2003b). Pulse rate, systolic and diastolic blood 
pressure, plasma Cortisol, adrenocorticotrophic hormone (ACTH) and NA were all 
increased in cocaine-abstinent subjects during the stress imagery, this indicates that 
. the, corticotrophin-releasing factor (CRF)-hypothalamic-pituitary-adrenal (HPA) 
system and noradrenalin (NA) system are taking an active part during this process 
(Schommer et al., 2003). 
Stress imposed by brief footshock is demonstrated to be as effective as heroin 
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exposure in reinstating drug-seeking in heroin-withdrawn animals, and even more 
effective than heroin in heroin-maintained animals (Shaham et al., 1996). 
Food-seeking behaviour, on the other hand, was not reinstated by footshock stress 
(Ahmed and Koob, 1997). Surprisingly, the adrenal hormone corticosterone (the 
corresponding physiological glucocorticoid in humans is Cortisol) is not involved in 
the stress-induced relapse of alcohol, heroin and cocaine in rats, while the 
hypothalamic hormone CRF is, thus implying that such induction is independent of 
the pituitary-adrenal axis (Shaham et a l , 1997; Erb et a l , 1998; Le et a l , 2000). 
Amygdala and the ')ed nucleus of stria terminalis (BNST) are the two brain areas that 
contain CRF receptors, and amygdala sends a dense CRF projection to BNST. 
Initially, it was amygdala which was thought to be the primal site of the CRF action 
due to its involvement in the reward pathway, but later researchers found that the 
effects on these areas by CRF are different. Amygdala seems to be responsible for 
the conditioned responses whereas BNST seems to be mediating the unconditioned 
responses such as the startle response (Lee and Davis, 1997). Erb and Stewart (1999) 
reported that injection of CRF receptor antagonist in BNST, but not in amygdala, 
resulted in complete blockade of footshock-induced reinstatement of cocaine-seeking 
behaviour. The coordination of BNST and amygdala in stress-induced relapse can be 
demonstrated by tl>«2 microinjections of B1 and B2 adrenergic receptor antagonists in 
to BNST or the central amygdala (CeA) (Aston-Jones et al., 1999a). The result 
showed a dose-dependent reduction of stress-induced reinstatement after injection 
into BNST and a complete abolishment of such reinstatement after injection into 
amygdala at any dosage. Combined with the previous results, it can be concluded 
that CeA may impose a modulating effect on BNST activity during stress stimulation 
through the control of NA and CRF transmission (Stewart, 2003). 
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In search of the neurotransmission mechanism of acute stress response induction, NA 
was a likely target because A2 adrenergic receptor antagonists can attenuate 
footshock-induced cocaine and heroin reinstatement (Erb et al., 2000; Shaham et a l , 
2000)，as well as because of the abundance of NA connections in BNST 
(Aston-Jones et al., 1999a). 
NA is the neurotransmitter that has been suggested to be the major mediator of the 
stress activated CRF system. There are two brain regions, LC and the lateral 
tegmental nuclei, which send NA projections towards the forebrain area (Stewart, 
2003). It is known that CRF correlates with the LC-NA system in the modulation of 
stress response by altering the discharge activity of LC neurons. CRF was proposed 
to have an enhancing effect on the information processing through LC concerning 
stressors or stress-related stimuli, resulting in stress responses, for example, arousal. 
However, this sensitization may not be a direct process (Dunn et al., 2004). The 
effect is probably due to persistent elevation of NA release in LC to its targets 
(Valentino et a l , 1993). CRF and endogenous opioids are exerting opposite effects 
on LC neurones, and their balance is important for the regulation of stress adaptation 
(Valentino and Van, 2001). Once an exogenous opioid, for example morphine, enters 
the system abruptly and disrupts this balance, the individual becomes less responsive 
to acute stress stimuli. The outcome is different if the opioid treatment is chronic 
when tolerance is developed. It was observed that chronic morphine treatment 
sensitised LC-NA neurones to CRF and induce NA-mediated hyperactive symptoms, 
such as hyperarousal and attention dysfunction, which trigger drug-seeking 
behaviour and thus augments the vulnerability of relapse (Xu et a l , 2004). In 
addition to LC, the CRF system also acts on amygdala, paraventricular nucleus (PVN) 
and other brain areas. An immunochemical study observed that CREB is prevalent in 
29 
CRF neurones in the central nucleus of amygdala and BNST under stress and these 
neurones were projecting towards LC (Curtis et a l , 2002). Nevertheless, injections of 
A2 adrenergic receptor antagonist, clonidine and its analogue, ST-91, into ventricles 
but not into LC produced apparent footshock stress-induced reinstatement, thus LC 
may not play a major role in the acute stress-induced reinstatement. 
1.5. Gene Polymorphisms and Opioid Dependence 
Family and twin studies showed drug dependence to be caused by genetics and 
enviroment faciort,. In a family study conducted by Merikanges et al (1998), the 
first-degree relatives of drug-use probands were shown to have an 8-fold increased 
risk of substance use disorders. The rate of hard drug use in the relatives of probands 
with opioid dependence was the highest followed by cocaine, cannabis and alcohol, 
suggesting there is specificity in familial aggregation of the predominant drug of 
abuse. Tsuang et al (1998) reported in a male twin study that heroin had the largest 
genetic influence and least family/non-family environmental influence when 
compared to other drugs including marijuana, stimulants and sedatives. In an 
adoption study carried out by Goodwin et al (1974)，they showed that the sons of 
alcoholics were 4 times more likely to become alcoholics than those with 
non-alcoholic paunts, and such likelihood was the same for adoptees and 
non-adoptees, implying that genetics is a major controtibutor to alcohol and drug 
dependence. » 
Linkage and association studies suggest a plethora of gene polymorphisms like single 
nucleotide polymorphisms (SNPs) and variable number of tandem repeats (VNTRs) 
may contribute to the liability to substance dependence. 
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1.5.1. Opioidergic System 
The main participants of the opioidergic system are opioid receptors and their ligands, 
endogenous and exogenous opioids. Opioid receptors are seven transmembrane 
(7TM) G protein-coupled receptors. Through coupling with the Gi-family 
heterotrimeric G proteins, they stimulate inwardly rectifying K+ channels, inhibit 
voltage-sensitive Ca^^ channels and alter gene expression, resulting in depression of 
neuronal excitability and neurotransmission. Opioid receptors are therefore capable 
of modulating pain perception and moods. 
Ligands for opioid receptors include endogenous opioid peptides (e.g. endorphin, 
enkephalin and dynorphin) and exogenous opioids (e.g. morphine). There are at least 
four types of pharmacologically distinct types of opioid receptors: fi (for morphine), 
K (for ketocyclazocine), d (for vas deferens), and nociceptin, which are encoded by 
separate genes. More subtypes are expected, they are due to posttranslational 
modifications, alternative mRNA splicing, tissue distribution and 
homo/heterodimerization (Waldhoer et al., 2004). Similar opioid receptors were 
found in other species such as mouse, rat, guinea pig, zebra fish and rhesus monkey. 
The typical features shared among all opioid receptors include: seven transmembrane 
helices connected by three extracellular and three intracellular domains, a 
glycosylated extracellular N-terminal and an intracellular C-terminal. In addition, 
therd are two conserved cysteine residues in the first and second extracellular loops 
which are suspected sites for disulphide bonds. Overall, the amino acid sequences of 
opioid receptors share about 60% homology, particularly the sequence for 
transmembrane helices, and the greatest diversity lies in the two terminals and the 
extracellular loops (Satoh and Minami, 1995). 
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Being the major receptor of morphine, heroin, methadone, fentanyl, as well as the 
endogenous jS-endorphin, /i-opioid receptor (MOR) is the most extensively studied 
opioid receptor. Genetic variations in the MOR gene are candidates for pain and 
addiction studies due to its role in analgesia and the development of substance 
dependence. Bond et al (1998) studied five SNPs in the MOR gene including A118G, 
which commands a substitution at amino acid residue 40 from asparagine to aspartate 
and which may lead to the loss of a putative N-glycosylation site. A118G allele 
frequency was found to be significantly different among the ethnic groups studied 
(African-American, Caucasians, Hispanic), and was more prevalent in non-opioid 
dependent individuals than opioid dependent subjects, thus the group suggested this 
SNP may possess a protective effect against opioid dependence. Although this SNP 
did not demonstrate a significant effect on binding affinities with most opioid 
peptides and alkaloids investigated, the allelomorph encoded by the G allele binds 
with approximately 3-fold greater affinity, as compared to the allelomorph encoded 
by the more common A allele. Moreover, the binding of j8-endorphin to the 118G 
variant receptor exhibited a 3-fold increase in potency of agonist-induced activation 
of G protein-mediated inwardly rectifying K+ channels (Bond et al., 1998). A recent 
study by Zhang et al (2005) observed that the level of 118A allele mRNA was 
1.5-2.5 fold more abundant than that of 118G allele in the brains of eight 
heterozygous individuals. The group further demonstrated through transfection 
experiments that 118G could cause a 1.5-fold decrease in MOR mRNA level and a 
10-fold decrease in MOR protein level when compared to the displacement of 
adenosine, thymidine or cytidine at the same nucleotide position. These findings 
imply that the 118G allele may reduce MOR receptor density in the brain, resulting 
in a change in the MOR system that influences one's sensitivity to both endogenous 
and exogenous opioids. 
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Due to its significant effects on MOR functions, A118G has intrigued researchers to 
investigate its association with addiction. Significant association between A118G 
allelic frequency and heroin dependence was found in Chinese (Szeto et al., 2001)， 
Indian (Tan et al., 2003) and Hispanic (Bond et al., 1998) populations. In spite of 
these reports, the association between A118G and substance dependence is 
challenged by substantial negative associations (Bond et al” 1998; Gelemter et al., 
1999; Franke et al., 2001; Shi et al., 2002). Variations between these reports may be 
caused by the difference in population ethnicity and country of origin. The reported 
control allelic frequencies of 118G allele range from 0.016-0.047 for 
African-Americans (Bond et al., 1998; Gelemter et al., 1999)，to 0.109-0.121 for 
Caucasians (Bond et a l , 1998; Franke et al., 2001; Bart et a l , 2004)，0.311 for 
Koreans (Kim et al., 2004b), 0.395 for Chinese (Szeto et al., 2001), 0.474 for Indians 
(Tan et a l , 2003) and 0.453-0.485 for Japanese (Gelemter et al., 1999; Ide et a l , 
2004). Research thus suggests that Asian populations carry a much higher 118G 
allelic frequency than European or African populations. Thus sometimes data from 
other populations are difficult to be interpreted as too few 118G carriers and 118G 
homozygous individuals exist in the sample. Compton et al (2003b) clearly 
demonstrated such difficulties in an association study between MOR gene 
polymorphism, pain tolerance and opioid addiction: among all the 64 subjects 
(consisting of Caucasians and African-Americans only), none carry 118G allele and 
only three individuals cany another MOR SNP, C17T. This finding has highlighted 
. the 'fact that the effect of a single SNP may not be applicable for every ethnic 
population in unveiling the mystery of addiction. 
Another SNP of interest in the MOR gene is CI031G located in intron 2, whose G 
variant allele frequency has been shown to be higher in Chinese heroin dependent 
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subjects (Szeto et al., 2001). A later study confirmed that this SNP is in complete 
linkage disequilibrium with A118G although no significant association with heroin 
dependence was observed within the limited sample size which combined four Asian 
ethnics. (Tan et al., 2003) 
The phenotypic effects of MOR gene polymorphisms may include nociception. Gene 
knockout animal studies provide evidence that baseline nociception is dependent on 
the presence of the MOR gene (Uhl et al., 1999). Sora et al (1997b) showed that 
nociceptive thresholds change in a gene dependent manner in mice: mice with no 
MOR have a lower pain threshold than heterozygous knockout mice, which have a 
lower pain threshold when compared to wild-type mice with intact MOR. In a human 
pilot study, Compton et al (2003b) attempted to correlate MOR gene polymorphism 
with pain tolerance and opioid addiction but failed due to the relatively small, 
ethnically-mixed sample size. A recent study conducted by Fillingim et al (2005) 
reported 118G variant allele might be associated with pressure pain threshold and 
heat pain perception in a sex-dependent manner. 
Apart from MOR, 5-opioid receptor (DOR) also demonstrates strong analgesic 
activity upon stimulation. Its primary opioid ligand is endogenous enkephalin, and 
exogenous substrates such as morphine and methadone. In the human brain, DOR 
was found in the claustmm, striatum, caudate, putamen, temporal cortex and 
amygdala. (Blackburn et a l , 1988) DOR mRNA was detected in olfactory bulb, 
hippocampus, amygdala, hypothalamus and basal ganglia (Simonin et a l , 1994). 
These properties reveal DOR's potential involvement in the reward pathway and 
addiction. 
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Mayer et al (1997) identified a silent SNP, T921C, in the DOR coding region. The 
group reported a significantly higher frequency of the C allele in heroin addicts than 
in controls within the sampled German population. The allele distribution of T921C 
was found to be significantly heterogeneous among various ethnic populations, 
including European Americans, African Americans, Ashkenazi Jews and Japanese 
(Gelemter and Tlrsnzler, 2000). However, another German population study did not 
show a significant difference between heroin- and alcohol-dependent subjects in both 
case-control and family-based approaches (Franke et al., 1999). A Southwest Chinese 
heroin case-control study also found no difference in genotypic and allelic 
frequencies (Xu et al., 2002). 
The most studied polymorphism in K opioid system that associated with opioid 
dependence is prodynorphin, which is the precursor of several peptides, including 
dynorphin A, dynorphin B and neoendorphin. Expression of prodynorphin can be 
triggered by the binding of DA on dopamine receptor Dl , hence dynorphin 
concentrations iaci-jase. Dynorphin is the agonist of KOR, which down-regulates DA 
neurotransmission upon stimulation. Thus, the dynorphin system acts on 
dopaminergic transmission as a negative-feedback mechanism. Prodynorphin is 
associated with drug abuse, mood disorders and epilepsy. 
Zimprich et al (2000) discovered a 68bp polymorphic sequence in the promoter 
regioh of the prodynorphin gene. It either appears in a singular form, or two, three or 
four tandem repeats (termed allele 1 to 4 respectively). This 68 bp sequence is a 
putative AP-1 transcription factor recognition site and a significant increase (-50%) 
of gene expression was observed under the activation of AP-1 expression allele 3 and 
4 when compaareJ with allele 1 and 2. However, the group did not find any 
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significant allelic or genotype distribution difference between heroin abusers and 
controls in a German population. The result in European Americans of a recent study 
by Ray et al (2005) was in accordance with the previous study in Germans, however, 
the group observed a weak association between this polymorphism and opioid 
dependence in African American population. These results imply this association 
may be ethnic-dependent. 
1.5.2. Dopaminergic System 
Dopamine receptor D2 (DRD2) is a 7TM G protein-coupled receptor located on 
Dopaminergic neurones. It imposes an inhibitory effect on adenyl cyclase, which 
hinders intracellular cAMP production and cAMP-dependent pathways. Two 
isoforms result by alternative splicing, D2L and D2S, which differ in their 
polypeptide lengths, locations and functions. The "longer" D2L contains an 
additional 29-amino-acid sequence in the third intracellular loop and mainly acts as a 
postsynaptic receptor, while the "shorter" D2S mainly acts as autoreceptor on 
presynaptic membranes (Picetti et al., 1997; Usiello et a l , 2000). Due to its role in 
Dopaminergic signalling, the DRD2 gene is extensively investigated in its 
association to addiction, pathological gambling, Parkinsonian moving disorders and 
tardaive dyskinesia. 
One of the most studied DRD2 gene polymorphisms is Taql A (polymorphic alleles 
are'termed Al and A2). It is a substitution of glutamate to lysine at amino acid 
residue 713 in another protein kinase gene (ankyrin repeat and kinase domain 
containing 1, ANKKl) located 9.5 kb downstream from the DRD2 gene (Neville et 
al., 2004; Dubertret et al., 2004). Although the function of this SNP and its role in 
DRD2 and/or ANKKl functionality remains unknown, there have been studies 
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showing that healthy A1+ individuals had a lower DRD2 density in various brain 
areas, implying it may cause a reduction in DRD2 expression (Thompson et al., 1997; 
Pohjalainen et al., 1998; Jonsson et a l , 1999). One of the potential effects of low 
DRD2 density in the brain is pain modulation. In a later psychophysical study 
conducted by H'\gelber et al (2002), healthy Finnish individuals with fewer available 
DRD2 receptors detected by positron emission tomography (PET) in their forebrain 
were likely to have higher cold pain threshold and tolerance, suggesting a higher 
tonic level of pain suppression in these individuals. 
Association studies between substance users and controls suggest that Taql A may 
associate with susceptibility to addiction. For opioid dependence, a study by Lawford 
et al (2000) followed a group of Caucasian opioid-dependent patients in an 
outpatient methadone treatment facility. The frequency of Al allele was found to be 
highest in patients with poor treatment outcome, followed by those who dropped out 
from the programme，and lowest in those with successful treatment outcome. Al 
allele frequency was significantly higher in opioid-dependent subjects when 
compared to controls that had no first-degree relatives who were current or past 
drug/alcohol abusers. Moreover, the average heroin consumption was two times 
more in A1+ patients than Al- patients. In an Iranian population, A1+ frequency was 
found to be higher in opioid-dependent subjects when compared with controls, and 
homozygous Al subjects had the highest mean daily opium use, followed by 
heterozygous subjects and was least in homozygous A2 subjects (Shahmoradgoli et 
al., 2005). These results suggest Al allele of Taql A may be a possible opioid 
dependence predisposing factor, as well as a predictor for treatment outcome. 
However, Xu 1 r.l (2004) reported an insignificant association between heroin 
dependence in Southwestern Chinese and Taql A, but rather with another DRD2 SNP, 
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Taql B. This SNP locates in exon 2 in DRD2 gene and is in strong linkage 
disequilibrium with Taql A (Hauge et al., 1991; Kidd et al., 1998). 
Dopamine receptor D3 (DRD3) gene is a candidate for opioid dependence as its 
expression is induced with behavioural sensitization through repeated administration 
of an indirect dopamine agonist, a process also observed during repeated 
administration of opiates and psychostimulants (Bordet et al., 1997; Duaux et al., 
1998). Homozygous opioid-dependent subjects of a DRD3 polymorphism, Bal I， 
were found to have higher Zuckerman's sensation seeking scores than controls and 
heterozygous subjects, but no significant difference was observed in 
homozygous-heterozygous distribution between subjects and controls (Duaux et al., 
1998). 
The dopamine receptor D4 (DRD4) gene has high homology to the DRD2 gene, and 
the pharmacological properties of DRD4 also resemble that of DRD2 but with higher 
affinity to clozapine, an antipsychotic (Van Tol et al” 1991). 
Van Tol et al (1992) reported a 48 bp sequence in the putative third cytoplasmic loop 
of human DRD4 existing in 2-fold (D4.2), 4-fold (D4.4) and 7-fold (D4.7) repeats. 
The longer form (D4.7) showed different ligand binding properties when compared 
to the shorter forms (D4.2 and D4.4), suggesting this polymorphism may determine 
. individual differences in susceptibility to psychiatric disease and in responsiveness to 
antipsychotic medication. Subsequent studies mainly focused on the association 
between DRD4 and personality. Long alleles were related to higher novelty seeking 
in Israelis, Americans, Japanese and Germans (Ebstein et a l , 1996; Benjamin et al., 
1996; Ono et al., 1997; Tomitaka et a l , 1999; Strobel et al., 1999). Kotler et al (1997) 
38 
observed an over-representation of the 7-repeat allele in a group of Israeli heroin 
addicts. Li et al (1997) found a significantly higher frequency of long alleles (5-7 
repeats) in a Han Chinese heroin-dependent population. These studies suggest a 
correlation between long alleles and heroin dependence. However, the group could 
not repeat this finding in a later study (Li et al, 2000). Franke et al (2000) also failed 
to observe a significant difference in long allele frequency between heroin dependent 
subjects and control. In the family-based associated study reported in the same 
journal, no preferential transmission of long allele to affected offspring was 
observed. 
A C—T nucleotide substitution was discovered by Mitsuyasu et al (1999) in the 
promoter region of the DRD4 gene in Japanese individuals, termed -521C/T. The T 
variant was found to reduce transcription efficiency when compared with the C 
wild-type (Okuyama et al” 2000). -52IT allele was reported to be associated with 
lower novelty seeking in Japanese males (Okuyama et a l , 2000) and Hungarian 
females (Ronai et al., 2001), extraversion in African American females (Bookman et 
al., 2002) and reduced social activity in Russians (Golimbet et al., 2005). These 
personality traits are closely related to illegal drug use. Significantly more -52IC 
homozygotes were observed in a certain Caucasian heroin-dependent population, and 
this relationship is enhanced by the presence of short hydroxytriptamine transporter 
linked polymorphism region (Szilagyi et al., 2005). 
In addition to DA receptors, enzymes that regulate the production and degradation of 
DA are essential to the functioning of reward pathway. One of these enzymes is 
catechol-O-methyltransferase (COMT). It metabolises catecholamines (i.e. dopamine, 
adrenaline, noradrenaline) by 0-methylation (Li et al., 1984; Cumming et al., 1992), 
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thus it is playing an important role in the modulation of dopaminergic and adrenergic 
neurotransmissions as well as in the degradation of catechol drugs. This property 
makes it a candidate genetic determinant for a variety of psychiatric illnesses, 
including Parkinson's disease, schizophrenia, bipolar disorder, attention deficit 
hyperactivity disorder and substance dependence. 
In the human COMT gene, a functional SNP was identified by Lachman et al (1996). 
It results in a substitution of valine {val) by methionine (met) at amino acid residue 
158 in its membrane-bound isoform or residue 108 in its soluble isoform. Individuals 
that were homozygous for met allele was found to have 3-to-4 fold decrease in their 
COMT activity when compared to val homozygous individuals. Moreover, low 
COMT activity is related to higher thermostability (Spielman and Weinshilboum, 
1981). 
Population genetic studies suggest this SNP may be associated with substance 
dependence. For opioid dependence, an Israeli study demonstrated an excess val 
allele and a trend of val/val genotype in heroin addicts compared to controls using a 
family-based haplotype relative risk strategy (Horowitz et al., 2000). Though the 
same report did noi observe an excess val allele in the case-control study, the group 
explained this result by population stratification as there was significant difference in 
COMT allele frequency among the three major ethnic subject groups. > 
Low COMT activity activates the dopaminergic system due to low DA metabolism. 
It was demonstrated in animal studies that, when low COMT activity persisted (in 
those with the phenotype of met/met), brain enkephalin concentrations decreased, 
subsequently triggering a compensatory increase of MOR concentration in certain 
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brain regions, the opposite was seen for high COMT activity (the phenotype of 
val/val genotype) (George and Kertesz, 1987; Chen et al” 1993; Unterwald et al., 
1994).. Zubieta et al (2003) studied the effects of COMT Val'^ ^^^^^Met genotype on 
the human brain /x-opioid system response after pain induction (saline injection at 
masseter muscle) by positron emission tomography (PET) and [^'C]carfentanil (a 
MOR selective radioactive tracer). The group observed that the /x-opioid system 
response was elevated for val/val, mildly increased for ml/met and diminished for 
met/met. A similar trend was observed in pain sensitivity, but pain-related sensory 
and affective ratings displayed a reverse trend. A recent study conducted by Berthele 
et al (2005) further validated the influence of COMT Val^ ^^^^^^Met polymorphism on 
MOR system in human brain by [^H]DAMGO receptor autoradiography, met carriers 
had a significantly higher number of MOR binding sites than homozygous val 
individuals in caudate nucleus, NAc and mediodorsal thalamus. This study also 
demonstrated that the met allele was associated with a higher preproenkephalin 
mRNA expression. 
1.5.3. Serotoninergic System 
5-HT is a crucial neurotransmitter that mediates a wide variety of physiologic 
functions including feeding, sleeping, thermoregulation and locomotion, and may be 
related to neuropsychological disorders such as depression and anxiety. In a post 
mortem human brain study, despite the level of serotonin in heroin users were 
relaitively normal, the concentrations of serotonin metabolite decreased, suggesting 
that serotoninergic activity was moderately down-regulated under chronic opioid 
exposure which could influence impulsive control (Kish et al.，2001). 
A functional polymorphism was identified in the promoter region of human serotonin 
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transporter gene (5-HTTLPR), whose short variant was found to be associated with 
lower expression level of serotonin transporter (5-HTT) (Collier et al., 1996). It has 
been shown that reduced serotonin uptake is related to affective illnesses, including 
depression, suicidal and violent behaviours. A higher short-short genotype frequency 
was observed in heroin-dependent than controls, particularly in those with violent 
behaviours (Gerra et al., 2004). A recent study reported the odds ratio for DRD4 
-52IC homozygotes to be heroin-dependent was doubled if the individual owned 
short-short 5-HTTLPR genotype (Szilagyi et al., 2005), indicating an interaction 
between dopaminergic and serotoninergic systems in terms of genetic 
polymorphisms. 
Serotonin receptors (HTRs) are targets for genetic study in heroin dependence as 
well. A serotonin receptor IB (5HT1B) SNP was identified by Lappalainen et al 
(1995) at G—C substitution at nucleotide 861 in the coding region. It was first 
reported by Lappalainen et al (1998) that a significant excess of 861C allele was 
present in antisocial alcoholics when compared to controls in a Finnish population. 
However, this result was challenged by later contrasting reports. (Hasegawa et al., 
2002; Sinha e. d ” 2003a; Soyka et a l , 2004). It is a potential functional 
polymorphism as the GG homozygotes were found to have 20% less 5HT1B 
receptors in the brain than the GC heterozygotes (Huang et al., 1999). In a 
four-ethnic association study, five 5HT1B SNPs were investigated including G861C, 
. only the variant allele of another SNP, A1180G, was associated with a protective 
effect from heroin dependence in Caucasians (Proudnikov et al., 2006). The Asian 
population was excluded in the ethnic-independent association study as there was 
only one heroin-dependent subject among 51 Asian subjects, therefore the 
association between opioid dependence and these SNPs in Asians is still uncertain. 
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1.5.4. Noradrenergic System 
NA is a major neurotransmitter in CNS and in postganglionic sympathetic nervous 
system. Apart from its role in regulating vital functions such as cardiac contractibility, 
it is also a precursor of adrenaline, a hormone released from adrenal medulla. In CNS, 
NA is highly concentrated in LC, the major adrenergic nucleus that mediates the 
control of attention, vigilance and the sympathetic nervous (Aston-Jones et al., 
1999b). The activity of LC had been shown to be inhibited by chronic opioid use and 
disinhibited abruptly during opioid abstinence (Aghajanian, 1978; Gold et a l , 1979). 
NA is produced through the hydrolysis of DA, a process catalyzed by 
dopamine-jS-hydroxylase (DBH). Low plasma concentration of DBH has been 
associated with psychosis and psychotic depression (Cubells and Zabetian, 2004). 
Lower DBH activity was observed in alcoholics than in controls (Kohnke et al., 
2002), which was suggested to be a result of NA neurone intoxiflcation under 
chronic ethanol exposure (Cubells and Zabetian, 2004). Therefore, gene 
polymorphisms that affect DBH expression or activity may predispose these 
diseases. 
The most potentially functional SNPs in DBH gene are -1021C/T and R535C, whose 
variant alleles were suggested to be associated with lower plasma DBH activity 
(Zabetian et a l , 2001; Cubells and Zabetian, 2004). Other ftinction candidates 
include A444G -4784-4803del，an upstream short tandem repeat polymorphism and 
C1603T. At present, there is no published study reported on the association between 
DBH gene polymorphisms and opioid dependence, nevertheless, considering the 
regulatory function of DBH on DA system, exploration on this association should be 
deserved. 
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1.5.5. GABAergic System 
GABA is a major inhibitory neurotransmitter. In mesocorticolimbic system, GABA 
acts as a regulator of DA signalling through inhibitory intemeurones. It has been 
proposed that the inhibition of VTA GABA intemeurones disinhibited VTA 
Dopaminergic neurons and enhanced DA release in the NAc (Kelley et al., 1980). 
Opiates interact with the GABAergic system through the inhibition of GABA cells 
(Renno et a l , 1992), thus in turn may activate the mesocorticolimbic system. MOR 
was found to be located predominantly on non-Dopaminergic intemeurones in VTA 
(Mansour et al,, 1987; Dilts and Kalivas, 1989)，which provided evidence for the 
interaction between opioidergic and GABAergic systems. 
GABAergic receptors are multi-subunit CI" channels which are formed by five 
membrane-spanning glycoproteins. GABA receptor subunits have many genetic 
variants, including a (6 types), jS (4 types), 7 (4 types), d (1 type)，and p (2 types), 
thus allowing a wide range of subunit combination. The two major GABAergic 
receptor subtypes, G A B A A and G A B A B , have different role and distribution in 
mesocorticolimoic system. G A B A B receptor agonist baclofen was found to 
significantly reduce heroin-reinforced self-administration behaviour as well as DA 
release in NAc (Xi and Stein, 1999), which were not observed when G A B A A 
receptor agonist muscimol was applied (Xi and Stein, 1998). Together with previous 
autoradiographic and animal studies, Xi and Stein (1999) concluded that G A B A A 
receptors located on both GABAergic intemeurones and Dopaminergic neurons in 
VTA, producing disinhibitory and inhibitory effects on mesolimbic DA release 
respectively upon activation, whereas G A B A B receptors located primarily on 
Dopaminergic VTA cells and inhibited mesolimbic DA release directly. A later study 
demonstrated G A B A B agonism by baclofen decreased cue-controlled response of 
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heroin (Di Ciano and Everitt, 2003), further displaying the role played by GABA 
system in heroin drug-seeking behaviours. 
Polymorphisms in GABA receptor subtype genes were associated mainly with 
alcoholism and smoking. For heroin dependence, Li et al (2002) reported no 
significant difference in GABAa72 G3145A polymorphism genotype or allele 
frequency was observed between heroin abuse and control subjects. Despite this 
negative result, genetic polymorphisms in GABA receptors are worth further 
investigation due to its role in heroin-seeking behaviour. 
1.6. Aim of Research 
Despite the resources spent on substance abuse treatment, the relapse rate of 
ex-heroin addicts remains high. Research into the physiological aspects of relapse 
may provide more information for clinicians and drug treatment providers to design 
more appropriate services for their clients. Since previous pain studies in 
methadone-maintained patients suggest that chronic opioid administration can induce 
hyperalgesia to cold-pressor pain, continued drug use may be encouraged to suppress 
the elevated pain sensitivity under opioid analgesic tolerance, thus hyperalgesia may 
be a relapse-inducing factor and individual hyperalgesic potential may be a 
predisposing factor to heroin dependence. 
Other factors related to pain control include personality and stress response. Clinical 
studies in chronic pain and major depression patients reported personality traits like 
neuroticism, extraversion, harm avoidance and sensation seeking are related to pain 
perception and response. These personality traits are found to be associated with 
substance use as well. Therefore, personality may influence the pain response in 
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heroin addicts and in turn determine their relapse risk. 
The role of stress response in self-administration of drug of abuse is crucial. The 
suppressed HPA axis by chronic opioid consumption has been shown to be 
up-regulated dramatically after acute opioid abstinence, in turn urging the users to 
relapse through physiological and psychological means. Facing this radical hormonal 
change, opioid abstainers with poor stress coping strategy will easily return to drugs 
again when facing life stresses including pain-induced stress. 
Genetic factors may play a substantial role in hyperalgesia, which may in turn affect 
the probability of heroin dependence and/or relapse. For example, A118G 
polymorphism affects the substrate affinity and gene expression of MOR. T921C 
polymorphism has been associated with heroin dependence probably through linkage 
disequilibrium with function polymorphisms that affect DOR facilitated opioid 
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analgesia. Val Met polymorphism alters the activity of COMT and has been 
related to pain tolerance in normal individuals through lower activation of MOR 
system. Prodynorphin 68bp-VNTR elevates the activation of gene expression, thus 
potentially affects dynorphin level in opioid analgesic system. Taql A polymorphism 
was found to be associated with cold-pain response probably through influencing the 
DRD2 density in brain. -521C/T polymorphism reduces DRD4 gene transcription 
and is associated with drug-use related personality traits. G861C polymorphism 
reduces 5HT1B density in brain and has been associated with depression and 
substance abuse. 
The present research aims at exploring the association between candidate gene 
polymorphisms and cold pain response with heroin dependence and relapse in a 
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Hong Kong Chinese population. We hypothesize that (i) heroin-dependent subjects 
will carry significant differences in allelic frequencies and genotypes and have 
different levels of pain sensitivity/tolerance to those who are not dependent; and (ii) 
heroin-dependent subjects who have relapsed after a short period of heroin 
abstinence will carry significant differences in allelic frequencies and genotypes and 
have different levels of pain sensitivity/tolerance to those who can sustain abstinence 
for a longer period. In addition, the associations between personality traits 
(neuroticism, extraversion, harm avoidance and sensation seeking) and pain-induced 
Cortisol change with cold-pain response at different relapse status are investigated. 
To explore the topic, Chinese male heroin-dependent subjects (fulfilled DSM-VI 
criteria) who were current opioid users and had a history of relapse (relapse group) 
and who were maintaining opioid abstinence for at least one year (no-relapse group) 
were recruited. Healthy, age-matched Chinese males were recruited as controls. 
Information on demographics, drug use history and detoxification experiences were 
collected by Addiction Severity Index (ASI) in a structured interview. Cold-pressor 
test (CPT) was performed on all subjects for measurement of cold-pressor pain 
response. Subjects were required to insert their non-dominant hand and forearm into 
a bucket of ice-cold water, pain threshold time was noted when the subjects notified 
the researcher of the first sensation of pain (verbally), and pain tolerance time was 
recorded when subjects could no longer tolerate the pain and withdrew their hands 
out of the bucket. Each subject donated 6 ml venous blood (stored in two 3 ml EDTA 
tubes) for genotyping. Gene polymorphism analyses were performed by restriction 
fragment length polymorphism (RFLP) method. Candidate gene polymorphisms 
include MOR A118G, DOR T921C, prodynorphin 68bp-VNTR, COMT Val^ ^^^^^^Met, 
DRD2 Taql A, DRD4 -521C/T and 5HT1B G861C. Personality traits (neuroticism, 
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extraversion, reward seeking, harm avoidance and sensation seeking) of all subjects 
were measured by NEO PI-R (neuroticism and extraversion facets), BIS/BAS and 
SSS-V. Salivary Cortisol level was also measured before and after CPT as an 
indicator of physiological stress response. Results of CPT, genotype and allele 
frequencies, peisoiiality traits and salivary Cortisol were compared among the three 
subject groups, and associations between these factors, heroin dependence and 
relapse were examined. 
» 
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CHAPTER 2 METHODS OF STUDY 
2.1. Subject Recruitment and Demographic Data Collection 
2.1.1. Heroin-dependent Subjects 
Two groups of unrelated Chinese male heroin-dependent subjects were recruited: (1) 
Relapse group: those who were current users of heroin and/or methadone with 
relapse history; and (2) No-relapse group: those who have abstained from heroin and 
methadone for one year or more, fulfilling Diagnostic and Statistical Manual IV 
(DSM-IV) criteria of no-relapse. 50 subjects were recruited from the Substance 
Abuse Assessment Clinic in Kwai Chung Hospital (KCH) into the ‘relapse’ group 
and 36 subjects were recruited from KCH and two rehabilitation organizations for 
substance abusers* into the 'no-relapse' group. Informed consent written in Chinese 
was obtained from all subjects prior to any test procedure. 
2.1.1.1 .Phenotype Assessment 
All heroin-dependent subjects were subjected to psychiatric assessment by 
psychiatrists at the Substance Abuse Assessment Clinic in KCH using DSM-IV. 
DSM-IV describes substance dependence as a maladaptive pattern of substance use, 
leading to clinically significant impairment or distress, as manifested by three (or 
more) of the following, occurring at any time in the same 12-month period: (i) 
tolerance (either having (a) a need for markedly increased amounts of the substance 
to • achieve intoxication or desire effect, or (b) markedly diminished effect with 
continued use of the same amount of substance); (ii) withdrawal (either having (a) 
the characteristic withdrawal syndrome for the substance, or (b) the same (or closely 
* Organizations participated include: Glorious Praise Fellowship and The Finnish Evangelical 
Lutheran Mission Ling Oi Centre 
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related) substance is taken to relieve or avoid withdrawal symptoms); (iii) that 
substance is often taken in larger amounts or over a longer period than was intended; 
(iv) a persistent desire or unsuccessful efforts to cut down or control substance use; 
(V) a great deal of time is spent in activities necessary to obtain the substance (e.g. 
visiting multiple doctors or driving long distances), use the substance (e.g. chain 
smoking), or recover from its effects; (vi) important social, occupational, or 
recreational activities are given up or reduced because of substance use; and (vii) use 
of substance is continued despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or exacerbated 
by the substance. 
A urine sample was taken from each heroin-dependent subject to detect any use of 
opioids, methadone, benzodiazepines, cocaine, amphetamines, cannabinoids, 
barbiturates and tricyclic antidepressants by an immunoassay test device (Triage 8 
Panel for Drugs of Abuse plus Methadone; Biosite Diagnostic, USA) on the day of 
test. 
Subjects from the relapse group were instructed to use heroin before 8 am on the day 
of test or methadone before 7 pm on the previous day of the test if necessary. Testing 
began at 10 am at the Substance Abuse Clinic of Kwai Chung Hospital. 
. 2.1.1.2.Socio-demographics Data and Substance Use History 
General information, living conditions and substance use history were collected in an 
one-hour structured interview conducted in Cantonese. The interview consisted of 
the following three components: addiction severity index (ASI; Appendix 1)， 
experience of first heroin use, history of detoxifications and relapse. 
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2.1.1.3.Addiction Severity Index (ASI) 
ASI aims to provide clinicians and counsellors a structured clinical interview 
designed to collect all the information need at intake to be able to develop an 
appropriate treatment plan for their clients. ASI rates the severity of a wide range of 
problems in the client's life. These problems need not to be directly related to 
substance abuse, but may affect the successfulness of the treatment. Areas concerned 
by ASI include medical status, employment and support status, drug/alcohol use, 
legal status, family history, social/family relationship and psychiatric status. A 
composite score for each domain was calculated as described by McGahan et al 
(1986)，which is an index ranges from 0 to 1，a larger value indicates higher severity. 
2.1.1.�History of Detoxifications and Relapse 
In addition to ASI, the interview also enquired about the detoxification history, this 
includes the total number of detoxification sessions attended, the type and duration of 
these detoxifications, the period of abstinence after leaving the treatment 
programmes, and the reasons of relapse (Appendix 2). 
All subjects received reimbursement of travel costs. 
2.1.2. Control Subjects 
170 healthy Chinese male control subjects were recruited through university notice 
boards in the campus of The Chinese University of Hong Kong for pain response test, 
personality trait measurement and genotype determination. Applicants who reported 
suffering from cardiac diseases, endocrine disorders, chronic pain conditions, major 
psychiatric illnesses or neurological disorders were excluded. None of the subjects 
had ever taken any known psychoactive substances, other than nicotine, caffeine 
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and/or alcohol. An extra 101 control subjects were recruited from The Chinese 
University medical clinic for genotype determination only. Informed written consent 
in Chinese was obtained from each subject. 
Control subjects were required to fill out a questionnaire that enquired about their 
employment status, drug/alcohol use, smoking habit and family history. (Appendix 
3 A — Chinese version used and 3B — English version for reference only) 
2.2. Pain Response Assessment using Cold-Pressor Test (CPT) 
Procedures for this test were adapted from (Doverty et al” 2001b). The test was 
performed in a quiet, isolated air-conditioned room (25°C) without any devices that 
would produce ticking or beeping sound during the test. All subjects had to perform 
CPT once at 12:00. 
Two plastic buckets (cylindrical, 28 cm in diameter, 39 cm in depth) were used. One 
contained warm water (34.5士0.5°C) and the temperature was maintained by a 
thermo-regulator (Unistat TUl, Thermoline Scientific, Sydney, Australia). The other 
one was filled with crushed ice and cold water (1-4°C). The temperature was 
maintained by adding ice. An aquatic pump was applied to create water circulation in 
order to prevent laminar warming around subject's limb. 
The subject was invited to sit on a stool next to the buckets and was instructed to 
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notify the researcher verbally when they first sensed pain (threshold) and to 
withdrawal their limb when they could no longer tolerate such pain (tolerance). 
Blood pressure and heart rate were measured before the test started and would be 
monitor during the test by a patient monitor (C3, Philips Medical Systems, USA). A 
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deflated blood pressure cuff was put on to the forearm of the non-dominant hand of 
the subject. An eye patch was used to cover the eyes of the subject to eliminate visual 
disturbance. 
The test then began with immersing the non-dominant hand and forearm of the 
subject into warm water for 2 min up to a level just below the elbow, with fingers 
wide apart and no part of the limb touching the bucket. At 1 min 45 sec, the blood 
pressure cuff was inflated to 20 mmHg below diastolic pressure to minimize the 
effects of vascular flow on the reaction to cold water. At 2 min, the researcher 
assisted the subject to transfer his hand and forearm to the cold water bucket. The 
limb was immersed to the same level as in the warm water bucket previously with 
fingers wide apart and no part of the limb touching the bucket. As soon as the limb 
was immersed to the right level, the timer started. The "threshold" time was recorded 
(in seconds) as the subject notified the researcher when he first felt pain, whereas the 
"tolerance" time was recorded (in seconds) as he withdrew his forearm and hand 
completely out of the cold water. Finally, the blood pressure cuff was deflated, eye 
patch was removed and a towel was given to the subject to dry his hand and forearm. 
2.3. Personality Trait Assessment 
All participants were required to fill up 3 sets of personality trait assessment 
questionnaires: > 
(1) Revised NEO Personality Inventory (NEO PI-R): Neuroticism and 
Extroversion facets (Costa and McCrae, 1992) (Appendix 4A — Chinese 
version used and 4B — English version) 
A Hong Kong Chinese version of NEO PI-R was employed (McCrae et al., 
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1996; McCrae et al., 1998), and only neuroticism and extroversion facets 
were used for this study as these traits were shown to be associated with 
substance abuse, dependence and relapse (McCormick et al., 1998; Verachai 
et al., 2003; Conner et al., 2004). Each facet contains six subscales 
(neuroticism: anxiety, angry hostility, depression, self-consciousness, 
impulsivity and vulnerability; extraversion: warmth, gregariousness, 
assertiveness, activity, excitement seeking and positive emotions). Subjects 
had to select their degree of agreement (0 = very disagree, 1 = disagree, 2 = 
indifferent, 3 = agree, 4 = very agree) on 96 items.. 
(2) Zuckerman 's Sensation Seeking Scale Form V (SSS-V) (Zuckeman, 1994) 
(Appendix 5A— Chinese version used and 5B — English version) 
This 40-item inventory consists of four subscales: thrill and adventure 
seeking, experience seeking, disinhibition and boredom susceptibility. 
Subjects had to choose between each pair of statements which statement 
best described themselves. 
(3) Behavioral Inhibition Scale/Behavioral Activation Scale (BIS/BAS) (Carver 
and White, 1994) (Appendix 6A _ Chinese version used; 6B 一 English 
version) 
This inventory includes four subscales: BAS drive, BAS flin seeking, BAS 
’ reward and responsiveness, and BIS. Subjects had to select their degree of 
agreement (1 = very agree, 2 = agree, 3 = disagree, 4 = very disagree) on 24 
items. 
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2.4. Genotype Analysis 
2.4.1. DNA Extraction 
Heroin-dependent subjects were required to donate 6 ml of blood for DNA analysis, 
while control subjects donated 3 ml. Blood were drawn from peripheral veins of the 
subjects. All blood samples were collected and stored in a 3 ml EDTA-coated tube at 
4°C during transportation. The samples were centrifuged at 3,000 rpm for 10 min at 
room temperature to separate the targeted buffy coat layer which was loaded with 
white blood cells. DNA was then extracted from the buffy coat by QIAamp DNA 
Blood Mini Kit (QIAGEN, Catalogue No. 51106，USA). First, 200 弘 1 of buffy coat 
was added into a 1.5 ml eppendorf tube with 20 [x\ of QIAGENE Protease K. 200 fi\ 
of Buffer AL was subsequently added and vortexed for 15 sec to mix well. The 
mixture was then incubated at 56°C for 15 min. 200 of 100% ethanol was added 
into the mixture and was vortexed again. The mixture was then transferred into a 
QIAamp Spin Column in a 2 ml collection tube. After centrifugation at 8000 rpm for 
1 min, the spin column, which trapped the genomic DNA, was placed in another 
clean 2 ml collection tube while the filtrate was discarded. 500 /xl of Buffer AWl was 
added into the spin column which was then centrifuged at 8000 rpm for 1 min. The 
spin column was placed in another clean 2 ml collection tube and the filtrate was 
discarded. Next, 500 /xl of Buffer AW2 was added into the spin column and was then 
centrifuged at 14000 rpm for 3 min. Afterwards, the filtrate was discarded and the 
spin column was placed in an autoclaved 1.5 ml microcentrifuge tube. Finally, 200 /xl 
of Buffer AE was added into the spin column.. After 1 min of incubation at room 
temperature, it was then centrifuged at 8000 rpm for 1 min. Through this process, 
genomic DNA trapped on the membrane of the spin column was eluted. DNA 




MOR A118G was genotyped in 168 controls and 84 heroin-dependent subjects. 
50ng DNA was added into a PGR reaction mix which composed of PCRx enhancer 
system (IX PCRx enhancer solution, IX PCRx amplification buffer and 1.5mM 
MgS04； Invitrogen, CA, USA), 0.2 mM dNTP mix (New England BioLabs, MA, 
USA), 20 pmol of each oligonucleotide primers (forward: 5’-TCA ACT TGT CCC 
ACT TAG ATC G-3'; reverse: 5'-ACG CAC ACG ATG GAG TAG AG-3'; 
nucleotide underlined was changed from G—C to generate an artificial cut site), and 
1 U Taq DNA polymerase (Invitrogen, CA, USA), resulting in a total volume of 25 
ix\. The purifiec DWA was then amplified under the following PGR procedures in a 
thermocycler (GeneAmp PGR System 9600 from Perkin Elmer, MA, USA): starting 
with an initial denaturation at 94 °C for 5 min, followed by 35 cycles of 
denaturation at 94°C for 30 sec, annealing at 54°C for 30 sec and elongation at 72°C 
for 30 sec, with a final extension at 72°C for 10 min. The amplified 151 bp PCR 
product was digested in 2 U Bsp68I (recognition sequence: 5'-TCG^CGA-3') (MBI 
Fermentas, ON, Canada) overnight at 37°C. Products were then resolved in a 5% 
agarose gel stained with ethidium bromide by electrophoresis. Homozygous AA 
genotype resulted in a 151 bp band while homozygous GG genotype resulted in a 
129 bp band. Heterozygous AG genotype resulted in 2 bands (151 bp and 129 bp). 
2.4'.2.2.DORT921C � 
DOR T921C was genotyped in 165 controls and 84 heroin-dependent subjects. 50ng 
DNA was added into a PCR reaction mix which composed of PCR buffer (100 mM 
Tris-HCl, pH 8.8 at 25°C; 500 ml KCl; 0.8% Nonidet P40 and 15 mM MgCb), 1 
mM MgCl2, 0.2 mM dNTP mix (New England BioLabs, MA, USA), 20 pmol of 
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oligonucleotide primers (forward: 5，-TTC GTC ATC GTC TGG ACG C-3'; reverse: 
5'-GGT TGA GGC TGC TAT TGG GGT A-3'; nucleotide underlined was changed 
from C—G to generate an artificial cut site), and 1 U Taq DNA polymerase 
(Invitrogen, CA, USA), resulting in a total volume of 25 fil The purified subject 
DNA was then amplified under the following PCR procedures in a thermocycler 
(GeneAmp PCR System 9600，Perkin Elmer, USA): starting with an initial 
denaturation at 95°C for 5 min, followed by 35 cycles of denaturation at 95°C for 30 
sec, annealing at 62°C for 30 sec and elongation at 72°C for 30 sec, with a final 
extension at 72°C for 7 min. The amplified 106 bp PCR product was digest in 3 U 
BstEll (recognition sequence: 5'-GIGTNACC-3') (MBI Fermentas, ON, Canada) 
overnight at 37°C. Products were then resolved in a 5% agarose gel stained with 
ethidium bromide by electrophoresis. Homozygous TT genotype resulted in a 82 bp 
band while homozygous CC genotype resulted in a 106 bp band. Heterozygous TC 
genotype resulted in 2 bands (82 bp and 106 bp). 
2.4.2.3.COMT Var^^^^^^Met 
COMT Valio8/i58Met was genotyped in 148 controls and 84 heroin-dependent 
subjects. 50ng DNA was added into a PCR reaction mix which composed of PCR 
buffer (100 mM Tris-HCl, pH 8.8 at 25°C; 500 ml KCl; 0.8% Nonidet P40 and 15 
mM M g C y , 1 mM MgClz, 0.2 mM dNTP mix (New England BioLabs, MA, USA), 
20 pmol of oligonucleotide primers (forward: 5'-ACT GTG GCT ACT CAG CTG 
TG-3，； reverse: 5'-CCT TTT TCC AGG TCT GAC AA-3，)，and 1 U Taq DNA 
polymerase (Invitrogen, CA, USA), resulting in a total volume of 25 [xl The purified 
subject DNA was then amplified under the following PCR procedures in a 
thermocycler (GeneAmp PCR System 9600, Perkin Elmer, USA): starting with an 
initial denaturation at 94°C for 5 min, followed by 35 cycles of denaturation at 94°C 
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for 45 sec, annealing at 61°C for 45 sec and elongation at 72°C for 30 sec, with a 
final extension at 72°C for 10 min. The amplified 169 bp PGR product was digest in 
5 U Nlalll (recognition sequence: 5，-CATGI-3，) (New England BioLabs, MA, USA) 
for at least 16 h at 37°C. Products were then resolved in a 5% agarose gel stained 
with ethidium bromide by electrophoresis. Homozygous val/val genotype resulted in 
a 114 bp band while homozygous met/met genotype resulted in a 96 bp band. 
Heterozygous val/met genotype resulted in 2 bands (96 bp and 114 bp). 
2.4.2.4.Prodynorphin 68bp-VNTR 
Prodynorphin 68bp-VNTR was genotyped in 163 control and 83 heroin-dependent 
subjects. 50ng DNA was added into a PCR reaction mix which composed of PCR 
buffer (100 mM Tris-HCl, pH 8.8 at 25°C; 500 ml KCl; 0.8% Nonidet P40 and 15 
mM M g C y , 2.5 mM MgCh, 0.2 mM dNTP mix (New England BioLabs, MA, USA), 
25 pmol of oligonucleotide primers (forward: 5'-CTG TGT ATG GAG AGG CTG 
AGT-3'; reverse: 5'-AGG CGG TTA GGT AGA GTT GTC-3'), and 1 U Tag DNA 
polymerase (Invitrogen, CA, USA), resulting in a total volume of 25 /xl. The purified 
subject DNA was then amplified in a thermocycler (GeneAmp PCR System 9600, 
Perkin Elmer, USA). The amplification started with an initial denaturation at 94°C 
for 5 min, then followed with five sets of cycling sequence. Each set were cycled 
three times, beginning with denaturation at 94°C for 30 sec, followed by a gradually 
decreased ("stepped down") annealing temperature of 66°C, 63°C, 60°C, 57°C and 
54冗，ending with an elongation at 72°C for 1 min. Thirty-five cycles were further 
performed with an annealing temperature of 52°C. The amplification ended by a final 
extension at 11。C for 7 min. PCR products were resolved in a 3% agarose gel 
electrophoresis stained with ethidium bromide. DNA samples showed bands with 
273 bp, 341 bp, 409 bp and 477 bp which carried one to four 68 bp repeats respectively. 
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2.4.2.5.DRD2 Taql A 
DRD2 Taql A was genotyped in 152 control and 84 heroin-dependent subjects. 50ng 
DNA was added into a PGR reaction mix which composed of PCR buffer (100 mM 
Tris-HCl, pH 8.8 at 25°C; 500 ml KCl; 0.8% Nonidet P40 and 15 mM M g C y , 1 
mM MgCh，0.2 mM dNTP mix (New England BioLabs, MA, USA), 20 pmol of 
oligonucleotide primers (forward: 5,-CCG TCG ACG GCT GGC CAA GTT GTC 
TA-3，； reverse: 5,-CCG TCG ACQ CTT CCT GAG TGT CAT CA-3，； nucleotides in 
italic were added to produce same length replicas), and 1 U Taq DNA polymerase 
(Invitrogen, CA, USA), resulting in a total volume of 25 /xl. The purified subject 
DNA was then amplified under the following PCR procedures in a thermocycler 
(GeneAmp PCR System 9600, Perkin Elmer, USA): starting with an initial 
denaturation at 94°C for 5 min, followed by 35 cycles of denaturation at 94°C for 45 
sec, annealing at 6 1 � C for 45 sec and elongation at 72°C for 30 sec, with a final 
extension at 72°C for 10 min. The amplified 318 bp PCR product was digest in 5 U 
Taql (recognition sequence: 5'-TICGA-3') (MBI Fermentas, ON, Canada) overnight 
at 65°C. Products were then resolved in a 1.5% agarose gel stained with ethidium 
bromide by electrophoresis. Homozygous A lAl genotype resulted in a 308 bp band 
while homozygous A2A2 genotype resulted in 2 bands (128 bp and 180 bp). 
Heterozygous A1A2 genotype resulted in 3 bands (128 bp, 128 bp and 180 bp). 
2.4.2.6.DRD4 -521C/T 
DRD4 -521C/T was genotyped in 160 controls and 84 heroin-dependent subjects. 
50ng subject DNA sample was added into a PCR reaction mix which composed of 
PCRx enhancer system (IX PCRx enhancer solution, IX PCRx amplification buffer 
and 1.5mM MP�S04; purchased from Invitrogen, CA, USA), 0.2 mM dNTP mix 
(New England BioLabs, MA, USA), 20 pmol of oligonucleotide primers (forward: 
59 
5'- CGG GGG CTG AGC ACC AGA GGC TGC T-3'; reverse: 5'- GCA TCG ACG 
CCA GCG CCA TCC TAC C-3，)，and 1 U Taq DNA polymerase (Invitrogen, CA, 
USA), resulting in a total volume of 25 /xl. The purified subject DNA was then 
amplified under the following PCR procedures in a thermocycler (GeneAmp PGR 
System 9600, Perkin Elmer, USA): starting with an initial denaturation at 94°C for 5 
min, followed by 35 cycles of denaturation at 94°C for 45 sec, annealing at 60°C for 
45 sec and elongation at 72°C for 30 sec, with a final extension at 72°C for 10 min. 
The amplified 284 bp PCR product was digest in 3 U Nsbl (recognition sequence: 5'-
TGCIGCA- 3') (MBI Fermentas, ON, Canada) overnight at 37�C. Products were 
then resolved ir a ^.5% agarose gel stained with ethidium bromide by electrophoresis. 
Homozygous CC genotype resulted in 2 bands (108 bp and 176 bp), while 
homozygous TT genotype resulted in a 284 bp band. Heterozygous CT genotype 
resulted in 3 bands (108 bp, 176 bp and 284 bp). 
2.4.2.7.5HT1BG861C 
5HT1B G861C was genotyped in 158 control and 84 heroin-dependent subjects. 
50ng DNA was added into a PCR reaction mix which composed of PCR buffer (100 
mM Tris-HCl, pH 8.8 at 25°C; 500 ml KCl; 0.8% Nonidet P40 and 15 mM M g C y , 1 
mM MgCb, 0.2 mM dNTP mix (New England BioLabs，MA, USA), 20 pmol of 
oligonucleotide prmers (forward: 5'-GAA ACA GAC GCC CAA CAG GAC-3’； 
reverse: 5，-CCA GAA ACC GCG AAA GAA GAT-3'; nucleotides in italic were 
added to produce same length replicas), and 1 U Taq DNA polymerase (Invitrogen, 
CA, USA)，resulting in a total volume of 25 /xl. The purified subject DNA was then 
amplified under the following PCR procedures in a thermocycler (GeneAmp PCR 
System 9600，Perkin Elmer, USA): starting with an initial denaturation at 94°C for 5 
min, followed by 35 cycles of denaturation at 94°C for 45 sec, annealing at 61°C for 
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45 sec and elongation at 72°C for 30 sec, with a final extension at 72°C for 10 min. 
The amplified 452 bp PCR product was digest in 5 U Hindi (recognition sequence: 
5'-GTPylPuAC-3') (MBI Fermentas, ON, Canada) overnight at 37°C. Products 
were then resolved in a 1.5% agarose gel stained with ethidium bromide by 
electrophoresis. 
Homozygous GG genotype resulted in a 452 bp band while homozygous CC 
genotype resulted in 2 bands (142 bp and 310 bp). Heterozygous GC genotype 
resulted in 3 bands (142 bp, 310 bp and 452 bp). 
2.5. Saliva Collection and Salivary Cortisol Measurement 
Five saliva samples were collected from each heroin-dependent subjects: 10 am, 
before CPT (12 noon), 20 min after the CPT, 3 pm, and 5 pm. Subjects were 
instructed not to brush their teeth, smoke, eat or take drinks containing stimulants 
(e.g. coffee anc' tea) an hour prior to each assigned collection time. Drinking water 
and rinsing mouth were prohibited 15 min before collection. 
Saliva samples were collected by salivettes (Sarstedt, Germany), which composed of 
a plastic capped tube, a sieve, and a neutral cotton roll for the subject to chew until 
saturated. The used salivettes were centrifUged at 3，000g for 3 min to obtain clear 
and fluid saliva samples without dregs and saliva matrix. The saliva samples were > 
stored at -20°C for less than 1 year before analysis. 
Salivary Cortisol was measured by a salivary Cortisol EIA kit (DSL, Germany). Inter-
and intra-assay coefficients of variance of this assay were 7.1% and 5.0%. Each 
sample was merisu： ed in duplication. 
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2.6. Statistical Analysis 
Data analysis was performed by SPSS v. 13 (SPSS Inc., USA) and graphs were 
plotted by Microsoft® Excel and SPSS. 
Demographic and drug use data were presented in terms of mean, standard deviation 
(SD) and percentage. The composite scores of each ASI domain of no-relapse and 
relapse groups were compared by Mann-Whitney test. Fisher's exact test was used to 
compare the percentages of relapse cases between short-term and long-term 
abstainers according to relapse reasons. 
CPT threshold time (in sec), tolerance time (in sec) and tolerance-to-threshold ratio 
(tol/thr) were normalized by natural log (Ln) transformation. Means (士 2SE) of 
Ln[threshold], Ln[tolerance] and Ln[tol/thr] were compared. One-way ANOVA was 
applied to compare these CPT measurements among subject groups and Bonferroni 
method was chosen as post-hoc test. Subjects were categorized into CPT tolerant 
(those who tolerated >50 s) and intolerant (those who tolerated < 50s) groups. 50 s 
was the 75% quartile of CPT tolerance time in the control group. The distribution of 
CPT tolerant and intolerant subjects was compared amongst the 3 groups by 
Pearson's 义 test. 
Results of personality traits were presented in mean scores (土 2SE)，and were > 
• compared among subject groups by one-way ANOVA with Bonferroni test as 
post-hoc test. Cronbach's o: coefficient was calculated for each scale to test for their 
reliabilities. 
Salivary Cortisol levels of the 3 subject groups at each time point were compared by 
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Kruskal-Wallis test. Salivary Cortisol change 20 min after CPT (i.e. the salivary 
Cortisol level difference between 12 noon and 12:20 p) of the 3 subject groups was 
also compared by Kruskal-Wallis test. 
Differences in the genotype distribution of each gene markers between control and 
heroin-dependent subjects and between 'relapse' and 'no-relapse' groups were 
determined by Pearson's ^ tests. Allele frequency differences between control and 
heroin-dependent subjects and between no-relapse and relapse groups were 
determined by Yate's test. 
In considering the effect of multiple comparisons, backward multiple regression was 
applied to identify the significant genetic and/or personality factors associated with 
Ln[threshold], Ln[tolerance] and Ln[tol/thr] in the presence of other factors. For each 
of the significant genetic factor, the differences of Ln[threshold], Ln[tolerance] and 
Ln[tol/thr] among genotypes and between allele carriers and non-carriers within each 
subject groups were determined by one-way ANOVA (Welch statistic was presented 
instead of F value when the assumption of equal variance was violated) and 
Student's t test respectively. 
P < 0.05 was considered as significant in all statistical tests. 
> 
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CHAPTER 3 RESULTS 
3.1. Demographics 
3.1.1. Age 
All subjects recruited in this research were males. The mean age of control, 
no-relapse and relapse groups were 41.8 土 10.9 yrs (range 24 - 60 yrs), 40.7 土 10.5 
yrs (range 2 4 - 5 8 yrs) and 45.3 土 10.6 yrs (range 24 - 66 yrs) respectively. 
3.1.2. Ethnicity 
Subjects were asked from which province in mainland their parents and grandparents 
originated. 92.3% of paternal and 84.5% of maternal origins were from Southern 
China, i.e. areas south of Yangzi River, of which 82.6% and 72.9% respectively are 
from Guangdong province (Table 1). 
3.1.3. District of Residence and Type of Housing 
71.0% of control and 55.6% of no-relapse groups resided in New Territories, whilst 
62.0% of relapse group resided in Kowloon (Table 2). 
Figure 1 showed the distribution of the types of housing of the subjects studied. Most 
heroin-dependent subjects lived in public housing (no-relapse: 63.9%; relapse: 64.0%) 
as oppose to 18.8% for control subjects. In contrast, 37.7% of controls lived in 
. private housing compared to less than 10% of heroin-dependent subjects (no-relapse: 
8.3%; relapse: 4.0%). The distribution of types of housing is significantly different 
among the 3 subject groups (Pearson's 0.0001). 
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Table 1. Parental origins of all subjects 
% of Subjects (n= 155) 
Provinces Paternal Maternal 
Southern China* 92.3 84.5 
Guangdong 82.6 72.9 
Fujian 3.9 4.5 
Hong Kong 1.9 2.6 
Zhejiang 1.3 0.6 
Guangxi 0.6 0 
Hainan 0.6 0.6 
Jiangxi 0.6 0 
Shanghai 0.6 2.6 
Macau 0 0.6 
Northern China* 0.6 1.3 
Shanxi 0.6 0 
Hubei 0 0.6 
Liaoning 0 0.6 
Unknown 7.1 14.2 
* Provinces lie south of Yangtze River are considered as Southern China, the rests are 
considered as Northern China (n = 155). 
> 
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Table 2. District of residence: control (n = 69)，no-relapse (n = 36) and relapse (n = 
50) groups. 
% of Subjects 
Control No-relapse Relapse 
(n = 69) (n = 36) (n = 50) 
Hong Kong Island 10.1 16.7 4.0 
Central and Western 2.9 0 2.0 
Eastern 5.8 8.3 0 
Southern 1.4 8.3 0 
Wan Chai 0 0 2.0 
Kowloon 18.8 27.8 62.0 
Kowloon City 7.2 2.8 2.0 
Kwun Tong 4.3 8.3 12.0 
Sham Shui Po 1.4 8.3 16.0 
Wong Tai Sin 1.4 2.8 12.0 
YauTsimMong ^ ^ 20.0 
New Territories 71.0 55.6 32.0 
Islands 1.4 2.8 0 
KwaiTsing 4.3 8.3 8.0 
North 7.2 2.8 0.0 
Sai Kung 4.3 2.8 6.0 
ShaTin 27.5 8.3 6.0 
Tai Po 8.7 0 4.0 
TsuenWan 1.4 8.3 4.0 
Tuen Mun 8.7 13.9 0 
Yuen Long ^ ^ 4.0 
Shenzhen 0 0 2.0 
> 
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Figure 1. Types of housing: control (n = 69)，no-relapse (n = 36) and relapse (n = 50) 
groups. The distribution of types of housing is significantly different among the 3 
subject groups (Pearson's 0.0001). 
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3.1.4. Education, Employment and Income 
Education level: Most heroin-dependent subjects received Form 3 secondary or 
below (no-relapse: 83.3%; relapse: 82.0%). In contrast, control subjects had a 
slightly higher education level with 60.8% and 24.6% having received Form 5 or 
below and University education respectively (Figure 2). 
Current employment status: Most of the heroin-dependent subjects were unemployed 
(no-relapse: 72.2%; relapse: 60.0%), whereas the majority of control subjects (89.9%) 
were in full-time； work (Figure 3). 
Monthly income: Average monthly incomes of no-relapse, relapse and control groups 
were HK$3,583 and HK$4,042 and HK$14，131 respectively. 
Sources of income: For the heroin-dependent groups, the major source of income 
was from comprehensive social security assistance (CSSA) (no-relapse: 69.2%; 
relapse: 56.0%), the rest came from employment, family or friends, illegal activities 
and insurance (Figure 4). It is interesting to note that 8.0% of relapse group earned 
their money through illegal means. Employment was the only source of income for 
the control group. 
Skills: The percentage of subjects reported to have acquired marketable skills is 
similar for the no-relapse (33.3%) and relapse (32.0%) groups. The most common 
skills were home restoration (39.3%), catering (21.4%) and hair-dressing (14.3%). 
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Figure 2. Education levels: control (n = 69), no-relapse (n = 36) and relapse (n = 50) 
groups. 
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Figure 4. Sources of income of heroin-dependent subjects (no-relapse: n = 36; 
relapse: n = 50). 
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Types of occupation during the longest-full time employment: 50% and 33.3% of 
subjects from the relapse and no-relapse group respectively are semi-skilled workers 
(e.g. truck drivers, dressmakers, watchmen, waiters, welders); whilst only 36.1% and 
24% of them are skilled manual workers (e.g. chefs, electricians, machinists, tailors, 
hair-stylists). Interestingly, 10% of subjects in the relapse group were reported to 
perform illegal activities as their full-time occupation compared to 2.8% in the 
no-relapse group (Figure 5). 
3.1.5. ASI Scores 
3.1.5.1 .Family/Social Relationship 
Marital status: Subjects from the no-relapse group were mostly single (69.4%) while 
52.0% of subjects from the relapse group were married. 26.0% of subjects from the 
relapse group were divorced compared to 11.1% in the no-relapse group. Relapse 
group showed a lower satisfaction towards their marital status than the no-relapse 
group (32.0% vs 56.0%). 
Living arrangement in the past 3 vrs: Subjects of the no-relapse group were mostly 
living in a supervised environment (e.g. rehabilitation centres; 63.9%), while subjects 
in the relapse group were mostly living with their family (50.0%). Subjects in the 
relapse group were less satisfied with their living arrangement compared to the 
no-relapse group (52.0% vs 72.2%). » 
Spending of free time: Twice was many subjects in the no-relapse group chose to 
spend their free time with their family and friends when compared to the relapse 
group (80.6% vs 44.0%). Reflected similarly, 44.0% of subjects in the relapse group 
preferred to spend time alone when compared to the no-relapse group (19.4%). 
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Figure 5. Job nature of the longest full-time employment of no-relapse (n = 36) and 
relapse (n = 50) subjects. 
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Relationship probltgrns: 38.0% and 54.0% of subjects in the no-relapse and relapse 
group respectively reported ever having relationship problems (e.g. chronic argument, 
animosity, lack of communication) with close family members (mother, father, 
siblings and partner). However, only 5.6% and 12.0% of subjects in the no-relapse 
and relapse groups reported having relationship problem with somebody in the past 
30 days. 
Composite score: Mean composite scores (土SD) of family/social relationship status 
of no-relapse and relapse groups were 0.09 ± 0.10 and 0.14 士 0.12 respectively with 
a trend towards significant difference (P = 0.073; Table 3). 
3.1.5.2.Employment and Support Status 
Composite score: Mean composite scores (士SD) of employment/support status of 
no-relapse and relapse groups were 0.81 土 0.25 and 0.88 士 0.17 respectively with no 
significant difference between them {P = 0.186; Table 3). 
3.1.5.3.Medical Status 
Self-report chronic problems: 22.1% of all heroin-dependent subjects (i.e. all subjects 
in relapse and no-relapse group) were reported to have long-term illnesses, including 
neurological diseases/damages, cardiac diseases, and respiratory diseases. In addition, 
14% of heroin-dependent subjects were reported to suffer from hepatitis B and/or C 
(Table 4). 
Medical problems in past 30 days: 74.9% of heroin-dependent subjects (i.e. all 
subjects in relapse and no-relapse group) claimed to have no medical problems in the 
past 30 days prior to interview, only 8.4% experienced medical problems for 
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Table 3. Comparisons of mean ASI composite scores (土SD) between 
heroin-dependent subjects (no-relapse: n = 36; relapse: n = 50) by Mann-Whitney 
test. Legal composite score was excluded from the comparison as nearly all subjects 
scored zero. Medical composite score of the no-relapse group was significantly 
higher than the relapse group whereas drug composite score was significantly higher 
in the relapse group when compared to the no-relapse group. 
M e a n score 土 S D 
No-relapse Relapse P 
Family/Social 0 . 0 9 土 0 . 1 0 0 . 1 4 土 0.12 0 . 0 7 3 
Employment/Support 0.81 ±0.25 0.88 ±0.17 0.186 
Medical 0.18 ± 0.24 0.07 ± 0.22- 0.030* 
Legal 0.00 0.03 土 0.08 -
Psychiatric 0.04 土 0.14 0.08 ±0.18 0.247 
Alcohol 0.03 ± 0.05 0.04 ± 0.08 0.347 
Drug 0.01 土 0.03 0.50 土 0.28 <0.0001# 
Level of significance: *P<0.05; * P < 0.001 
Table 4. Medical conditions reported by control (n = 69), no-relapse (n = 36) and 
relapse (n = 50) groups. 
No. of Subjects 
Control No-relapse Relapse 
Long-term illness 0 8 11 
Neurological disease / damage 0 4 6 
Cardiac disease 0 0 2 
Respiratory disease 0 3 1 
Others 0 1 2 
,Hepatitis B or C 0 9 3 
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15 days or more within the past 30 days prior to interview. 
Composite score: Mean composite scores (士SD) of medical status were significantly 
different {P = 0.030; Table 3) between no-relapse (0.18 土 0.24) and relapse group 
(0.07 士 0.22). 
3.1.5ALegal Status 
Current legal status: Three subjects in the no-relapse group and one subject in the 
relapse group were participating in the mandatory treatment programme 
recommended by criminal justice system. One subject in the relapse group reported 
was still on parole at the day of interview. 
Composite score: Mean composite scores (士SD) of legal status of no-relapse and 
relapse groups were 0 and 0.03 士 0.08 respectively (Table 3). This parameter was 
excluded from Mann-Whitney test as nearly all heroin-dependent subjects scored 
zero. 
3.1.5.5.Psychiatric Status 
Psychological treatment: 16% of heroin-dependent subjects (both relapse and 
no-relapse groups) claimed to have received psychological/emotional treatment: 10 
subjects claimed to receive treatment for depression while 3 subjects received 
treatment for insomnia. 
Psychological problems in the past 30 days: 11.1% and 22.2% of subjects in the 
no-relapse and relapse group respectively experienced psychological/emotional 
problems. Their psychological/emotional problems included feeling depressed, 
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anxious, having trouble in concentrating or having suicidal thoughts. 8.3% and 
10.0% of subjects from the no-relapse and relapse groups respectively reported 
taking psychiatric medications in the past 30 days. 
Composite score: Mean composite scores (士SD) of psychiatric status of the 
no-relapse and relapse group were 0.04 土 0.14 and 0.08 士 0.18 respectively with no 
significant difference between them {P = 0.247; Table 3). 
3.1.5.6.Drug Use Status 
Table 5 and 6 showed the drug use history of heroin-dependent subjects and their 
drug use pattern in the past 30 days respectively. 
Heroin: Subjects from the no-relapse and relapse group have consumed on average 
for 23.2 土 10.1 yrs and 23.3 士 10.4 yrs respectively. 40% of the subjects of the 
relapse group on average used heroin for 21.6 土 11.2 days in the past 30 days. For 
every heroin-used day, they on average used 1.45 土 0.85 g of heroin (Table 6). The 
main route of heroin administration was intravenous (IV) injection (no-relapse: 
80.6%; relapse: 76.0%), following by “chasing the dragon" (no-relapse 16.7%; 
relapse: 24.0%) and only one no-relapse subject (2.8%) used heroin by smoking. 
Problems caused by heroin: 63.9% and 84.0% of subjects from the no-relapse and 
relapse groups respectively commented that heroin brought them problems mostly 
related to finance, family relationship and health. 
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Table 5. Drug use history (life time, past 12 months, and past 30 days) of 
heroin-dependent subjects (no-relapse: n = 36; relapse: n = 50). 
% of Subjects 
Ever Past 12 months Past 30 days 
No-relapse Relapse No-relapse Relapse No-relapse Relapse 
(n = 36) (n = 50) (n = 36) (n = 50) (n = 36) (n = 50) 
Heroin 100.0 100.0 - 100.0 - 80.0 
Methadone 94.4 96.0 - 86.0 - 78.0 
Alcohol 83.3 66.0 47.2 52.0 30.6 42.0 
Tranquillizers 77.8 60.0 2.8 40.0 0 24.0 
Marijuana 75.0 56.0 0 6.0 0 2.0 
Amphetamines 69.4 52.0 0 6.0 0 2.0 
Organic solvents 36.1 8.0 0 0 0 0 
Opiates 30.6 24.0 0 0 
Ketamine 11.1 20.0 0 4.0 0 0 
Hallucinogens 13.9 10.0 0 0 0 0 
Cocaine 13.9 38.0 0 4.0 0 0 
Barbiturates 36.1 22.0 0 0 0 0 
"Ecstasy" 33.3 16.0 0 4.0 0 0 





























































































































































































































































































Methadone: 78% of subjects from the relapse group had used 45.64 士 29.94 mg 
(mean 士 SD) of methadone for an average of 24.9 土 8.8 days in the past month 
(Table 6). 54.0% of these subjects also took methadone and heroin on the same day, 
in which some of them also used tranquillizers as well (Table 7). 
Composite score: Mean composite scores (士SD) of drug use status were significantly 
different (P = <0.0001; Table 3) between the no-relapse (0.01 土 0.03) and relapse 
(0.50 士 0.28) groups. 
3.1.5.7.Alcohol Use Status 
Last alcohol consumption: 83.3% and 66.0% of subjects from no-relapse and relapse 
have ever consumed alcohol, with only 30.6% and 42.0% of them reported to having 
a drink within the past 30 days (Table 5). On average, they drank 3.18 土 3.19 and 
2.81 土 2.18 cans of beer (土 SD) respectively on average per drinking day (Table 6). 
Composite score: Mean composite scores (土SD) of alcohol use status of no-relapse 
and relapse groups were 0.03 土 0.05 and 0.04 土 0.08 respectively with no significant 
difference between them (P = 0.347; Table 3). 
3.1.6. Tranquillizer Use Status 
The most common tranquillizer taken was triazolam/midazolam, it was either taken 
solely or injected/inhaled with heroin. In the past 30 days, 24.0% of relapse subjects 
reported they had used tranquillizers for an average (士 SD) of 20.9 士 13.2 days. On 
average, they used 3.33 士 3.96 pills per usage day (Table 6). On the day of 
tranquillizer use, all of these subjects also used heroin. Table 7 shows the pattern of 
tranquillizer used in combination with heroin and methadone. 
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Table 7. Types of drug used with heroin on the same day (excluding alcohol and 
cigarette) of relapse subjects (n = 50) in the past 30 days. 
% of Subjects 
(n = 50) 
Heroin & methadone 50.0 
Heroin & triazolam/midazolam 6.0 
Heroin & triazolam/midazolam at the same time ^ 
with methadone ‘ 
Heroin, triazolam/midazolam and methadone ^ � 
used separately . 
> 
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Problems caused by tranquillizers: 13.9% and 8.0% of subjects from the no-relapse 
and relapse groups respectively chose tranquillizer as the main drug that brought 
them major problems, namely lost of consciousness and the hazardous behaviours 
with further a 11.1% (no-relapse) and 4.0% (relapse) of subjects are concerned with 
street tranquillizers contaminated with unknown adulterants which may cause serious 
health conditions when injected. 
Reasons of using tranquillizers: Subjects who tried tranquillizers 
(triazolam/midazolam) in combination with heroin attributed their first trial of such a 
combination mainly to 'experience effects other than produced by heroin' (Figure 6). 
3.1.7. Smoking Status 
Nearly all heroin-dependent subjects have ever smoked. Among these subjects, all 
relapse and 38.9% of no-relapse subjects had smoked within the past 30 days (Table 
5). The average smoking days within the past 30 days (土 SD) were 28.0 士 6.9 
(no-relapse) and 29.8 土 1.4 (relapse) days. For each smoking day, they smoked on 
average 17.21 土 10.71 and 17.98 土 6.67 cigarettes (Table 6). 
18.0% of control subjects have ever smoked, of which only 12.0% continued to 
smoke within the past 12 months. The current smokers smoked on average 9.0 土 2.5 
days (土 Sp) in the past 30 days. For each smoking day, they consumed on average 
7.00 土 6.03 cigarettes (士 SD). ‘ 
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Figure 6. Reasons given why the combination of heroin+triazolam/midazolam was 
tried (n = 37). 
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3.1.8. Detoxification and Relapse 
Detoxification times: The average number of opioid detoxification attempts (士 SD) 
made by no-relapse and relapse subjects were 13.6 土 10.1 and 9.6 土 7.1 times 
respectively, in which 62.1% (no-relapse) and 51.7% (relapse) were reported as 
voluntary participations. 
Mode of detoxification (valid cases: n = 275): The most common type of 
detoxification (detox) programme participated was imprisonment/compulsory detox 
organized by Hong Kong Correctional Service Department (39.6%), followed by 
voluntary hospitalisation/detox (35.3%) and self-arranged detox (25.1%), which 
included shutting oneself up, going for a trip and taking prescribed/non-prescribed 
medication etc. Compared to the relapse group, subjects from the no-relapse group 
had participated significantly more in voluntary detoxifications (voluntary 
hospitalisation/detox and self-organized detox) than compulsory detoxifications 
(imprisonment/compulsory detox programme; Pearson's 义 = 3 . 9 0 8 ; P = 0.048; 
Figure 7). 
Grouping these detox modes into compulsory and voluntary (voluntary detox 
programme and self-arranged detox) detox, the success rate for sustaining abstinence 
for one year or more was three times significantly higher in the voluntary detox 
group than the compulsory detox group (OR = 3.113; P = 0.010). > 
Reasons for relapse (Valid cases: n = 230): Craving, or the heroin-dependent subjects 
referred as "the constant preoccupation of heroin in my mind，，，was the most 
common cause of relapse. 
83 
Figure 7. Different modes (compulsory, voluntary and self-arranged) of 
detoxification that subjects from the no-relapse (n = 36) and relapse (n = 50) groups 
participated in. Percentage of total reported detoxifications (no-relapse: n = 121; 
relapse: n = 154) for each mode of detoxification is shown. 
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Figure 8 shows the reasons of relapse for subjects in both the no-relapse and relapse 
groups who had undergone different modes of detoxification. Table 8 compared the 
reasons of relapse between long-term and short-term abstinence cases (defined by 6 
months abstinence) for various types of detoxification. 
Imprisonment/compulsory detox programme (valid cases: n = 107) 
The most common reasons of relapse in this mode of detoxification were craving 
(34.6%) and peer influence (26.2%). Craving is also the most common reason in 
comparison to the other 2 modes of detoxification (Figure' 8). Craving was reported 
to be significantly less in long-term abstinence cases (x^ 】）=8.677; P = 0.003). In 
contrast, significantly more long-term abstinence cases reported peer influence as the 
major reason of relapse = 4.544; P = 0.033; Table 8). 
Voluntary hospitalisation/detox programme (valid cases: n = 61) 
Craving was the most common reason of relapse (32.8%), followed by life stresses 
(14.8%), intolerable withdrawal symptoms and idleness being the next most common 
reasons (14.8%). The last common being no intention to seek treatment (Figure 8). 
Significant difference was observed only in life stresses between long-term and 
short-term abstinence cases 0(^ (2) = 17.947; p = 0.0002). Intolerable withdrawal was 
reported only in short-term abstinence cases (Table 8). 
Seif-arranged detox (valid cases: n = 62) 
Apart from craving (27.4%) being the most common, peer influence (17.7%), 
idleness (17.7%) and life stresses (16.1%) were the second most common reasons of 











































































































































































































































































































































































































































































































































































































































































































































































short-term abstinence group compared to the long-term abstinence group = 
5.005; p = 0.041). On the contrary, all cases reported life stresses as the major relapse 
cause for relapse were from the long-term abstinence group 0(^2) = 17.646; p < 
0.0001; Table 8). 
3.2. Cold-Pressor Test (CPT) 
CPT was performed on 69 controls, 35 ‘no-relapse，and 50 'relapse' subjects. The 
mean CPT threshold time 土 2 SEM for the control, no-relapse and relapse groups 
were 11.88 士 2.74 s, 13.35 土 3.56 s and 13.16 土 2.06 s respectively. The mean CPT 
tolerance time 士 2 SEM were 55.80 士 18.90 s, 56.72 土 28.79 s and 26.97 土 4.45 s 
respectively for the above mentioned groups. Out of all the subjects, 6 control and 3 
subjects from the no-relapse group reached the maximum limited of 300 s for 
tolerance time. 
CPT threshold, tolerance and tolerance-to-threshold ratio (tol/thr) were normalized 
by natural log algorithm (Ln) prior to statistical analyses. No significant difference 
was observed in both pain threshold (F = 1.455; P = 0.237) and pain tolerance (F = 
2.386; P = 0.095) amongst groups. However, pain tol/thr ratio was significantly 
different among groups (F = 12.77; P = 0.0007) in which the ratio of the relapse 
group was significantly lower than those of the control and no-relapse groups (P = 
0.0003 and 0.049 respectively; Figure 9). > 
Subjects were further subdivided into CPT tolerant and intolerant groups: those with 
CPT tolerance time > 5 0 s were classified as CPT tolerant and those with CPT 
tolerance time < 50 s were classified as CPT intolerant. 50 s was the 75% quartile of 
CPT tolerance time in control group. Walsh et al (1989) and Compton et al (2003b) 
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Figure 9. Mean (土2SE) CPT threshold, tolerance and tolerance-to-threshold ratio 
(tol/thr) of controls (n = 69)，no-relapse (n = 35) and relapse (n = 49) groups. 
Significant diflerence among groups was only detected in tol/thr (*P = 0.0007; 
one-way ANOVA). Post-hoc test (Bonferroni) showed that tol/thr of the relapse 
group was significantly lower than those of control and no-relapse groups (P = 
0.0003 and 0.049 respectively). 
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used 60 s to be their cut-off point as the previous described cold-pain tolerance 
hierarachy in Anglo-Saxon males was evidenced at 60 s (Walsh et al., 1989). 
However, Orientals were demonstrated to be less cold-pain tolerant than the 
Anglo-Saxons and the blacks (Woodrow et al., 1972), thus a lower pain tolerance 
cut-off point should be adopted for our Chinese subjects. Compared to the controls, 
the relapse group had nearly 20% more subjects fell into the CPT intolerant category 
(75.4% vs 94%). Pearson test showed a significant difference in the distribution of 
CPT tolerant and intolerant subjects among the 3 groups (x\2) = 7.156; P = 0.028; 
Table 9). 
3.3. Personality Traits 
3.3.1. NEOPI-R 
69 controls, 35 and 50 subjects in the no-relapse and relapse groups respectively 
completed neuroticism and extraversion facet of NEO PI-R. Table 10 shows the 
mean scores in each subscale of the 3 subject groups. 
In the neuroticism facet, there is an overall higher mean score in the relapse group 
when compared to the controls {P < 0.001; a = 0.900). Amongst the 6 subscales, the 
relapse group had significantly higher mean scores in depression (P < 0.001; a = 
0.757)，self-consciousness (P = 0.009; a = 0.545), impulsivity (P = 0.006; a = 0.441) 
and vulnerability {P < 0.001; a = 0.735). Furthermore, there is also a significantly 
higher depression scores in the no-relapse group when compared to the controls {P = 
0.021). In the extraversion facet, there is an overall trend of a lower mean score in 
the relapse group when compared to the controls (P = 0.077) with only warmth {P = 
0.001; a = 0.660) and positive emotions subscales (P < 0.001; a = 0.643) showing 
significantly lower scores. 
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Table 9. Distriouixon of CPT tolerant and intolerant subjects in control (n = 69)， 
no-relapse (n = 35) and relapse (n = 49) groups. Subjects with CPT tolerance time > 
50 s are considered as CPT tolerant, the rest are defined as CPT intolerant. Pearson x^  
test shows significant difference in distribution of tolerant and intolerant subjects 
among the 3 subject groups {P = 0.028). 
No. of subjects (%) 
CPT Intolerant CPT Tolerant 
Control 52 (75.4%) 17 (24.6%) 
No-relapse Group 28 (80.0%) 7 (20.0%) 
Relapse Group 47 (94.0%) 3 (6.0%) 










































































































































































































































































































































































































































































































































































































































































66 controls, 33 and 41 subjects in the no-relapse and relapse groups respectively 
completed the BIS/BAS measures. Table 11 showed the mean scores of BIS/BAS. 
No significant difference was observed in the BIS/BAS scores amongst the 3 
groups. 
3.3.3. SSS-V 
66 controls, 33 and 41 in no-relapse and relapse groups respectively completed the 
SSS-V measures. Table 11 showed the mean scores of SSS-V. There is no overall 
significant in SSS-V score amongst 3 groups although a significantly higher score 
for the disinhibition subscale was found in the relapse group when compared to the 
controls (P = 0.025; a = 0.696). A significantly higher score in the boredom 
susceptibility subscale was also found in the relapse group when compared to the 
no-relapse group {P = 0.041; OL= 0.373). 
3.4. Salivary Cortisol Levels 
Figure 10 showed the baseline salivary Cortisol levels of all subject groups recorded 
from 10 am to 5 pm on the day of CPT. 32 controls, 29 and 22 subjects from the 
no-relapse and relapse groups respectively provided valid salivary samples. CPT 
was performed at 12 noon and salivary Cortisol levels were measured 20 min after 
the test. Baseline salivary Cortisol levels were significantly higher (apart from 12:20 
pm) in the relapse group when compared to the no-relapse and control groups (10 
a m P < 0.0001; 12 a m P = 0.003; 3 p m P = 0.004; 5 p m P = 0.042). The change in 

























































































































































































































































































































































































































































































Figure 10. Baseline salivary Cortisol levels of control (n = 32), no-relapse (n = 29) 
and relapse (n = 22) groups from 10 am to 5 pm on the day of CPT are shown. CPT 
was performed at 12 noon and salivary Cortisol levels were measured 20 min after 
the test. All time points of the baseline salivary Cortisol levels of relapse group (apart 
from 12:20 pm) were significantly higher than those of no-relapse and control groups 
(Kruskal-Wallis test: 10 am P < 0.0001; 12 am 尸=0.003; 3 pm 尸=0.004; 5 p m P = 
0.042). Change in salivary Cortisol level after CPT was not significantly different 
among groups (Kruskal-Wallis test: P = 0.071). 
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3.5. Genotype and Allele Frequencies of Gene Polymorphisms 
3.5.1. MOR A118G Polymorphism 
Figure 11 and Table 12 shows the genotyping result of the MOR A118G 
polymorphism. 
Genotyping was performed on 168 controls, 35 ‘no-relapse，and 49 'relapse' subjects. 
The genotype distributions of control and heroin-dependent groups did not deviate 
from Hardy-Weinberg equilibrium (HWE). The allele frequencies of G allele in 
controls and heroin-dependent subjects were similar (32.7% vs 34.5%). No 
significant difference was observed in genotype and allele distributions between 
control and heroin-dependent subjects. However, the no-relapse group carried a 
relatively higher G allele frequency than the relapse group (41.4% vs 30.5%), which 
was due to a higher AG frequency (54.3% vs 34.7%) and a lower AA frequency 
(31.4% vs 53.1%; iable 12). 
3.5.2. DOR T921C Polymorphism 
Figure 12 and Table 13 show the genotyping result of the DOR T921C 
polymorphism. 
Genotyping was performed on 165 controls, 35 'no-relapse' and 49 ‘relapse’ subjects. 
The genotype distributions of control and heroin-dependent groups did not deviate 
from Hardy-Weinberg equilibrium (HWE) significantly. Heroin-dependent subjects > 
had similar C allele frequency to control subjects (26.1% vs 27.4%). No significant 
differences in genutype and allele frequencies were observed between control and 
heroin-dependent subjects, as well as among subject groups (Table 13). 
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Figure 11. Genotyping result of MOR A118G polymorphism on a 4% agarose gel. A 
50bp DNA ladder was loaded on the first lane on the left. A single 151bp represents 
homozygous AA, a single 129bp band represents homozygous GG and the presence 
of these two bands denotes heterozygous AG. 
50 bp 
DNA 
Ladder A A AG GG 
•
~ 151 bp 
« ~ 129 bp 
Table 12. Genotype and allele frequencies of MOR A118G polymorphism in control 
and heroin-dependent subjects. Number of subjects and percentage of subjects in 
each subject group are listed. The genotype distributions of both control and 
heroin-dependent groups did not deviate from Hardy-Weinberg equilibrium (HWE) 
significantly (Person's 七,P = 0.633 and 0.294 respectively). P values represent 
analyses (i) between control and heroin-dependent subjects; and (ii) between 
no-relapse and relapse groups (bolded value). No significant difference in genotype 
and allele distribution was detected in all comparisons. 
Genotype Frequency Allelic Frequency 
n ^ n ^ 
AA AG GG P A G P 
Control 79(47.0) 68(40.5) 21 (12.5) 226(67.3) 110(32.7) 
• Heroin-dependent 37(44.0) 36(42.9) 11 (13.1) 0.905 110(65.5) 58(34.5) 0.689 
No-relapse 11 (31.4) 19(54.3) 5 (14.3) 41 (58.6) 29(41.4) 
Relapse 26 (53.1) 17(34.7) 6(12.2) 0.131 69 (69.5) 29 (30.5) 0.112 
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Figure 12. Genotyping result of DOR T921C polymorphism on a 5% agarose gel. A 
50bp DNA ladder was loaded on the first lane on the left. A single 106bp represents 
homozygous TT, a single 82bp band represents homozygous CC and the presence of 
these two bands denotes heterozygous TC. 
50 bp 
DNA 
Ladder CC TC TT 
H
一 106 bp 
Table 13. Genotype and allele frequencies of DOR T921C polymorphism in control 
and heroin-dependent subjects. Number of subjects and percentage of subjects in 
each subject group are listed. The genotype distributions of both control and 
heroin-dependent groups did not deviate from HWE significantly (Person's = 
0.748 and 0.825 respectively). P values represent x^ analyses (i) between control and 
heroin-dependent subjects; and (ii) between no-relapse and relapse groups (bolded 
value). No significant difference in genotype and allele distribution was detected in 
all comparisons. 
Genotype Frequency Allelic Frequency 
n ^ r ^ 
TT TC CC P T C P 
Control 91 (55.2) 62(37.6) 12 (7.3) 244 (73.9) 86 (26.1) 
Her6in-dependent 46(54.8) 30(35.7) 8 (9.5) 0.817 122 (72.6) 46(27.4) 0.752 
• No-relapse 23 (65.7) 10(28.6) 2(5.7) 56 (80.0) 14(20.0) 
Relapse 23(46.9) 20 (40.8) 6 (12.2) 0.214 66(67.3) 32(32.7) 0.070 
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3.5.3. COMT Va”08/i58Met Polymorphism 
Figure 13 and Table 14 show the genotyping results of COMT Val^ ^^^^^^Met 
polymorphism. 
Genotyping was performed on 148 controls, 35 'no-relapse' and 49 ‘relapse，subjects. 
The genotype distribution of control and heroin-dependent groups did not deviate 
from HWE. The met allele frequencies of controls and heroin-dependent subjects 
were 26.0% and 25.6% respectively. There is no significant difference in genotype 
and allele frequencies between control and heroin-dependent subjects and amongst 
subject groups (Table 14). 
3.5.4. Prodynorphin 68bp-VNTR 
Figure 14 and Table 15 show the genotyping results of prodynorphin 68bp-VNTR. 
Genotyping was performed on 163 controls, 34 ‘no-relapse，and 49 ‘relapse’ subjects. 
The genotype distributions of both controls and heroin-dependent groups did not 
differ from HWE. Allele frequencies of 1-, 2-, 3- and 4-copy allele in control group 
were 1.2%, 86.2% 12.3% and 0.3%. The most common genotype in controls was 2/2 
(75.5%), followed by 2/3 (18.4%), while the frequencies of other genotypes (1/2, 3/3 
and 2/4) were lower than 5%. No significant differences in genotype and allele 
frequencies were observed between control and heroin-dependent subjects and 
. amongst subject groups (Table 15). 
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Figure 13.Genotyping result of COMT Val'^ ^^^^^Met polymorphism on a 4% agarose 
gel. A 50bp DNA ladder was loaded on the first lane on the left. A single 114bp 
represents homozygous val/val, a single 96bp band represents homozygous met/met 
and the presence of these two bands denotes heterozygous val/met. 
50 bp 
DNA 
Ladder met/met val/val val/met 
• 
~ 96 bp 
Table 14. Genotype and allele frequencies of COMT Val'^^^'^^Met polymorphism in 
control and heroin-dependent subjects. Number of subjects and percentage of 
subjects in each subject group are listed. The genotype distributions of both control 
and heroin-dependent groups did not deviate from HWE significantly (Person's 七.P 
=0.674 and 0.773 respectively). P values represent x^ analyses (i) between control 
and heroin-dependent subjects; and (ii) between no-relapse and relapse groups 
(bolded value). No significant difference in genotype and allele distribution was 
detected in all comparisons. 
Genotype Frequency Allelic Frequency 
n ^ 
val/val val/met met/met P val met P 
Control 82(55.4) 55(37.2) 11 (7.4) 219(74.0) 77(26.0) 
Heroin-dependent 46 (54.8) 33 (39.3) 5 (6.0) 0.888 125 (74.4) 43 (25.6) 0.921 
• No-relapse 21 (60.0) 12(34.3) 2(5.7) 54(77.1) 16(22.9) 
Relapse 25(51.0) 21 (42.9) 3(6.1) 0.709 71 (72.4) 27 (27.6) 0.492 
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Figure 14. Genotyping result of prodynorphin 68bp-VNTR polymorphism on a 3 % 
agarose gel. A 1 OObp DNA ladder was loaded on the first lane on the left. One, two, 
three and four copies of the 68 bp sequence are represented by bands of 273 bp, 341 
bp, 409 bp and 477 bp respectively. 
100 bp 
DNA 
Ladder 2/2 1/2 2/3 2/4 
•
^ ~ 477 bp 
^ ~ 409 bp 
^ 3 4 1 bp 
^ ~ 273 bp 
Table 15. Genotype and allele frequencies of prodynorphin 68bp-VNTR 
polymorphism in control and heroin-dependent subjects. Number of subjects and 
percentage of subjects in each subject group are listed. The genotype distributions of 
both control and heroin-dependent groups did not deviate from HWE significantly 
(Person's x^: P = 0.903 and 0.891 respectively). P values represent 受 analyses (i) 
between control and heroin-dependent subjects; and (ii) between no-relapse and 
relapse groups (bolded value). No significant difference in genotype and allele 
distribution was detected in all comparisons. 
Genotype Frequency n (%) 
1/2 2/2 2/3 3/3 2/4 ？ 
Control 4 (2.5) 123 (75.5) 30(18.4) 5 (3.1) 1 (0.6) 
Heroin-dependent 2(2.4) 61 (73.5) 19(22.9) - 1 (1.2) 0.498 
No-relapse - 27 (79.4) 6(17.6) - 1 (2.9) 
Relapse 2(4.1) 34(69.4) 13(26.5) - - 0.284 
• Allelic Frequency n (%) 
1 2 3 4 P 
Control 4(1.2) 281 (86.2) 40(12.3) 1 (0.3) 
Heroin-dependent 2(1.2) 144 (86.7) 19(11.4) 1 (0.6) 0.959 
No-relapse - 61(89.7) 6(8.8) 1(1.5) 
Relapse 2 (2.0) 83 (84.7) 13 (13.3) - 0.303 
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3.5.5. DRD2 Ta^I A Polymorphism 
Figure 15 and Table 16 show the genotyping results of DRD2 Taql A polymorphism. 
Genotyping was performed on 152 controls, 35 'no-relapse' and 49 'relapse' subjects. 
The genotype distribution of both control and heroin-dependent groups did not differ 
from HWE significantly. A2 allele was higher than that of Al in all subject groups 
studied. No significant difference in genotype and allele frequencies was observed 
between control and heroin-dependent groups and between no-relapse and relapse 
groups (Table 16). 
3.5.6. DRD4 -521C/T Polymorphism 
Figure 16 and Table 17 show the genotyping results of DRD4 -521C/T 
polymorphism. 
Genotyping was performed on 165 controls, 35 'no-relapse' and 49 ‘relapse’ subjects. 
In both control and heroin-dependent groups, genotype distribution deviated from 
HWE significantly (P < 0.0001 and 0.012). The results were genotyped again using 
the same protocol which confirmed the initial effect. All subject groups showed a 
higher T allele frequency. Although the T allele frequency of the heroin-dependent 
subjects (69.0%) was about 10% higher than that of the controls (59.7%), the 
difference only reaches marginal significance (Yate's x\i) = 3.778; P = 0.052). 
i 
102 
Figure 15.Genotyping result of DRD2 Taql A polymorphism on a 2% agarose gel. A 
lOObp DNA ladder was loaded on the first lane on the left. Homozygous A l A l is 
represented by a single band (309 bp), homozygous A2A2 is represented by two 
bands (180 bp and 128 bp), and heterozygous A1A2 is represented by the presence of 
all three bands. 
100 bp 
DNA 
Ladder AIM A1A2 A2A2 
B^ ~ 309 bp 
^ ~ 180 bp 
^ ~ 128 bp 
Table 16. Genotype and allele frequencies of DRD2 Taql A polymorphism in control 
and heroin-dependent subjects. Number of subjects and percentage of subjects in 
each subject group are listed. The genotype distributions of both control and 
heroin-dependent groups did not deviate from HWE significantly (Person's x^: P = 
0.326 and 0.351 respectively). P values represent 义 analyses (i) between control and 
heroin-dependent subjects; and (ii) between no-relapse and relapse groups (bolded 
value). No significant difference in genotype and allele distribution was detected in 
all comparisons. 
Genotype Frequency Allelic Frequency 
r ^ 
A l A l A1A2 A2A2 ？ K\ Kl ? 
Control 24(15.8) 80(52.6) 48(31.6) 128(42.1) 176(57.9) 
Heroin-dependent 15 (17.9) 36 (42.9) 33 (39.3) 0.345 66(39.3) 102 (60.7) 0.551 
‘ No-relapse 9 (25.7) 12(34.3) 14(40.0) 30 (42.9) 40(57.1) 
Relapse 6(12.2) 24 (49.0) 19(38.8) 0.211 36 (36.7) 62 (63.3) 0.423 
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Figure 16. Genotyping result of DRD4 -521C/T polymorphism on a 4% agarose gel. 
A 50bp DNA ladder was loaded on the first lane on the left. Homozygous CC 
resulted in a single band of 285 bp, two bands (176 bp and 109 bp) for homozygous 
TT and three bands (285 bp, 176 bp and 109 bp) for heterozygous CT. 
50 bp 
DNA 
Ladder T T C T C C 
^ ~ ~ 285 bp 
^ ~ 176 bp 
^ ~ 109 bp 
Table 17. Genotype and allele frequencies of DRD4 -521C/T polymorphism in 
control and heroin-dependent subjects. Number of subjects and percentage of 
subjects in each subject group are listed. The genotype distributions of both control 
and heroin-dependent groups deviated from HWE (Person's x^： P < 0.0001 and 0.012 
respectively). P values represent x^ analyses (i) between control and 
heroin-dependent subjects; and (ii) between no-relapse and relapse groups (bolded 
value). Compare to control group, heroin-dependent group had comparatively higher 
T variant allele frequency (P = 0.052). 
Genotype Frequency Allelic Frequency 
CC CT TT P C T P 
Control 45(27.3) 43 (26.1) 77(46.7) 133 (40.3) 197(59.7) 
Heroin-dependent 13(15.5) 26 (31.0) 45 (53.6) 0.114 52 (31.0) 116(69.0) 0.052 
• No-relapse 5(14.3) 13 (37.1) 17(48.6) 23 (32.9) 47(67.1) 
Relapse 8(16.3) 13(26.5) 28 (57.1) 0.583 29 (29.6) 69 (70.4) 0.778 
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3.5.7. 5HT1B G861C Polymorphism 
Figure 17 and Table 18 show the genotyping results of 5HT1B G861C 
polymorphism. 
Genotyping was performed on 158 controls, 35 'no-relapse' and 49 'relapse' subjects. 
The genotype distribution of both control and heroin-dependent groups did not 
deviate from HWE. The C variant allele frequencies of control and heroin-dependent 
subjects were similar (45.9% vs 48.2%). No significant differences in genotype and 
allele frequencies were observed between control and heroin-dependent subjects and 
amongst subject groups. 
3.6. Association of Gene Polymorphisms, Personality Traits and CPT 
Multivariate analyses were performed to study the association of CPT, gene 
polymorphisms and personality traits. Table 19 shows the backward linear regression 
models for CPT results (dependent variables: Ln[threshold], Ln[tolerance] and 
Ln[tol/thr]) using genotypes (all 7 genetic markers studied) and personality traits 
(neuroticism, extraversion, BAS total, BIS and SSS total) as predictors in control and 
relapse groups. The genotypes of all markers studied, apart from ProDYN, were 
denoted as 0 (wild-type homozygotes), 1 (heterozygotes) and 2 (variant 
homozygotes). ProDYNR 68bp-VNTR was denoted as 0 (short-allele carriers) and 1 
(long-allele carriers). > 
In the control group, only the regression model of Ln[threshold] was significant (厂(2) 
=3.737，P = 0.029，adjusted R^ = 0.075) with DRD4 -521C/T (standardized beta = 
-0.222, P = 0.063) and COMT Val^ ^^^^^^Met (standardized beta = 0.204, P = 0.086) as 
predictors. The models for Ln[tolerance] and Ln[tol/thr] were insignificant. 
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Figure 17. Genotyping result of 5HT1B G861C polymorphism on a 1.5% agarose gel. 
A lOObp DNA ladder was loaded on the first lane on the left. Homozygous GG 
resulted in a single band of 452 bp, two bands (310 bp and 142 bp) for homozygous 
CC and three bands (452 bp, 310 bp and 142 bp) for heterozygous GC. 
100 bp 
DNA 
Ladder C C G C G G 
452 bp 
^ 3 1 0 bp 
^ ~ 142 bp 
Table 18. Genotype and allele frequencies of 5HT1B polymorphism in control and 
heroin-dependent subjects. Number of subjects and percentage of subjects in each 
subject group are listed. The genotype distributions of both control and 
heroin-dependent groups did not deviate from HWE significantly (Person's j^'.P = 
0.381 and 0.505 respectively). P values represent 七 analyses (i) between control and 
heroin-dependent subjects; and (ii) between no-relapse and relapse groups (bolded 
value). No significant difference in genotype and allele distribution was detected in 
all comparisons. 
Genotype Frequency Allelic Frequency 
n (%) n (%) 
GG GC CC P G C P 
Control 49 (31.0) 73 (46.2) 36 (22.8) 171 (54.1) 145(45.9) 
Herdin-dependent 21 (25.0) 45(53.6) 18(21.4) 0.511 87(51.8) 81 (48.2) 0.625 
• No-relapse 9(25.7) 20 (57.1) 6(17.1) 38(54.3) 32 (45.7) 



















































































































































































































































































































































































































































































In the relapse group, Ln[threshold] was significantly predicted (F�=4.113, P = 
0.023，adjusted R^ = 0.113) by COMT Val^ ^^^^^^Met (standardized beta = 0.349，P = 
0.015) and ProDYN 68bp-VNTR (standardized beta = 0.269，P = 0.058). Ln[tol/thr] 
was significantly predicted (厂(3) = 6.596, P = 0.001，adjusted R^ = 0.255) by 
personality traits neuroticism (standardized beta = 0.334, P = 0.023), extraversion 
(standardized beta = -0.405，P = 0.020) and SSS total (standardized beta = 0.414, P 
=0.010). 
3.7. Association of Gene Polymorphisms and CPT 
3.7.1. COMT Var“38/i58Met Polymorphism 
Figure 18 shows the CPT results of various subject groups according to subjects' 
Val Met genotypes. No significant difference in all CPT outcomes among 
genotypes was observed within each subject group by one-way ANOVA. In the 
relapse group, Ln[threshold] of the vallval and val/met individuals was significantly 
lower than that of met/met individuals {P = 0.033). 
3.7.2. DRD4 -521C/T Polymorphism 
Figure 19 presents the CPT results of the three subject groups according to -521C/T 
genotypes. In the control group, one-way ANOVA showed the difference in 
Ln[threshold] amongst genotypes was marginally significant (Ln[threshold]: F = 
3.047，P = 0.054), but such difference was not observed in no-relapse and relapse » 
groups. In the control group, Ln[threshold] of the TT individuals was significantly 
lower than that of the CC and CT individuals (P = 0.016). 
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Figure 18.Mean (士2SE) Ln[threshold], Ln[tolerance] and Ln[tol/thr] of control, 
no-relapse and relapse groups classified according to Val^ ^^^^^^Met genotypes. No 
significant difference in these measurements among genotypes was observed within 
each subject group by one-way ANOVA. Ln[threshold] of the valNal and ml/met 
individuals in the relapse group was significantly lower than that of met/met 
individuals (Student's t test P = 0.033). 
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Figure 19. Mean (士2SE) Ln[threshold], Ln[tolerance] and Ln[tol/thr] of control, 
no-relapse and relapse groups classified according to DRD4 -521C/T genotypes. 
One-way ANOVA showed that the difference in Ln[threshold] amongst genotypes 
were marginally significant in control group (Ln[threshold]: F = 3.047，P = 0.054). 
Ln[threshold] of the TT individuals in control group was significantly lower than 
that of the CC and CT individuals (Student's t test P = 0.016). 
Control No-relapse Group Relapse Croup 
5 . 0 -
• Ln threshold 
• Intolerance 
H Ln tol/thr 
4 . 0 -
- t I 
‘ i 网 n rli 
3.0 — i Ii： ：：  { i l l i „ iji p i S ili i i Ni iij I J i^ i 
" i l l 1 , 1 [ 11 II 1。 III III III II [111 I III lll II 
1 < • • • . _ 1 • • • • • . • • • • . • • , 
I I I I 丨 1 1 1 1 1 , 
r j L l l J I . i l i JLiLI 
CC CT TT CC CT TT CC CT TT 
ultid'ncnsional facet approach towards the study of predictors of relapse. 
> 
110 
CHAPTER 4 DISCUSSIONS AND CONCLUSIONS 
This project aims to study in Chinese male heroin-dependent subjects, drug use 
pattern, cold-pain relapse, and gene polymorphisms related to heroin-dependence 
and comparing the difference between no-relapse and relapse cases. Further study 
also aims to explore any association in pain response and gene polymorphisms 
amongst the controls, no-relapse and relapse groups. We discovered that 
DRD4 -521C/7 ^nd COMT Val^ ^^ ^^ ^^ Met polymorphisms are associated with 
cold-pain response in controls and ‘relapse’ subjects respectively. These 
polymorphisms may influence the risk of relapse by predisposing distinct 
nociceptive response at various stages of opioid treatment. In addition, the relapse 
group showed significantly higher neuroticism and basal Cortisol levels. 
4.1. Demographics and Potential Environmental Factors of Relapse 
In the present study, most of our subjects originated from the Southern China. 
Nearly 85% of their parents originated from Guangdong province (Table 1). This 
homogeneity in population is an advantage to our genetic study which has a limited 
sample size as geographic stratification can be avoided. 
Distinct patterns of family/social relationship, residential, employment and financial 
status were observed between no-relapse and relapse groups. These factors may be a 
reflection of the adaptation of relapse prevention. 
The district in which the heroin-dependent subjects reside reflects not only the living 
standard but also indicates the accessibility of illegal drugs as well as methadone. In 
Hong Kong, areas with the busiest heroin-related activities are concentrated in 
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Kowloon. Hong Kong Central Registry of Drug Abuse (2005) reported that about 
26% of heroin abusers lived in Sham Shui Po (14.4%) and Yau Tsim Mong (11.8%), 
followed by Kwun Tong (10.7%) and Wong Tai Sin (7.5%). In the New Territories, 
Tuen Mun (9.6%) and Yuen Long (6.1%) ranked the highest. These areas provide 
mainly public housing and bunk-bed rentals. In the present study, the most reported 
districts of residence were Yau Tsim Mong and Sham Shui Po for 'relapse' subjects, 
and Tuen Mun for 'no-relapse' subjects (Table 2). Although most of the 
heroin-dependent subjects were living in public housing, there were more 
‘no-relapse’ subjects living in family- or self-owned estates compared to the 'relapse' 
subjects (Figure 1). This difference in housing pattern showed that the ‘relapse’ 
subjects continue to live in an environment where heroin is readily available and may 
contribute to increase chances of relapse. It is suggested that the relocation to a 
"heroin-cleaner" district may be beneficial to ex-heroin users for the maintenance of 
abstinence, and the improvement of living condition may also protect them from 
heroin-related activities. 
Family and social relationship is crucial for the maintenance of well-being in the 
ex-heroin addicts. Harmonious social relationship encourages communication 
between these subjects with the society. Family support has been shown to be 
successful in improving treatment retention and maintaining opioid abstinence 
(Carroll et al, 2001; Fals-Stewart and O'Farrell, 2003). Poor family and social 
relationship imposes stress on these subjects, which in turn can lead to their return to 
heroin use as an escape from their problems. In our study, the relapse group when 
compared to the no-relapse group showed a lower satisfaction level in marital status 
(32% vs 56%), and had a higher divorce rate (26% vs 11%). The majority of 
‘no-relapse，subjects reported spending their free time with family and friends (81%) 
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while most of the 'relapse' subjects chose to spend their free time alone (56%). 
Despite similar percentage of subjects reported ever having relationship problems 
with their next of kin (parents, partner and/or children) in both heroin-dependent 
groups, the incident rate of having any relationship problem in the past 30 days was 
twice as many in the relapse group than in the no-relapse group (12% vs 5.6%). 
Thus, the present data indicates that ‘no-relapse’ subjects have a comparatively 
better family and social relationship than 'relapse' subject, suggesting that this factor 
is valuable in the prevention of relapse. However, it should be noted that most 
‘no-relapse，subjects (72.2%) were living in rehabilitation centres or halfway houses, 
and were allowed to return home on a regular basis, this policy implied that these 
subjects had less time to spend with family members with whom they had problems 
with and hence there are less opportunities for stressful conflict situations. 
Furthermore, the more structured life in these rehabilitation environments prevents 
conflicts. Therefore, a controlled environment provides additional benefits in 
offering a stable interpersonal setting for ex-heroin addicts who are undergoing a 
period of heroin abstinence. 
Employment and financial status directly affects the quality of life of heroin addicts, 
it also influences family relationship and reflects the risk of illegal activities. 
Employment history of ex-heroin addicts may reflect on the chances of employment 
after returning to the society. Both unemployment and idleness may also induce 
relapse due to financial stress and lack of self-esteem. The present data showed that 
more than 60% of heroin-dependent subjects were unemployed (Figure 3) and were 
receiving CSSA from the government. There are more subjects in the no-relapse 
group who are in this "employment and financial" category (Figure 4), which may 
explain their on-going participation in some form of treatment. A greater number of 
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'relapse' subjects made their living through illegal activities or through borrowing 
money from family or friends (Figure 4). There are also more skilled manual workers 
(e.g. chefs, electricians, tailors, hair-stylists) in the no-relapse group whilst subjects 
in the relapse group consists more of semi-skilled workers (e.g. truck drivers, waiters, 
watchmen) and unskilled workers (e.g. illegal activities, messengers, cleaners, 
construction workers) (Figure 5). Although the current data do not suggest that 
subjects with no-relapse history would be more marketable after leaving the 
treatment programme because their marketability depends on the skill they acquired. 
It is postulated that subjects from the relapse group, which comprised of more 
semi-skilled or unskilled workers, may put them at a higher relapse risk since they 
may have a higher chance of unemployment and may have to depend on illegal 
activities, usually selling heroin or other illegal drugs to make a living. Vocational 
training and counselling may improve their chance of employment and thus decrease 
their risk of relapse. 
4.1.1. Medical and Psychological Status 
The ASI medical composite score assesses the patient's recent medical conditions 
and the need for immediate or further medical treatment. 
Despite 22% of all heroin-dependent subjects reported having various long-term 
illnesses, only 8% of all heroin-dependent subjects reported experiencing medical 
problems for more than 15 days in the previous month, indicating that most of the 
long-term disease patients had received adequate medical care and their conditions 
were already stabilized. 
The ASI medical composite scores of both heroin-dependent groups were low, 
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indicating that their medical condition, at least perceived by themselves, was not 
significantly affecting their daily lifes. The ASI medical composite score of the 
no-relapse group was significantly higher than that of the relapse group which 
suggested that the 'no-relapse' subjects had more severe recent medical conditions 
than the 'relapse' subjects. There are more 'no-relapse' subjects reported having 
hepatitis B or C compared to 'relapse' subjects. There are no reports of subjects 
having AIDS or being a carrier of HIV. This self-report given by the ‘no-relapse， 
subjects may not necessarily reflect the real situation with heroin users in general 
since hepatitis and HIV status will not undetected unless they enter a detoxification 
programme. Those who undergo detoxification will receive medical attention and 
their health conditions are constantly monitored by the rehabilitation centres or by 
the out-patient clinics. Subjects may also try to conceal their disease status in order 
to prevent embarrassment. 
Although ASI is not designed for psychiatric diagnosis, the self-report “emotional 
experience" provides insight to the need of psychiatric care to these patients. In the 
present study, the most common psychological problem experienced by 
heroin-dependent subjects was depression, which is reported by Ross et al (2005) as 
one of the major psychiatric co-morbidities in heroin users. Other problems include 
psychiatric distress, attempted suicide and post-traumatic stress disorder. It was also 
shown that major depression is associated with suicide attempts among heroin users 
(Darke et al., 2004) and female heroin users are more likely to have major 
depressive episode than their male counterparts (Teesson et al., 2005). Depressive 
condition can hinder the progress of opioid treatment (Havard et al, 2006), thus 
clinicians are advised to provide depression treatment for their heroin-dependent 
patients. Clinicians are also reminded of the potential depression-induced side effect 
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of naltrexone in opioid treatment, although this claim remains controversial with 
positive and negative reports (Ritter, 2002). 
Opioid treatments have been shown to lower the rate of current major depression in 
heron users (Havard et al., 2006). The present data coincide with this trend as 
subjects in the no-relapse group has a lower ASI psychiatric composite score and 
there is a lower percentage of subjects experiencing emotional problems including 
depression in the past 30 days when compared to subjects in the relapse group. 
4.1.2. Substance Use Status 
The heroin-dependent subjects showed that they have tried all listed substances of 
abuse. However, the most currently consumed drugs apart from heroin are alcohol 
and tranquillizers in both the no-relapse and relapse groups. In the no-relapse group, 
there was a decline in the use of alcohol and cigarettes, even a cessation of 
tranquillizer use, this could be attributable to the continuing participation of 
rehabilitation programmes. It was apparent that during the period of detoxification 
and rehabilitation that there is a declined use of opioids, tranquillizers and other 
party drugs (e.g. ‘ecstasy，，ketamine) from the past 12 months to the past 30 days. 
The augmented use of alcohol during heroin abstinence should be cautioned as 
ex-heroin users may fall into alcoholism although only two subjects were also 
shown to be alcoholics. A few subjects mentioned about such high alcohol 
consumption could be reduced if they relapsed back to heroin. This suggests that 
some ex-heroin users may use alcohol as a substitute for their heroin addiction. 
The use of tranquillizers (mainly triazolam/midazolam) together with heroin is the 
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most common in Hong Kong (Central Registry of Drug Abuse 54th Report, 2005). 
Triazolam/midazolam abuse increases dramatically from 1995 to 2004，now ranks 
second in the list of most commonly abused psychotropic drugs in Hong Kong 
(Central Registry of Drug Abuse 54th Report, 2005). Triazolam/midazolam is a CNS 
depressant that produces hypnotic effects and is used for insomnia treatment. 
Midazolam is also used in ultra-rapid opioid detoxification with opioid antagonists 
(e.g. naltrexone) to put the patient into deep sedation during acute withdrawal 
(Lorenzi et al., 1999). However, these drugs are addictive and have been reported to 
produce delirium, memory impairment and transient global amnesia (Bixler et al, 
1991). Withdrawal symptoms of these drugs include insomnia, tremor, perspiration, 
dysphoria and perceptual disturbances (Tsoi, 1991). Recent animal studies showed 
an interaction between opiate and benzodiazepine. Walker et al (Walker and 
Ettenberg, 2001) demonstrated in rats that a single dose of the benzodiazepine, 
alprazolam, potentiated the rewarding properties of a low dose of heroin which was 
unrewarding by itself. Moreover, a later study by the same group showed that the 
administration of an unrewarding alprazolam dose with an unrewarding bilateral 
intra-VTA heroin dose resulted in a significant conditioned place preference, 
suggesting VTA may be the site in which such an interaction takes place (Walker 
and Ettenberg, 2005). 
In the present project, heroin-dependent subjects reported the motivations for 
abusing triazolam/midazolam include poor quality of street heroin, wanting to 
reduce the amount of heroin use, wanting to obtain other effects not experienced by 
using heroin alone or wanting to lengthen the effects of heroin. Nearly 15% of 
subjects considered triazolam/midazolam as the drug that caused major health 
problems instead of heroin. Their most concerned problem was the unawareness of 
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committing bodily harm acts whilst undergoing the strong sedative effects of this 
drug. Since triazolam/midazolam was injected intravenously with heroin, adulterants 
in these drugs became particularly hazardous to the users. 
4.1.3. Detoxification and Relapse 
Motivation for detoxification treatment has been shown to predict retention in 
methadone treatment (Joe et al., 1998)，long-term residential rehabilitation 
programmes (DeLeon G et al., 1997) and post-discharge opiate abstinence (Murphy 
et al., 2003) by measuring the participant's readiness for treatment, their desire to 
stop using the substance, and their confidence in resisting the urge of heroin use 
outside treatment. In the present study, subjects in the no-relapse group 
demonstrated a higher average number of detoxification attempts and a higher 
percentage of voluntary detoxification participation than subjects from the relapse 
group. Moreover, there were more ‘no-relapse’ subjects reported to have their 
longest period of opioid abstinence that exceeded one year than ‘relapse’ subjects; 
their longest period of abstinence being 8 years. These observations may be 
explained by their higher motivation, but others factors including genetics and 
environmental factors should also not be discounted. It seems from the present study 
that heroin addicts who are highly motivated towards detoxification-approached 
drug treatment more frequently are able to maintain longer drug abstinence than 
those with lower motivation regardless of their drug use history. 
> 
Despite the importance of motivation in treatment outcome, relapse may not be 
prevented just by high motivation alone, psychological and environmental factors 
contribute to the induction of relapse as well. In the present study, the most common 
reason of relapse is craving, followed by peer influence, idleness, life stresses, lack 
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of detoxification intentions, and finally intolerable tolerance symptoms. This result 
suggests that psychological dependence is the strongest inducer of relapse, followed 
by environmental factors and the least influential being physical dependence. 
However, the stage of detoxification, the period of abstinence, and the mode of 
detoxification should also be considered in the assessment of relapse risk. 
The mode of detoxification may influence the treatment outcome. We grouped 
detoxification into three modes: (1) imprisonment/compulsory detoxification 
programme (compulsory detox) administered through the criminal justice system; (2) 
voluntary hospitalization/detoxification programme (voluntary detox) which is 
mainly voluntary but some are recommended by the criminal justice system; and (3) 
self-arranged detoxification (self-arranged detox), whose participation in detox 
programmes are either self-motivated or family-motivated. Craving was the most 
common reason of relapse in all detoxification modes, the percentage of craving 
declined if subjects fell into the voluntary or self-arranged detox programmes. Peer 
influence ranked the second for the compulsory detox group but ranked last for 
those in the voluntary detox mode. Life stresses is the most reported reason of 
relapse in both the voluntary detox and self-arranged detox groups, indicating that 
environmental factors such as interpersonal relationships and employment status 
could have a significant impact on ex-heroin addicts, triggering relapse during 
stressful life situations. Physical discomforts caused by withdrawal symptoms 
induced relapse occur mostly in voluntary detox participants and less so in other 
detox modes. This shows that different risk factors for relapse may be associated 
with different detoxification modes. 
To further elucidate whether the length of abstinence may be correlated to the 
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various factors that contribute to the risk of each relapse, we divided the cases 
according to their modes of detoxification into long-term ( > 6 months) and 
short-term abstiner^ce (< 6 months). Results showed that compulsory detoxification 
long-term abstainers (sustained at least 6-month abstinence) are less susceptible to 
craving-induced relapse, but are more sensitive to peer influence and idleness. As 
the participation of this type of detoxification programme is compulsory, 
participants are expected to lack self-motivation for detoxification, thus the effects 
of psychological dependence treatment were not prominent. Peer influence seems to 
play a major role in the risk of relapse when subjects are released from a more 
controlled environment like a prison. Subjects have a tendency to meet with other 
inmates or friends and schedule their heroin use together. 
In the voluntary dotox group, long-term abstainers who have stopped using heroin 
for at least 6 months are more susceptible to relapse due to life stresses when 
compared to short-term abstainers (Table 8). Surprisingly, subjects from this mode 
of detoxification were more vulnerable to physical discomforts than those from the 
self-arranged detox group which lacks professional medical care as these 
detoxifications are organized at the subject's home or during vacation. In the 
self-arranged detox group, ex-heroin users had a lower risk of craving-induced 
relapse after the first 6 months of abstinence. However, at this stage of abstinence, 
they are more likely to relapse under life stresses. Although craving is the major 
reason of relapse in these two types of voluntary detoxification, its impact is 
relatively less r-OLipared to that in the compulsory detox group, supporting the 
argument that the mode of detoxification is an important factor in relapse prediction. 
Life stresses become a significant factor that induces relapse in voluntary and 
self-arranged detoxifications. Stress management programmes and counselling 
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service may therefore help prevent relapse. 
4.2. Cold-Pressor Test (CPT) 
CPT measures the sensitivity and tolerance of the subjects towards cold stimulus, 
which is a method thought to mimic pain of chronic diseases (Rainville et al, 1992; 
Mitchell et al., 2004). In opioid addiction studies, CPT has been widely used to 
assess pain response in opioid addicts and controls. It was shown that opioid addicts 
had higher hyperalgesia towards cold-pressor stimulation but not towards electrical 
stimulation (Doverty et al., 2001a; Athanasos et al., 2006). In the present study, 
heroin-dependent subjects also mentioned feeling frightened to touch cold water 
during detoxification and thus would prevent taking a cold shower. These results 
suggest that heroin addicts are particularly sensitive to cold stimuli, thus CPT is a 
resourceful method to estimate pain sensitivity and tolerance in heroin-dependent 
subjects. 
Chronic opioid users were shown to have increased cold pain threshold (Pud et al” 
2006) and decreased cold pain tolerance than controls regardless of the acute effects 
of opioids (Compton et al., 2000; Compton et al., 2001; Doverty et al., 2001a; Pud et 
al, 2006). Acute morphine dependence can induce a decrease in cold pain tolerance 
in healthy controls after precipitating withdrawal by naloxone (Compton et al., 
2003a). These results suggest both chronic and acute opioid dependence can result in 
hyperalgesia, which may be a factor leading to repetitive opioid consumption in 
order to prevent the elevation of pain sensitivity. Our data concurred with these 
results in showing the lowest tolerance and pain tol/thr ratio in ‘relapse’ subjects, 
that is, those who were current heroin users (Figure 9). However, our 'relapse' 
subjects had presented a higher pain threshold than control subjects, this is in 
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agreement with that reported by Pud et al (Pud et al., 2006) although it is contrast to 
that reported by Doverty et al (2001a). They reported methadone-maintained 
patients having a significantly lower cold pain threshold compared to control 
subjects, this threshold level was elevated 3 hours after the daily methadone dosage, 
indicating that pain response is influenced by plasma opioid concentration. Our 
‘relapse’ subjects did not show any signs of withdrawal and were instructed to take 
their last heroin or methadone dose for at least 4 hours or 16 hours respectively 
before the test, thus their CPT performance should reflect the cold pain response at 
their typical daily plasma opioid concentration, i.e. not in an opioid-flooded or 
-deprived state. Thus, the relatively higher pain threshold observed in the subject of 
the relapse group may be due to the effects of chronic heroin exposure and not due 
to effects of meiiiaclone in the blood stream. 
The biological basis for the opioid-induced hyperalgesia was postulated by White 
(2004) to be the inappropriate tonic neuronal discharge in neurons that originates in 
MOR-rich region in the medulla that facilitates pain perception through a 
descending pathway, resulting in inappropriate pain sensitivity. This hypothesis was 
supported by a number of animal studies, for example, opioid-induced hyperalgesia 
could be blocked by the inactivation of rostral ventromedial medulla and 
dorsolateral funiculus (Vanderah et al, 2001; White, 2004); mice lacking MOR did 
not develop opioid-induced hyperalgesia (Li et al” 2001); and morphine-induced 
hyperalgesia could be blocked by naloxone (Mao et al., 2002; White, 2004). 
In the present study, pain tol/thr ratio was significantly increased as relapse state 
improved, implying that the net pain tolerance of former opioid users was restored 
towards the level of controls as abstinence continues (Figure 9). However, whether 
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this restoration of antinociception is due to resumption of the CNS opioid system or 
the participation of other analgesic systems cannot be verified in this study. 
Liebmann et al (1997) conducted CPT on a group of ex-heroin addicts who had 
maintained opioid abstinence for an average of 8 months, they observed that these 
subjects had a significantly higher pain threshold than controls which could not be 
reversed by naltrexone. The authors suggested the persistent analgesia observed in 
ex-addicts might be caused by the activation of non-opioid mechanism to 
compensate for the dysfunctional opioid pain suppression system. Nevertheless, Pud 
et al (2006) demonstrated that chronic opioid users who abstained from opioid for 
28 days did not differ in cold-pressor pain onset latency and tolerance when 
compared to those who abstained on for 7 days or more before detoxification. These 
contrasting results imply that change in pain response of ex-opioid addicts depends 
on the length of opioid abstinence. The present finding is in contrast to Liebmann et 
al (1997) ing no significant difference in pain response between 'no-relapse' 
subjects and controls. This may be due to genetic factors or ethnic differences. This 
will be discussed in section 4.5. 
4.3. Personality Traits 
In the present study, ‘relapse’ subjects showed significantly higher neuroticism 
scores than control subjects, particularly in the depression, self-consciousness, 
impulsivity, vulnerability and anxiety (marginally significance only) subscales 
(Table 10). Conversely, in the extraversion facet, the 'relapse' subjects scored 
significantly lower in warmth and positive emotions, and presented a relatively 
lower overall extraversion score. This is in agreement with a previous report 
showing ‘relapse’ subjects having a neurotic-introverted personality when compared 
to abstainers (Verachai et al.，2003). For ‘no-relapse，subjects, apart from depression, 
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all other scores in the NEO PI-R were not significantly different to those of controls. 
Neuroticism relates to negative coping styles such as withdrawal, hostile reactions, 
sedation, escapist fantasy while extraversion relates to positive styles such as 
positive thinking, rational action and seeking help (McCrae and Costa, Jr., 1986). As 
substance misuse is also considered as a negative coping style, the personalities 
displayed by our 'relapse' subjects seemed to be favourable to a negative coping 
style. Ex-heroin addicts who are more neurotic and less extroverted in personality 
may adopt a more negative style to cope with their life stressors (e.g. finance, family 
and health), thus increasing their risk of relapse. Compare to 'relapse' subjects, the 
'no-relapse' subjects were less neurotic and more extraverted although their 
socio-economic conditions were similar, thus the present result suggests that 
neuroticism and extraversion personality traits may determine the risk of relapse. 
In BIS/BAS, only a marginal significance was observed in BAS reward 
responsiveness in which the relapse group scored higher than the other groups 
(Table 11). Higher scores in this inventory represents higher disagreeableness to the 
corresponding traits, therefore, ‘relapse，subjects tend to be less responsive to 
rewards than both controls and ‘no-relapse，subjects. 
In SSS, ‘relapse’ subjects were showing significantly higher levels of disinhibition 
and boredom susceptibility than controls and ‘no-relapse’ subjects (Table 11). High 
disinhibition may explain the high tendency of antisocial behaviour, while high 
boredom susceptibility may provide explanation to why idleness (mainly due to 
unemployment) becomes a factor of continuous drug consumption and relapse. 
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4.4. Salivary Cortisol 
Cortisol is a hormone released from the adrenal medulla to signal alertness and to 
prepare for "fight or flight” under stressful conditions. Its effects include changing 
metabolic processes such as enhancing gluconeogensis, adopting acute stress 
responses such as increasing heart rate, damping immune activity, and altering CNS 
functions. Stress regulation is one of the key factors for many psychiatric diseases. 
Dysregulation of Cortisol has been shown to be related to psychiatric diseases such 
as depression (Steckler et al, 1999; Parker et al., 2003), post-traumatic stress 
disorder (Lindley et al., 2004) and alcoholism (Sher et al., 2006). It was shown in 
both human and animal studies that both chronic and acute use of opioids imposes 
significant effect on the hypothalamic-pituitary-adrenal (HPA) axis, a component of 
the stress-response system. In human, acute or initial opiate use suppresses the 
stress-response systems whereas chronic opiate administration causes a continuous 
suppression of the HPA axis (Kreek, 2002). Both endogenous opioids and the MOR 
system had been shown to play important roles in HPA axis modulation (Kreek, 
2002). Kreek et al (1984) reported a dramatic increase in adrenocorticotrophic 
hormone (ACTH; a pituitary hormone that stimulates the secretion of Cortisol) level 
in heroin abstainers without treatment compared to a mild increase in 
methadone-maintained heroin abstainers which was similar to normal subjects. This 
normalization effect on HPA axis by chronic use of long-acting opioids such as 
methadone had been shown in many studies as well (Kreek, 2002). 
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Stress response is intriguing in substance abuse as it contributes to 
self-administrat'op of drugs of abuse, including opiates, alcohol and cocaine. 
Clinical studies revealed that stress-induced emotional states, for example anxiety, 
neuroticism and nervousness, were positively related to the latency of opiate relapse 
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(Powell et al, 1993; Liebmann et al, 1998). Moreover, other stress-related factors 
such as withdrawal symptoms, depression, insomnia and uncontrolled pain can also 
contribute to the relapse risk of dependence (Jones et al., 2003). Acute stressful 
responses can be provoked by just imagining or describing craving experiences 
which subsequently triggers stress-induced relapse mechanisms (Weinstein et al, 
1997; Sinha et al., 2003b). 
In the present study, the baseline salivary Cortisol level from 10 am to 5 pm was 
significantly higher in ‘relapse’ subjects than no-relapse and control subjects by 
nearly 0.2 /ig/ml, whereas no significant difference was found between no-relapse 
and control subjects. Tennant et al (1991) reported a low Cortisol level in the 
daytime while a high level was observed in the evening. In contrast to this report, 
the present results showed a continuous elevated daytime Cortisol level in the relapse 
group. This discrepancy could be due to the difference in measurement time range 
and drug-taking schedule. Moreover, some of the patients had tapered their opioid 
use prior to the experiment to prepare for detoxification, thus their Cortisol level 
might be elevated thus affecting the group mean. Psychological factors might also 
influence Cortisol level, for example hypercortisolism was found in depressed 
patients (Parker et al., 2003). Although only a small percentage of our 'relapse' 
subjects claimed to be receiving psychiatric treatment prior to this study, our 
personality trait study revealed that these subjects were more depressed overall. 
Nonetheless, the present data were in accordance with the theory of the suppression 
of the HPA axis response resulting from chronic opioid consumption. Since the 
CPT-induced Cortisol change in the ‘relapse’ subjects was comparatively lowered 
than that of the no-relapse group, this suggests chronic opioid use encourages 
continue consumption in the easing of pain-induced stress. 
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4.5. Association of Gene Polymorphisms, Personality Traits and Cold-Pressor Test 
4.5.1. MOR Al 18G Polymorphism 
Bond et al (1998) showed that MOR A118G polymorphism caused the lost of a 
putative N-glycosylation site and the binding affinity for jS-endorphin of the G 
variant receptor was three times higher than the A wild-type. This SNP is frequently 
studied in predisposition for heroin, nicotine and alcohol addiction. In a recent study 
conducted by Zhang et al (2005), the functions of A118G on MOR gene expression 
were revealed. mRNA expression and MOR protein level of G allele was 1.5 fold 
and 10 fold lower than the substitution of adenosine, cytosine and thymine at 118 
position, indicating that the G allele is a functional variant with deleterious effect on 
both mRNA and protein yield of MOR. A118G was recently shown by Drakenberg 
et al (2006) to be associated with the expression of preproenkephalin and 
prodynorphin. ihe mRNA levels of these opioid neuropeptide precursors were 
prominently down-regulated in the brains of G allele carrying heroin subjects with 
increased dynorphin and enkephalin concentrations when compared with their 
homozygous A counterparts, suggesting A118G may influence peptide processing of 
these opioid neuropeptides. 
Various population studies had evaluated the association of MOR A118G with 
heroin addiction, the G allele frequency in controls is ranged from 1.6% - 48.6%, 
amongst different ethnic groups. A higher G frequency was observed in Hispanic 
(Bond et al.，1998), Indian (Tan et al, 2003)，Chinese (Szeto et al., 2001) and 
Caucasian European (Drakenberg et al, 2006) heroin-dependent subjects than their 
ethnic-match controls. Szeto et al (2001) previously reported a significant different 
{P = 0.016) G frequency of 29.4% in control and 39.5% in heroin-dependent 
subjects in a Hong Kong Chinese population that is significantly different. Tan et al 
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(2003) also reported a higher G frequency in Chinese heroin-dependent subjects 
(35.1%) than Chinese controls (29.8%) of a Singaporean population. The G allele 
frequency of overall heroin-dependent subjects (34.5%) observed in this study is 
similar to controls (32.7%). However, these results should be interpreted cautiously 
as the sample size is limited. 
The significant role of MOR in opioid-induced analgesia was clearly demonstrated 
in knockout mice studies (Matthes et al, 1996; Sora et al, 1997a; Sora et al” 1997b; 
Kitanaka et al” 1998). Mice homozygous for MOR knockout exhibited no heroin or 
M6G analgesia (Kitanaka et al., 1998). Previous clinical studies associated MOR 
118G allele with decreased potency of morphine and M6G, with decreased analgesic 
effects and higher alfentanil dose demand (Lotsch et al, 2004). This suggests A118G 
may influence the effectiveness of analgesia imposed by both endogenous and 
exogenous opioids. Compton et al (2003b) attempted to evaluate the relationship 
between A118G and opioid dependence in terms of thermal/mechanical-stimulated 
pain, but due to the lack of G carrier patients, the group failed to detect any 
association with p^in tolerance and opioid addiction. Although with a larger sample 
size and higher sample G frequency, we were also unable to detect any significant 
difference in cold-pressor pain responses among A118G genotypes in both 
univariate and multivariate analysis. Thus, the present data do not suggest an 
association between MOR A118G and cold-pressor pain response. However, one 
should be reminded that endogenous opioid level may be augmented in brains of G 
carriers (Drakenberg et al” 2006) to replenish the scarcity of MOR as G allele 
down-regulates its expression (Zhang et al., 2005)，thus the net analgesic effects of 
G and non-G carriers may not differ significantly. 
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4.5.2. DOR T921C Polymorphism 
DOR T921C was reported by Mayer et al (1997) to be associated with heroin 
addiction in a German population as a significantly higher C allele and CC 
homozygote frequencies were observed in heroin addicts. However, in this study, no 
significant difference was detected in genotype and allele frequencies of DOR 
T921C between controls and heroin-dependent subjects. In a larger scale population 
study, Xu et al (2002) also observed no difference in genotype distribution and allele 
frequency between 304 controls and 450 heron-dependent subjects in a Southwest 
Han Chinese population. The allele frequencies of control subjects reported in our 
study (T: 73.9%, C: 26.1%) are similar to their results (T: 77%, C: 23%). Therefore, 
it can be concluded that T921C is probably not associated with heroin dependence in 
Southwest and Southeast Han Chinese populations. 
For CPT response, significant difference in pain tol/thr ratio was observed and is 
significantly correlated to T921C genotypes in the no-relapse group with a decrease 
in pain tol/thr ratio correlated with an increased dose of C allele. These results 
suggest that T921C is associated with cold-pain tolerance in opioid abstainers; 
however, since these differences were not observed in the control group, this 
polymorphism may impose its effects only during recovery of the opioid system. 
Furthermore, this result needs to be confirmed using a larger sample size. 
The effects of T921C on DOR functions and expression are uncertain. Since T921C > 
is a silent SNP (Mayer et al., 1997), it should not impose a conformational change 
on DOR protein structure, but it is possible that other DOR SNPs in linkage 
disequilibrium (LD) with T921C may collectively result in such differences in pain 
response. It had been shown in animal studies that DOR-induced analgesia is 
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dependent on its interaction with MOR (Sanchez-Blazquez and Garzon, 1989; Sora 
et al., 1997a; Matthes et al., 1998; Scherrer et al., 2004). Analgesic effect of DOR 
agonists was weakened in MOR knockout mice (Sora et al., 1997a; Matthes et al., 
1998). A recent finding of enhanced morphine intrathecal analgesia in mice by 
heterodimerization of DOR and MOR demonstrates the role played by DOR in 
facilitating opioia-mediating analgesia (Gomes et al., 2004). Therefore, 
polymorphisms in MOR which are in linkage disequilibrium with T921C may be 
responsible for the present findings. 
4.5.3. COMTValio隱Met 
COMT Valio8/i58Met is a functional SNP that causes a 3-to-4 fold reduction in 
COMT activity (Lachman et al., 1996) and hence affects the DA availability in brain. 
The “high，，activity val allele was associated with polysubstance (Vandenbergh et al., 
1997) and methamphetamine abuse (Li et al., 1997), while the “low，，activity met 
allele was associated with alcoholism (Kauhanen et al., 2000; Wang et al., 2001). 
1 AOyi CO 
The correlation between COMT Var_MMet and heroin dependence remains 
unclear, only one family-based study reported an excess val allele in heroin addicts 
(Horowitz et al., 2000)，however, this could not be observed in case-control studies 
(Horowitz et al, 2000; Cao et al., 2003). In accordance with these case-control 
1 AO/I CO 
studies, we also did not observe any significant difference in COMT Val Met 
genotype and allele frequencies between control and heroin-dependent subjects in 
the" present study. It may be difficult to detect significant difference due to the 
presence of a high val allele frequency in the “ Chinese population. Our results 
showed a control val allele frequency of 74% which is similar to that reported by 
Wan (2004), which was focused on Hong Kong Chinese youths (73%). 
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The present CPT data suggested an association between Val Met and cold-pain 
response. Multiple regression detected Val'^ ^^ ^^ ^Met as the only significant predictor 
for pain threshold in the relapse group (standardized beta = 0.349; P = 0.015), 
suggesting that met allele elevates cold-pain threshold only under chronic opioid use. 
Although it did not reach statistical significance, a similar trend in pain tolerance 
was observed in the relapse group (Figure 18). These results are in contrast to that 
reported by Zubieta et al (2003), in which they reported that the met allele was 
related to lower pain tolerance, higher pain related sensory and affective ratings, and 
reduced /^-opioid system activation. It was proposed that chronic activation of 
dopaminergic tnnrmission, due to low COMT activity, reduced enkephalin level in 
the brain which in turn up-regulated MOR concentration in various brain regions. 
Thus, the analgesic effect induced by low COMT activity would be lower since less 
enkephalin was present to activate the MOR system. However, a later clinical study 
on cancer pain patients observed a significantly lower morphine requirement for 
pain relieve in met/met patients than in val/val patients, which was explained by the 
increased MOR density in met/met individuals enhancing the effectiveness of 
morphine effect (Rakvag et al., 2005). Therefore, a possible explanation for the 
present observation in relapse group could be that the MOR availability in met 
carriers is higher even after exogenous opioid occupancy, hence upon pain 
stimulation, mere ’moccupied MOR are left for endogenous opioids to exert their 
analgesic effects. 
» 
The postulation of Zubieta et al (2003) was challenged by a recent post-mortem 
human brain study conducted by Berthele et al (2005), which demonstrated that the 
mRNA expression of preproenkephalin, the precursor protein of enkephalin, was 
significantly higher in met/met homozygotes in the striatum despite the MOR 
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binding site in these individuals was significantly higher in the striatum and 
thalamus as observed by Zubieta et al. This result suggests that enkephalin may not 
be the direct link between COMT function and MOR expression, other endogenous 
MOR ligands may contribute to this effect. Moreover, another pain study with a 
larger sample size and mixed ethnicity failed to demonstrate the involvement of 
COMT Valio8"58Met in pain sensitivity (Kim et al, 2004b). The authors attributed 
this discrepancy to the difference in pain induction method (cold-pressor vs injection 
of hypertonic saline into masseter muscle) and in the duration of pain generation. 
COMT activity provide partial explanation to the development of substance abuse 
related personality traits since other molecules, such as monoamine oxidases (MAOs) 
and dopamine receptors, are also involving in the dopaminergic system regulation. 
Reuter et al (2006) recently reported significant interactions amongst COMT 
Vali08/i58Met and DRD2 Taql A polymorphisms with BAS. va/- /Al- and va/+/Al+ 
carriers were scoring higher in total BAS score. They suggested that these subjects 
had a disequilibrium between DA catabolism and dopamine receptor density, which 
resulted in an elevated DA activity and in turn a heightening of positive emotions. In 
addition to DA, other neurotransmitter systems such as 5-HT and NA are likely to 
take part in the construction of addiction-related personalities. For example, 
Benjamin et al (2000) reported in the presence of COMT val/val genotype and long 
serotonin transporter promoter region (5-HTTLP), a higher score in novelty seeking 
of TPQ was observed in subjects who carried DRD4 seven-repeat allele than those 
who did not. Therefore, with the present results, which only include COMT 
Va”08/i58Met，should be subjected to further interaction analyses with other SNPs 
and with an increased sample size. 
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4.5.4. Prodynorphin (ProDYN) 68bp-VNTR 
Down-regulation of preprodynorphin expression was observed in post-mortem 
heroin addict brains (Drakenberg et al., 2006), implying that the level of dynorphin, 
the product of ProDYN, may be crucial in the development of opioid dependence. 
Acute exposure to morphine in rat brain elicited an increase of preprodynorphin and 
KOR expression (Wang et al, 1999). The candidate polymorphism, ProDYN 
68bp-VNTR, was suggested to cause a difference in promoter activity:�50% 
increase in expression was observed in 3- and 4-repeat alleles than 1- and 2-repeat 
alleles (Zimprirh ot al., 2000). However, there was no association observed in a 
German population between heroin addicts and controls (Zimprich et al., 2000). The 
present data are consistent with this report with no significant difference in genotype 
and allele frequencies found among all three subjects groups. Our frequencies of 
1+2 and 3+$ alleles are similar to the controls reported in a Japanese population 
(1+2: 86%; 3+4: 14%) (Nomura et al., 2006). However, our sample has a higher 2/2 
genotype frequencies when compared to the Japanese population (74% vs 65%). In 
contrast, when compared to Americans of European, African and Hispanic ancestries 
reported by Chen et al (2002), our sample has a much lower 3+4 allele frequency 
(14% vs 63%) and 3/3 genotype frequency (3.1% vs 44.2%). This observation 
suggests that this polymorphism is significantly different across ethnicity. 
Although the present data did not support the involvement of this polymorphism in 
heroin addiction, it was shown to be related to other substances of abuse, including > 
cocaine (Chen et al, 2002; Dahl et al” 2005) and methamphetamine (Nomura et al., 
2006). Moreover, other SNPs in the ProDYN gene may participate in the process. 
For instance, Yuferov et al (2004) discovered a novel SNP in human KOR that had 
to have a point-wise significant association with opioid dependence status, but no 
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further study has been conducted to explore its function. 
Since the sample Jze is limited in our study, subjects were categorized into two 
groups: those who carried at least one 3- or 4-repeat allele were classified as the 3/4 
group, and the rest who carried only short alleles (1- or 2-repeat allele) were 
classified as the 1/2 group, for the analysis of CPT result and personality traits. 
Within group comparison showed that long (3/4) and short (1/2) allele groups did 
not differ significantly in their CPT results. Thus, it can be concluded that this 
polymorphism may not contribute to cold-pressor responses in controls and in 
heroin-dependent subjects. 
Despite failing to observe any association between ProDYN 68bp-VNTR and 
cold-pressor pain, x-opioid system is still a major participant in the regulation of 
antinociception. Simonin et al (1998) demonstrated in a KOR knockout mice study 
that the lack of KOR would result in heightened sensitivity to chemical visceral pain 
but remained unchanged to thermal and mechanical stimuli. Morphine withdrawal 
syndromes were also less severe in mutant mice, implying that /c-opioid system is 
playing a substantial role in mediating opioid withdrawal. 
4.5.5. DRD2 Ta^ I A Polymorphism 
Taql A polymorphism is located in the 3'-untranslated region of DRD2 gene, and 
causes a substitution of glutamate to lysine at 713 amino acid residue in another 
» , 
gene, ANKKl, which is 9.5kb downstream to DRD2 gene. Its biological function is 
uncertain, but A1+ is suspected to cause lower DRD2 brain density than Al— 
(Thompson et al, 1997; Pohjalainen et al., 1998; Jonsson et al., 1999). Due to this 
potential functionality, Taql A polymorphism has been speculated to associate with 
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substance abuse/dependence, including alcoholism, opioids (Shahmoradgoli et al., 
2005)，cocaine (Noble et al., 1993) and polysubstance use (O'Hara et al., 1993). 
In the present study, no significant difference in genotype and allele frequency was 
observed between controls and the heroin-dependent group. However, this 
conclusion is challenged by the limited sample size. In accordance to other studies in 
Han Chinese in Taiwan (Lu et al” 1996; Chen et al., 1997; Tsai et al., 2002), 
Southwest (Li et al, 2002; Xu et al., 2004) and Southeast China (Szeto, 2000), the 
present data also did not observe any significant difference in Taql A genotype and 
allele distributions between heroin users and controls. It should be noted that the 
genotype and allele frequencies reported in these studies are distinct from each other, 
which may be explained by difference in geographic locations, difference in 
male/female ratio and difference in subjects' heroin addiction severity (i.e. abuse or 
dependent) and opioid abstinence state. Despite the lack of difference in genotype 
and allele frequencies between control and heroin users, there are some studies that 
support the A1+ allele being related to opioid addiction severity, including poorer 
treatment outcome (Lawford et al., 2000), higher opioid consumption 
(Shahmoradgoli et al., 2005), and stronger cue-elicited heroin craving (Li et al, 
2006). Thus, A1+ may have a stronger association phenotype such as heroin 
addiction severity and the risk of relapse than the predisposition of heroin 
dependence itself. 
> . 
In CPT, Taql A polymorphism demonstrated a potential effect in the no-relapse 
group. Pain threshold and tolerance of A1+ 'no-relapse' subjects were similar to 
those of ‘relapse，subjects, and were lower than their A l - counterparts. This 
observation implies Al allele is related to the inhibition of pain sensitivity reduction 
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during long-term ofioid abstinence. It also suggests that Al allele may be a predictor 
of relapse. 
Taql A polymorphism was postulated to be associated with pain modulation due to its 
potential influence on DRD2 density in the human brain (Thompson et al., 1997; 
Pohjalainen et al., 1998; Jonsson et al” 1999). Hagelberg et al (2002) demonstrated 
in a group of healthy Finnish subjects that DRD2 binding potential of certain brain 
areas was negatively correlated with cold-pressor pain threshold and tolerance. The 
authors concluded that fewer available DRD2 in the forebrain is likely to have a high 
tonic level of pain suppression. Combining these empirical results with the potential 
function of Taql \ polymorphism, it is speculated that A1+ may cause higher 
cold-pressor pain threshold and tolerance due to lower DRD2 binding potential. 
However, the present data did not suggest A1+ affects cold-pressor pain response on 
healthy controls. Such deviation may be due to the ethnicity difference in the study 
samples since frequency of A1+ heroin-dependent subjects is 60.4% in our study, 
whereas it is 96.3% and 49% reported in German (Xu et al., 2004) and Iranian 
(Shahmoradgoli et al, 2005). In fact, all in vivo DRD2 binding potential studies 
related to Taql A polymorphism included primarily Caucasians, mostly Finnish. 
There was only one study conducted in the United States, which included 50 
European American, 16 African American and one Asian participants, however, it 
objected the Al al' l^e influence on DRD2 density in the human brain (Laruelle et al, 
•1998). This contrasting result implies the expression of the proposed Al biological 
effect depends on ethnicity, and the significant findings reported previously may be 
caused by linkage disequilibrium between this polymorphism and some major 
genetic contributors to DRD2 expression in certain ethnics only. For example, 
another DRD2 intronic SNP, Taql B, was reported to be associated with heroin 
136 
addiction in Southwest Han Chinese (Xu et al., 2004). B1 allele is associated with 
lower DRD2 density in brains of healthy volunteers (Jonsson et al., 1999). Moreover, 
Taql A was found to be responsible for an amino acid change in the ANKKl gene. A 
recent study conducted by Fossella et al (2006) reported that A1+ carriers show 
gene-associated functional activation in an anatomically specific, dopamine-rich 
region of the brain comprising the anterior cingulate gyms and suspected linkage 
disequilibrium between the two genes. 
Although the relationship between Taql A polymorphism and human brain DRD2 
density remains uncertain, the potential role of DRD2 on pain control should not be 
overlooked. This relationship was demonstrated in both in vivo animal and human 
studies. Magnusson and Fisher (2000) reported DRD2 antagonists in dorsolateral 
striatum increased formalin-induced nociception while agonists decreased such 
nociception in rats. Hagelberg et al (2002) observed a negative correlation between 
human DRD2 binding potential in striatum and cold-pressor pain threshold by PET 
scan. It should be noted that binding potential could be influenced by receptor 
density and binding site availability, i.e. low receptor binding potential could be due 
to high basal DA level. Laruelle et al (1997) reported that endogenous DA occupies 
in vivo about 20% of DRD2, thus basal DA level may impose error in the in vivo 
DRD2 receptor density estimation with PET or single photon emission computerized 
tomography (SPECT). Endogenous DA level must be taken into account in the in 
vivo study to distinguish the effect of DRD2 on receptor density. If basal DA level 
was the major effector to cause lower DRD2 binding potential in the study of 
Hagelberg et al (2002), then both animal and human studies suggest the activation of 
DRD2 system may reduce nociception. 
137 
Liebmann et al (1997) reported ex-heroin addicts display persistent cold-pressor 
pain analgesia that cannot be reverse by naltrexone, suggesting the endogenous 
opioid system is malfunction whereas the non-opioid analgesic system is evoked. In 
a later study, the group observed a higher risk of early relapse in pain sensitive 
ex-addicts compared to their pain insensitive counterparts (Liebmann et al” 1998). 
The authors propose that the non-opioid mechanism may fail to completely 
compensate for the dysfunction of opioid pathways in these patients, hence leading 
to the observed higher early relapse rate. DRD2 has been shown to participate in 
non-opioid analgesia. For example, histogranin, a peptide that disperses in various 
rat tissues including brain, can induce antinociception in mouse tail-flick assay in 
the presence of naloxone, but not in the presence of raclopride, a DRD2 antagonist 
(Ruan et al., 2000). Base on these findings, if the present observation is confirmed, it 
would suggest that Al allele may be an early relapse risk factor as it may predispose 
a deficiency in the non-opioid system, in turn causing an incapability of 
compensating the dysfunctional endogenous opioid system after heroin withdrawal. 
4.5.6. DRD4 -521C/T Polymorphism 
T allele of DRD4 -521C/T polymorphism has been shown to reduce transcription 
efficiency of the DRD4 gene (Okuyama et al., 2000). Correlations between this 
polymorphism and personality traits, particularly novelty seeking, were found in 
various ethnic groups such as the Japanese, Hungarian (Ronai et al., 2001)，African 
Americans (Bookman et al, 2002), Korean (Lee et al., 2003), and Russian 
> 
(Golimbet et al., 2005) populations. Due to this, -521C/T became a candidate gene 
for psychiatric diseases, including alcoholism, schizophrenia, mood disorders, and 
substance dependence across many nations. 
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In the present study, marginal significant difference in allele frequencies of -521C/T 
was observed between heroin-dependent and control subjects {P = 0.052). 
Heroin-dependent subjects had a higher T allele frequency (69.0%) than control 
subjects (59.70/0)，with a shift of genotype frequency from CC (control vs 
heroin-dependent: 27.3% vs 15.5%) to TT (control vs heroin-dependent: 46.7% vs 
53.6%). Similar genotype and allele frequencies were observed between no-relapse 
and relapse groups. Therefore, the present results suggest this polymorphism may be 
associated with heroin dependence but not with relapse state. However, the genotype 
frequency of both the control and heroin-dependent subjects deviated from HWE. 
We genotyped the same samples again although DNA sequencing should be 
performed; however, we still obtained the same results. Possible reasons for this 
deviation include: (1) genetic drift due to small sample size; (2) presence of other 
alleles due to mutation which could not be detected by the present genotyping 
method; and (3) migration of the heroin-use population, e.g. Guangdong province 
where living standard is lower and cheaper heroin can be obtained. With the current 
study, the most likely reason being small sample size. A larger sample size will 
minimize the effect of genetic drift. 
Previous studies reported contrasting results. A previous study in a Southwest 
Chinese population did not observe any association between -521C/T and heroin 
dependence (Li et al., 2000). Another study reported heroin-dependent group had 
higher CC homozygotes, and this association is strengthened under the control of 
5-HTTLPR genotype (Szilagyi et al., 2005). Thus, the present data should be 
confirmed with a larger sample size. Furthermore, linkage disequilibrium between 
-521C/T polymorphism and other polymorphisms should also be addressed in future 
investigations. 
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In the present study, a marginal significant association was also observed 
between -521C/T and pain threshold of control subjects in multivariate regression 
(standardized beta = -0.222，P = 0.063), suggesting that their pain threshold decreased 
as the dose of C allele decreased. Non-C control carriers (i.e. TT homozygotes) 
displayed a significantly lower pain threshold than C carriers in the same group (P = 
0.016), implying C allele may be responsible for reducing cold-pain sensitivity in 
normal Chinese males (Figure 19). However, such phenomenon was not found in the 
no-relapse and relapse groups. 
DRD4 is the most abundant D2-like receptor in the prefrontal cortex and is localized 
in GABAergic intemeurones (Mrzljak et al, 1996). Activation of DRD4 inhibits 
GABA neurotransmission in the striatal-pallidal area, hippocampus, hypothalamus, 
supraoptic nucleus and the subthalamic area (Shin et al., 2003; Azdad et al., 2003; 
Floran et al, 2004; Baimoukhametova et al” 2004; Romo-Parra et al., 2005) which is 
likely to be mediated through GABAA receptors (Wang et al, 2002; Asaumi et al, 
2006). It was shown that in the nucleus raphe magnus, a major nucleus of pain control, 
an antagonist of GABAA receptors can reduce morphine-induced analgesia in normal 
rats but not in morphine-tolerant rats (Ma and Pan, 2006), this result suggests that 
GABAA agonist contributes to morphine-induce analgesia which becomes 
desensitized under chronic opioid use. Although DRD4 distribution in theismajor 
nuclei of pain control remains to be explored, we propose that DRD4 activation may 
‘ 'suppress GABA neurotransmission which in turn may trigger analgesia, and chronic 
sensitization of this system may promote the development of opioid tolerance. T allele 
of DRD4 -521C/T is related to lower transcription of DRD4 gene (Okuyama et al” 
2000). Therefore, lower DRD4 availability under T carrying status may lead to 
uninhibited GABA neurotransmission that hinders the production of analgesia. The 
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present data on genetics and cold-pain response supported this hypothesis as 
heroin-dependent subjects have a higher T allele frequency and did not display any 
difference in CPT response among genotypes, whereas pain threshold of control 
subjects decreased as T allele dosage increased. 
4.5.7. 5HT1B G861C Polymorphism 
5HT1B G861C is a silent polymorphism which had been associated with receptor 
binding in brain (Huang et al., 1999). In brains of suicides victims with major 
depression and alcoholism, it was found that the mean 5HT1B receptor binding sites 
reduced by about 10% (Huang et al., 1999). These results suggested a potential 
physiological mechanism for G861C association with antisocial behaviour in 
alcoholism (Lappalainen et al., 1998; Hasegawa et al., 2002; Soyka et al, 2004) as 
well as substance abuse and major depression (Huang et al, 2003). However, so far, 
there was no report on its association with heroin. 
The present result did not support an association between 5HT1B G861C and heroin 
dependence as no significant difference in genotype and allele frequencies among 
subject groups and between controls and heroin-dependent subjects was observed. 
The association between this polymorphism and CPT responses was not supported 
by the current results as well. 
G861C heterozygotes have been reported to have lower 5HT1B receptor binding 
than GG homozygotes in postmortem human brain (Huang et al, 1999), which may 
be caused by a lower level of 5HT1B expression. However, this proposed 
physiological effect is still illusive as too few CC homozygotes were included and 
postmortem measurement of biomolecules can be affected by many experimental 
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factors, thus it should be ascertained by in vivo studies. Since G861C is a synonym 
SNP, it has been suggested that it is in linkage disequilibrium with SNPs in the 
promoter region which actually cause the effect. Duan et al (2003) observed a 
difference in transcription activity between haploytypes, which consist of three 
5HT1B SNPs in its promoter region (-261T/G, -161A/T and -181ins/del). Two of 
these SNPs, -261T/G and -161A/T, were found to be in linkage disequilibrium with 
G861C in a European ancestry with the capability of modifying transcription factor 
binding. This report implies future association study should include haploytype of 
these SNPs with G861C in various populations for validation of G861C function. 
4.5.8. Personality Traits 
Personalities play significant roles in pain perception. Many chronic pain studies 
observed a higher neuroticism in chronic pain patients than in controls (Stembach 
and Timmermans, 1975; Johansson et al., 1979; Wade et al., 1992a; Wade et al., 
1992b; Affleck et al, 1992; Ramirez-Maestre et al, 2004; Asghari and Nicholas, 
2006). Pain-related variables such as pain sensitivity, pain sensation intensity, pain 
unpleasantness and suffering, have been shown to be related to high neuroticism as 
well (Asghari and Nicholas, 2006). In contrast, higher extraversion was associated 
with higher pain tolerance (Russo et al, 1997; Ramirez-Maestre et al., 2004; 
Ferracuti and De, 2005). It was postulated that neuroticism and extraversion are 
linked with pain perception and response through the determination of stress-coping 
strategies (Hewitt and Flett，1996). Neuroticism is related to the choice of coping » * 
strategies that may result in poor stress adaptation (e.g. catastrophizing), hence is 
related to higher perceived pain intensity. On the contrary, extraversion is associated 
with the choice of coping strategies that may result in better adaptation (e.g. 
expressing their situation to others), thus associated with lower perceived pain 
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intensity (Ramirez-Maestre et al., 2004). 
In the present study, ‘relapse，subjects displayed the highest neuroticism and lowest 
extraversion with the lowest pain tol/thr ratio. This result supports that 
neurotic-introverted personality being associated with more vigorous pain response. 
Surprisingly, when focusing on the relapse group solely, a positive correlation was 
observed between neuroticism and pain tol/thr ratio (standardized beta = 0.334，P = 
0.023) while a negative correlation was observed between extraversion and pain 
tol/thr ratio (standardized beta = -0.405, P = 0.020) in multivariate analyses. This 
contradicting result may be explained from a physiological aspect. Lower 
neuroticism was found in physically active men with lower plasma basal 
iS-endorphin level (Lobstein et al., 1989). Lower neuroticism was also related to 
lower CSF jS-endorphin level in chronic pain patients with higher SSS score 
(Johansson et al., 1979). These reports suggest the high /3-endorphin level associated 
with high neuroticism could be a compensating mechanism to overcome the 
increased pain sensitivity by providing extra analgesia. Therefore, this mechanism 
may explain the positive correlation between neuroticism and pain tol/thr ratio in 
'relapse' subjects. 
Apart from neuroticism and extraversion, SSS total score was also found to be 
positively correlated with pain tol/thr ratio in the multivariate regression model 
(standardized beta = 0.414，P = 0.010). The correlation between sensation seeking 
and pain response had been demonstrated in clinical studies. A higher SSS score was 
related to better pain adaptation in schizophrenics (Watson and Jacobs, 1977) and a 
lower SSS score was observed chronic pain patients (Johansson et al., 1979) and 
headache sufferers (Ginsburg and Pollack-Fels, 1991). Define by Marvin Zuckerman, 
sensation seeking is a trait involving "the seeking of varied, novel, complex, and 
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intense sensations and experiences, and the willingness to take physical, social, legal, 
and financial risks for the sake of such experience，，(Donohew and Bardo, 2001). 
Zuckerman (1994) stated that high sensation seekers tend to be less pain sensitive, 
which may be explained by their insensitivity to unconditioned punishment, such as 
pain, and they are less actively in avoiding danger. Moreover, high sensation seeking 
is related to substance abuse (Dervaux et al, 2001; Wagner, 2001) and hence may be 
a potential relapse factor even they may endure pain better during opioid withdrawal. 
4.6. Limitations 
Due to small sample size, the comparisons of genotype and allele frequencies could 
only obtain 50% power (calculated by Genetic Power Calculator (Purcell et al.’ 
2003)) to distinguish a 10% significant difference (a = 0.05) in allele frequencies. To 
augment the power to 80%, about 150 cases and 300 controls are required. Due to 
the time limitation of this study and the extensive time spent on each subject in data 
collection, such a large sample size is not possible at the moment. 
It was argued that the difference in personality traits (neuroticism, extraversion and 
sensation seeking) between subjects from the relapse and no-relapse groups might 
be influenced by opioid use in the relapse subjects, thus the present result failed to 
demonstrate certain personality traits would lead to earlier relapse. Costa and 
McCrae (2006)，however, stated that the age-related change of personality were 
modest after 30 years of age in which environmental influences and biologically 
based intrinsic maturation play more a role prior to this age. Costa et al (2005) 
reported that the scores in neuroticism, extraversion, openness, and 
conscientiousness of depression patients who responded to treatment differed before 
and after the treatment. These findings supported that despite the stability of 
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personality traits in adulthood, personalities are still subjected to change by 
psychiatric diseases and therapeutic intervention. Therefore, our subjects should be 
followed-up at different stages of abstinence (e.g. before detoxification, just after 
detoxification, 1 month, 3 months and 6 months after detoxification) to determine 
change in personality related to relapse. 
Since our prime consideration with this study is the difference in relapse status, we 
have obtained subjects whose prime diagnosis is heroin dependence. We excluded 
subjects who had any psychiatric comorbidity. Some psychiatric illnesses, for 
example, schizophrenia and depression are associated with drug dependence. These 
psychiatric illnesses also share some gene variants, like COMT and DRD2 alleles 
with substance abuse. Thus, the exclusion of psychiatric comorbidity may limit the 
full analysis of the current data. 
4.7. Potential Clinical Application 
The cold-pain hyperalgesic resopnse observed in the relapse subjects suggests that 
continued use of opioids, including the synthetic opioids for maintenance therapy 
such as methadone and buprenophine, fails to resume the antinociception 
mechanism that alleviates chronic pain in heroin addicts; as a result, this may 
augment their vulnerability to relapse. This suggests that pain management in 
maintenance therapy is as important as in detoxification in treating heroin addiction. 
> 
The contribution of persoanlity traits in pain response of heroin addicts was 
demonstrated in the present study. This is in agreement to that reported by Verachai 
et al (2002), which reported that high neuroticism and low extraversion predicted 
higher relapse risk in heroin-dependent patients. In addition, our study also suggests 
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that sensation seeking maybe another personality trait that will influence pain 
response. Heroin addicts with lower sensation seeking tendency may require pain 
management since they are more hyperalgesia Practitioners may want to take these 
factors into account in their pain management programmes of heroin addicts. 
Abstinence is always a challenge for substance abusers. Life stresses were shown to 
play an important role in long-term abstinence. This suggested that long-term stress 
management may be needed during in follow-up treatment. Demographic data 
revealed that these life stresses were mainly originated from poor family relationship 
and unemployment, thus family and employment counselling should relief some of 
these problems and prevent relapse. 
4.8. Conclusion 
To conclude, the present study shows that 'relapse' subjects were displaying distinct 
cold-pain response, personality traits and Cortisol baseline level. Genotype and allele 
frequency analyses showed there are no associations between MOR A118G, DOR 
T921C, COMT Vail鎖58Met，drd2 Taql A, DRD4 -521C/T, 5HT1B G861C and 
1 A C / 1 
heroin dependence and/or relapse. However, COMT Val Met was shown to 
correlate with cold-pain threshold level in ‘relapse’ subjects, suggesting the 
modulation of cold-pain sensitivity is the result of the interaction between this SNP 
and opioid use. In addition, DRD4 -521C/T may also participate in cold-pain 
•sensitivity of normal individuals. Furthermore,- high neuroticism, low extraversion 
and high sensation seeking personality traits were shown to be associated with high 
cold-pain tol/thr ratio in the ‘relapse，subjects. These results demonstrate that these 
genetic factors and personality traits can play crucial roles in modulating cold-pain 
response, particularly under chronic opioid use. It seems that pain response during 
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APPENDIX 1 
A D D I C T I O N S E V E R I T Y I N D E X ( A S I ) | 
W I T H A D D I T I O N A L Q U E S T I O N S F O R H E R O I N U S E R S _ _ 
, � T PART II FAMILY HISTORY PART I GENERAL INFORMATION 
Province of origin of . . . 
� Name: (12)Your father: 
(2) Sex: n M a l e • F e m a k (13)Your paternal grandfather: 
(14) Your paternal grandmother: 
(3) Date of Birth: • • / • • / • • 懷 麵 
(15)Your father's education level: ~ 
(4) Home district: —— 1-None 
2 = Primary 
(5) Which kind of housing are you living in? 口 3 = Se^cond^ 
1 = Temporary housing 5 = others (Please specified: ) 
2 = Rented bunk 
4 二 二hfaO二ifg (Rented) (16)Your father's present employment status: U 
5 = Private housing (Owned) 1 = Full-time 
6 = Home Owning Scheme housing 2 = Part-time 
7 = Others (Please specified: ) 3 = Unemployed 
4 = Retired 
(6) How long have you been living in your current address? 5 = Others (Please specify: _ _ ) 
I II L Y R S . P I IMOS. 6 = Deceased 
f7�n . 广.. Province of origin of... � � P r o v i n c e of ongin: 
(17)Your mother: 
(8) Your education level: U (18)Your maternal grandfather: 
1 = Primary (19)Your maternal grandmother: 2 = Secondary (F.1-F.3) 
r = = i 二二 - ) F . 7 ) (20)Yourn.other'seducation level: 口 
5= University l=None 
6 = Others (Please specified: J 2 = Primary 
3 = Secondary 
(9) Religious preference U �：^^^(‘：。specify: ) 
1 = None 
3 = 二 二 (21)Your mother's present employment status: [ 
4 = Buddhism I = Full-time 
5 = Daoism 2 = Part-time 
6 = Islamic 3 = Housewife 
8 = Others (Please specified: J 4 = Retired 5 = Others (Please specify: f 
(lO)Have you been in a controlled environment in the past 30 6 = Deceased 
days? l—J � 
l = N o n e 4 0 1 2 ( 2 2 ) Y o u r p a r e n t s ' m a r i t a l s t a t u s : l r , 
2 = Jail (If both are deceased, refer to the status before the first one 
3 = Alcohol or Drug Treatment passed away) 
4 = Medical Treatment 1 = Unchanged 
5 = Psychiatric Treatment 2 = Separated 
6 = Others (Please specified: ) 3 = Divorced 
4 = Remarried 




(23)Have any of your relatives had psycho problem, smoking, drinking, gambling or drug using habit? Does this habit cause any 
problem which requires treatment? 
0 = ‘No’ for this relative in this category 
1 = 'Yes' for this relative in this category, but treatment is/was not required 
2 = ‘Yes，for this relative within this category and treatment is/was required or should have been needed 
X = Uncertain/I don't know 
Father's Side 
Smoking Alcohol Gambling Drugs (Specify) Psych (Specify) 
Grandmother _ _ _ _ _ _ 
Grandfather _ _ _ _ _ _ _ _ 
Father — _ _ _ _ 
Aunt — _ 
Uncle — — — _ _ 
Mother's Side 
Smoking Alcohol Gambling Drugs (Specify) Psych (Specify) 
Grandmother _ 
Grandfather — — — . 
Mother — _ 
Aunt _ _ 
Uncle I I I I I I I I [ 
Siblings 
Smoking Gambling Alcohol Drugs (Specify) Psych (Specify) 
Brother 1 _ — _ — _ 
Brother 2 _ — — _ _ 
Sister 1 • • 口 • | 
Sister 2 _ — _ — — 
^ART III FAMILY/SOCIAL RELATIONSHIPS 
(咖our marital status: 口 (27)Usual living arrangements (past 3 yrs.) [ 
1 = Married 4 = Separate 1 = With sexual partner and children 
2 = Remarried 5 = Divorced 2 = With sexual partner alone 
3 = Widowed 6 = Never married 3 = With children alone 4 = With parents 
(之5)How long have you been in this marital status? 5 = With family 
(If never married, since age 18) 6 = With friends 
‘ I I I v m~~k/f 7 = Alone 
u u Y rs.LJLJM0S. 8 = Controlled environment 
‘ 9 = No stable arrangement 
、奶)Are you satisfied with this situation? | | Q (28)How long have you lived in these arrangements? 1 = Indifferent (Ifmth parents or family, since age 18) 2 = Yes |~~|r~lYrs.nr~]Mos. 
(29)Are you satisfied with these living arrangements? _ 
0 = No 
1 = Indifferent 
2 = Yes 
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(30)DO you live with anyone who: (36)Did any of these people abuse you: 
0 = No 1 =Yes A �T , 、， In 
~ 0 = No 1 = Yes Past 30 your Has a current alcohol problem? _ days life ~ a. Emotionally (make you feel bad through ~ ~ Uses non-prescribed drugs? U harsh words)? U U ~ b. Physically (cause you physical harm)? • [ (31)With whom do you spend most of your free time: _ 
1 = Family c. Sexually (force sexual advances or sexual 一 一 
2 = Friends acts)? 
3 一 i^ lone 
(37)How many days in the past 30 have you had serious (32)Are you satisfied with spending your free time this way? 1 = Yes 
0 No a. With your family? [ 1 = Indifferent __ 
2 = Yes b. With other people? (excluding family) [ _ 
(33)HOW many close friends do you have? • For questions (38) and (39)，please ask 
patient to use the patient's rating scale 
Direction for (34) to (36): 
0 = ‘No’ for all relatives in this category (3S)How troubled or bothered have you been in the past 30 days 
1 = 'Yes' for any relative within this category by these: 
X = Uncertain/I don't know a. Family problems [ 
(34)Would you say you have had close, long lasting, personal b. Social problems \_| 
relationships witih any of the following people in your life: 
0 = No 1 = Yes (39)//bw important to you now is treatment or counselling for 
a. • Mother these: 
b. • Father a. Family problems • 
c. • Brothers/Sisters b. Social problems [ 
d. • Sexual Partner/Spouse INTERVIER SEVERITY RATING 
e. • Children __ (40)How would you rate the patient's need for family and/or f. Friends . , „. „ ~ social counselling? __ 
(35)Have you had significant periods in which you have ^ „ � … ‘ J . 1 Confidence Ratings experienced senous problems getting along with: 
In 
0 = No 1 = Yes Past 30 your (41)Is the above information significantly distorted by: 
days life 0 = No 1 = Yes 
a. Mother Q Patient's misrepresentation? \ _ 
b Father Patient's inability to understand? [ 
c. Brothers/Sisters • [ 
d. Sexual partner/spouse • [ 
e. Children 口 [ 
f. Other significant family member 
(Specify: , ) ~ ~ 
8- Close friends _ — 
h. Neighbours 一 — 
i. Co-workers — — 
！ 
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For questions (54) and (55), please ask 
PART IY EMPLOYMENT/SUPPORT STATUS patient to use the patient's rating scale 
(42)Do you have a profession, trade or skill? • (54Wow troubled or bothered have you been by these 
0 = N o 1 = Yes (Specify: _ ) employment problems in the past 30 days? U 
(43)Do you have a valid driver's license? • {55)How important toyou now is counselling for these 
0 = No 1 = Yes employment problems? 
(44)Do you have an automobile available for use? • TNTFPVTFT^ SF.VF.RTTY RATING 
(Answer 'No'if no validdriver 's license) 。讽 ^ould you rate the patient's need for employment 
0 = No 1 = Yes \ counselling? ~~ 
(45)How long was your longest full-time job? 
• • Y r s . IMOS. Confidence Ratings 
|—I (57)ls the above information significantly distorted by: 
(46)Usual (or last) occupation 0 = No 1 = Yes 
Patient's misrepresentation? • 
(Specify in detail) 厂 Patient's inability to understand/ I__I 
(47)Does someone contribute to your support in anyway? | _ 
0 = No 1 = Yes 
(ONLYIF (47) IS'YES') 
(48)Does this constitute the majority of your support? L 
0 = No 1 = Yes 
(49)Usual employment pattern, past 3 yrs. I— 
1 = Full-time (40 hrs/wk) 
2 = Part-time (regular hrs) 
3 = Part-time (irregular, daywork) 
4 = Student 
5 = Service 
6 = Retired/disability 
7 = Unemployed 
8 = In controlled environment 
(50)How many days were you paid for working in the past 30? 
(include "under the table “ work) |_Jl_|Days 
(51)How much money did you receive ixom the following 
sources in the past 30 days? 
a. Employment (net income) 
b. Comprehensive Social Security $••，••• 
I Assistance (CSSA) ， 
c. Mate, family or friends 口 口 口 
(Money for personal expenses) ‘ 
d. Insurance , 
e. Illegal $••，••• “ 
(S�How many people depend on you for the majority of their 
food, shelter, etc.? L 
(幻)iiow many days have you experienced employment 
problems in the past 30 days? • u D a y s 
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PARTV MEDICAL STATUS PART VI LEGAL STATUS 
(58)How many times in your life have you been hospitalized for (68)Was this admission prompted or suggested by the criminal 
medical problems? justice system Gudge, probation/parole officer，etc.)? 
(Include o.d. 's, d.t. 's, exclude detox) • • D a y s 0 = No l=Yes L 
(59)HOW long ago was your last hospitalization for a physical (69)Are you on probation or parole? I 
problem? I IVrs.l iMos. ago 0 = No 1 = Yes 
( 6 0 ) D O you have any chronic medical problems which continue (70)How many times in your life have you been arrested and 
to interfere with your life? charged with the following: 
0 = No • a. Shoplifting/vandalism | || 
1 = Yes (Please specify: ) b. Parole/probation violations | || 
(61)Are you taking any prescribed medication on a regular basis c. Drug charges ——II——I 
for a physical problem? 丄 Forgery |""“||~ 
0 = No 1 =Yes • 從 门门 e. Weapons offence 
(62)DO you receive a pension for a physical disability? (Exclude f. Burglary, larceny, B & E I II 
psychiatric disability) g. Robbery •口 
0 = No • ^ ^ 
1 = Yes (Please specify: ) h. Assault U L 始 . i. Arson II 
\W)How many days have you experienced medical problems in __ __ 
the past 30 days? • • D a y s ^ape LJL_ 
k. Homicide, manslaughter 一 | 
For questions (64) and (65), please ask j Prostitution 
patient to use the patient's rating scale , m. Contempt of court |""“||~ 
troubled or bothered have you been by these medical 
problems in the past 30 days? __ 
fficNrr ^ ，. ， (71)How many of these charges resulted in convictions? 
^"•^Jaow important to you now is treatment for these medical .. 
problems? 口 
INTERVIEWER SEVERITY RATING ^ ' ' ^ f X v l ^ "^鹏丨“^^ ^ 丨丨卩。have you been charged with the 
(66�14� , , , , , . , , , . . . , a. Disorderly conduct, vagrancy, public 11 ~ 
^ would you rate the patient s need for medical intoxication ~ ” ~ 
atment? b. Driving while intoxicated 
Confidence Ratings c. Major driving violations e.g. reckless ~ ~~ 
driving, speeding, no license, etc.? 
the above information significantly distorted by: 0 = No 1 = Yes (73)How many months were you incarcerated your life? 
！ Patient's misrepresentation? • _II__ |MOS. 
Patient's inability to understand? • __ __ 
- (74)How long was your last incarceration? 11 |MOS. 
) 
‘ (75)What was it for? Q 
(Use code a-n in (70). If multiple charges, code most 
severe) 
(76) Are you presently awaiting charges, trial or sentence? 
0 = No 1 = Yes [ 
(77) What was it for? L 
(If multiple charges, code most severe) 
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(78)How many days in the past 30 were you detained or For questions (88) and (89), please ask � ~III patient to use the patient's rating scale incarcerated? LJLJDays , 
(SS)How much have you been troubled or bothered by these 
(79)HOW many days in the past 30 have you engaged in illegal psychological or emotional problems in the past 30 days? 
activities for profit? •口Days C 
For questions (80) and (81), please ask {S9)Hom> important to you now is treatment for these 
to use the patient's rating scale psychological problems? • 
serious do you feel your present legal problems are? . . . . . . 
The following items are to be completed bv the interviewer (Exclude civil problems) __ 
(90) At the time of the interview, is patient: (81 )How important to you now is counselling or referral for 0 = No 1 = Yes 
these legal problems? _ a. • Obviously depressed/withdrawn 
INTERVIEWER SEVERITY RATING b. 口 Obviously hostile 
(82)HOW would you rate the patient's need for legal services or c. • Obviously anxious/nervous 
counselling? — j H a v i n g trouble with reality testing thought 
• disorders, paranoid thinking 
Confidence Ratings ~~ Having trouble comprehending, concentrating, 
e. remembering 
(83)Is the above information significantly distorted by: ^ 门 Having suicidal thoughts 
0 = No 1 = Yes • 
Patient's misrepresentation? • TNTERVIEWER SEVERITY RATING 
Patient's inability to understand? _ 
(91)How would you rate the patient's need for psychiatric/ 
psychological treatment? _ 
PART VII PSYCHIATRIC STATUS � � 
Confidence Ratings 
二 d f o r a n y (难^^^。， i n f o m ^ ^ ^ f i c a n t l y disto彻dby: 
In a hospital ^ ^ Patient's misrepresentation? C 
b. As an Opt. or Priv. patient • • patient's inability to understand? • 
(85)Do you receive a pension for a psychiatric disability? 
0 = No 1 =Yes [ 
(86)Have you had a significant period (that was not a direct 
result of drug/alcohol use), in which you have: 
Past In 
0 = No 1 = Yes 30 your Days life 
a. Experienced serious depression __ _ 
b. Experienced serious anxiety or tension __ _ 
c. Experience hallucinations __ _ 
d. Experienced trouble understanding, 
concentrating or remembering 
e. Experienced trouble controlling violent 
behavior 
f. Experienced serious thoughts of suicide • [ _ 
g. Been prescribed medication for any 1~~| 
psychological/emotional problem 
(幻)How many days in the past 30 have you experienced these 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































；97)In the list of drugs in Q(93), which substance is the major For questions (106) and (107), please ask 
p ? gj— I— patient to use the patient's rating scale 
(Please code as above or (106) How troubled or bothered have you been in the past 30 
SOO = No problem days by these: 
514 = Alcohol & Drug (Dual addiction) , , 
515 = Polydrug a. Alcohol problems U 
When no clear, ask patient.) b. Drug problems [ _ 
(98)HOW long was your last period of voluntary abstinence from (107) How important to you now is treatment for these: 
this major substance? a. Alcohol problems _ 
00 = Never abstinent II lYrsJ 11 IMOS. b. Drug problems Q 
( 9 9 ) H O W many months ago did this abstinence end? INTERVIEWER SEVERITY RATING 
00 = Still abstinent II lYrs.l__||_|MOS. (108) How would you rate the patient's need for treatment for: 
finnwT u a. Alcohol abuse UOO) How many times have you: ~ a. Had alcohol d.t's • • b. Drug abuse • 
b. Overdosed on drugs _ | | _ 
(101) How many times in your life have you been treated for: 
a. Alcohol abuse _ | | _ 
b. Drug abuse _ _ | | _ 
(102) How many of these where detox only? 
a. Alcohol abuse _ | | _ 
b. Drug abuse _ _ | | _ 
(103) How much would you say you spent during the past 30 
days on: 
a. Alcohol $ I II I.I__II__II_ 
b. Drugs $ I II LL II II 
(104) How many days have you been treated Days 
in an outpatient setting for alcohol or 
drugs in the past 30 days? (including 
NA,AA) 
(105) How many days in the past 30 have you experienced: 
a. Alcohol problems (Specified: ) _||__[Days 
b. Drug problems (Specified: ) _ | | _ jDays 
» 
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^ARTIX PATH OF SUBSTANCE ABUSE PARTX PATH OF HEROIN ADDICTION 
吵'addiction \ we mean the compulsive physiological need for (115) Before using heroin, what substance did you use most 
^ particular substance. frequently? (Answer by the code listed in Q(93)) s\Z\\Z 
How old w e . you when you f ^ t tried 
If it was heroin (SOI) • Q(116) S•口 U U Y e a r s old 
[110) How old were you when you trie. ： th‘ first substance (117) Where did you first obtain heroin from? L_ 
(EXCLUDE alcohol and tobacco)! • • Y e a r s old 1 = Friends 5 = Relatives 
2 = Schoolmates 6 = Other 
(111) How frequent did you use this drug since the first trial? : ： ？ ( S p e c i f y : ) 
a. • Once a day 
b. • 1 - 6 times a week (118) Where did you first try heroin? • 
c. n 1 - 3 times amonth ^ ~~ 2 = Friend's home d. _ Less than once a month 3 = Disco/Rave parties 
e. • Without fixed frequency 5 = slTeT^^t^AUey Karaoke 
6 = Video game centre � 2) How long after the first trial did you FIRST notice that 7 = Karaoke 
you were addicted to this drug? g = Public toilet 
9 = Shenzhen 
After Day(s) OR 10 = Other (Please specify: ) 
Week(s) OR 
Month(s) OR (119) What motivated you to take heroin for the first time? 
Year(s) (Tom may choose more than one answer) 
• Never addicted a. • Peer pressure 
b. • Seek for fun and excitement 
(113) Where did you obtain the drug? • c. • Relief of boredom/depression 
1 = Friends 5 = Family members , ~ ^ . , . .•八 2 = Schoolmates 6 = Pharmacies d. U Trademark for matunty and braveness 
3 = Triad members 7 = Other e. • Appear to be fashionable 
4 = Drug dealers (Specify: ) _ f. __ Curiosity 
(114) What motivated you to take drug for the first time? g. • Escape from problems 
(You may choose more than one answer) 
a. • Peer pressure h. • Relaxation 
, ~ . I ~ Seek for new sensation apart from that b. • Seek for fun and excitement i. U caused by the drug used before 
c. • Relief of boredom/depression j. • Seek for more extreme euphoria 
d. • Trademark for maturity and braveness k 门 Compensate the negative feelings cause __ “ ~~ by the drug used before 
e. • Appear to be fashionable i. 口 Others (Please specify: ) 
f. • Curiosity 
g. • Escape from problems (120) How frequent did you use heroin since the first trial? 
, ‘ a. • Once a day n. __ Relaxation __ . ~ ’ b.' 1 - 6 times a week |_J Others (Specify: ) 
c. • 1 - 3 times a month 
d. • Less than once a month 
e. 1_J Without fixed frequency 
‘ 159 
(121) How long after the first trial did you FIRST notice that (126) Why do you use such combination (the most frequent 
you were addicted to heroin? one)? 
After Day(s) OR Induce more intense euphoria which is 
Week(s) OR • obtained from heroin 
Month(s) OR b. • Reduce withdrawal symptoms of heroin 
Year(s) c. • Decrease heroin used 
(122) At maximum, how frequent did you take heroin each d. 口 uni^jje sensation which can't be , „ ^ obtain from either substance alone day? __ 
• • T i m e s / d a y e. 口 Other (Specify: ) 
~ ~ ~~II~ (127) (For users ever tried heroin with tranquillizers) Why did "23) How much was taken each time? _ _ __||__|mg you try such combination? 
(124) Which effects were created after the use of heroin? ^ ~ To experience effects other than that 
(You may choose more than one answer) ‘ ~ produced by heroin 
a. � Make you feel better when depressed b. • To enhance the effects of heroin 
b. — Help you to stop worrying c. • To reduce the amount of heroin use 
c. • Help you to relax d. • To prolong the effects of heroin 
d. • Make you feel euphoric/elated e. • To relieve heroin withdrawal symptoms 
e. • Just get really stoned/intoxicated f. • Curiosity 
f. • Enhance your sex performance g. • Other (Specify: ) 
g. • Help you to stay awake 
h. 一 Help you to lose weight 
~ Help you to fall asleep/Improve sleep 
. ~ quality 
j. • Help you to enjoy more with friends 
k. • Help you to concentrate in work/study 
1 ~ Enhance your activity e.g. in sport, listening 
‘ t o music 
m. • Help you to feel a task less boring 
n. • Improve the effects of other substances 
0. • Ease the after-effects of other substances 
p. • Other (Specify: ) 
(125) Have you ever taken other drugs TOGETHER with 
heroin? _ 
0 = Never 
1 = Yes, specify combination: 
(Answer by the code listed m Q(93)) 
Most frequently used:|__||_|+|__||__|+1_||_ 
Quite frequently used:|_ __|+|_||__|+|__||_ ， 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































： 對照組問卷 1 
請於橫線上塡入有關資料及在每題最合適的空格中塡入�Z�號。 
⑴姓名： （15)你過往有沒有吸煙的習慣？ 
(2)性別： 1•男 2•女 1•有 2 • 沒 有 屠 
(3)出生年份 ： 年 
(16)你多久前才停止這個習慣？ 
(4)聯絡電話 ： 1 • 年前 
(5)居住地區 ： z D 7 - 1 2個月前 
(6)居所類型： 3CII 1 — 6個月前 
i Q 臨時房屋 4 口 過去3 0曰內 
^ ^ ^ (17)你有沒有飲酒？ 
公共房屋 1 口 有’幾乎每天也有飲 
4CI私人樓宇（租住） 有’大槪每星期1一 3天會飲 
私人樓宇（自己或家人擁有） 3 0間中有，只在特別場合才飮 
居者有其屋計劃 4 口 從 來 棘 + 到 ( 2 】 ) 題 
其他（胃@日月‘ ） （18)你從哪時起開始飲酒？ m 
(7)教育程度： 
门 (19)你最常喝甚®MM的酒？ 
l U 小學 
2口 初中中一至中三 ) (20)平均每次會飲多少酒？ 一 罐 / 一 支 
s Q 高中（中四至中五） （21)你有沒有賭博的習慣？ 
預科（中六至中七） 1 • 經 常 2 • 間 中 3 • 沒 有 
大學 （22)你有沒有濫用藥物？ 
0 其他（請註明： ) 门 棚 掛 门 门 〜 女 
, � � 1 —經常 2 —間中 3 _ 沒有 
(8)就業情況： 
0 全 日 I 作 （雕二青況： 
1 獨居 
2 J 兼職工作 ^ 
n ^ ^ 與父母同住 ^LJ 學生 ~ 
门 . 日 , s D 與伴侶和/或孩子同住 
1 退休 1—1 ；门 h进 與親戚同住 失業 
5 口 與朋友同住 
(9)每月平均收入 $ • • ， • • • e D 其他（請註明： ) 
(10)籍貫 ： ‘ 
； 請反轉到額W 
⑴)你現在有沒有吸,煙？ 




)你平均每天吸煙多少支？ 每天 支 
I4)你平均每星期吸煙多少天？ 






I經常 2間中 3沒有 
a吸煙 • • [ 
b飲酒 • LJ L 
C 賭博 _ _ I I _ _ I I 





I經常 2間中 3沒有 
a吸煙 • • C 
b飲酒 口 CD 匸 
C賭博 • • C 
d吸毒 • • C 
(33)你的家人有否曾經濫用藥物？ 
i Q 有（親屬關係： -
藥物： ) 
2 口 沒 有 
你的家人有否曾患精神病（例：抑窓症、焦慮症、精 
神分裂、恐慌症）？ 
i Q 有（親屬關係： 
病稱： 
2口 沒有 
— 問 卷 完 ~ ~ 
‘； 多謝你的參與！ 
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L 
APPENDIX 3B 
I : *^ESTIONNAIRE FOR CONTROL SUBJECTS | 
(1) Name: (15)Have you ever smoked? 
(2) Sex: iDMale zCDFemale lOYes 2nNever go to (17) 
(3) Year of Birth: ‘ � u , 令 „ (16)How long ago did you stop smoking? 
(4) Contact no.: years ago 
(5) District of residence: 2口 7 - 1 2 months ago 
sD 1 - 6 months ago (6) Which type of housing are you living in? 
Temporary housing 4口 within past 30 days 
2口 Rental bunk (l7)Do you take alcoholic drinks? 
3口 Public housing iD Yes, nearly everyday 
4口 Private housing (rented) Yes, for 1 - 3 days per week 
5口 Private housing (owned) 3口 Very seldom, only in special occasions 
Home Owing Scheme housing 4口 Never go to (21) 
7口 Others (Please specified: ) (18) At what age did you start drinking? 
(7) Education level: 
I • Primary (^  9) What kind of alcoholic drinks do you mostly take? 
2口 Secondary (F.l -F .3) 
3口 Secondary (F.4 - F.5) (20)How much do you drink in average each time? 
^D Pre-university (F.6 - F.7) 
门 tt . •“ can(s)/ bottle(s) 
5 口 University <0 Others (Please specified: ) (21 )Do you gamble? f»\ X, , - , ‘ iDAlways zdSeldom sDNever …J Mode of employment: 
I 口 Full-time (22)Do you abuse any substances? 
2口 Part time i d Always Seldom sDNever 
3D Student 
4口 Retired (23)Living condition: 
1 口 Alone 
幻 Unemployed 2口 With parent(s) 
(9) Average monthly income $ • • , • • • �口 With partner and/or children 
4口 With other family members 
“O)0rigin: 5D With friends 
(11)Do you smoke? 6口 Others (Please specified: ) 
••Always 2nSeldom ‘ sDNo go to 0 (24)Origin (Father): 
» 
(12)At what age did you start smoking? (25)Origin (Grandfather): 
(13)How many cigarettes do you smoke per day in average? (26)Origin (Grandmother): . 
cigarette(s)/day (27)Does your father... 
Always Seldom Never 
'^ )How many days do you smoke per week in average? a Smoke • • • 
iQl day 2D2 一 4 days sDS - 7 days bTake alcoholic drinks • • 口 
c Gamble • • • 




(30)0rigin (Grandmother): . _ 
(31)Does your mother.. • 
Always Seldom Never 
.Smoke • • • 
bTake alcoholic drinks • • • 
c Gamble • • • 
d Abuse substances • • • 
(32)Do any of your family members abuse substances? 
I口 Yes (Relationship: 
Name of substance: ) 
2O No 
(33)DO any of your family members have psychiatric problems? 
(e.g. depression，anxiety disorder, schizophrenia) 
1 口 Yes (Relationship: 
Problem: ) 
zD No 
— E N D — 












1.必須回答每條問題。 t . 
每題只能有-個答案。薩縣的答案是塡寫ffiM的方格內。 G 不 無 I 
如果你臨時改變主意’可以答案’然後再重新選擇。 同 同 意 同 同 
答案並沒有對錯之分’我們只需要你最真誠的答案。 意 意 見 意 意 
JLH^不：^個充滿煩惱的人。 I 丨 I 丨 I 卜 
真的很_大部份我—的人。 = = = = 二 2 
LJUATR待我的方式常使我感到憤怒。 = = = = = 3 
l^grt避開人群。 — 4 
^^很少感到寂寞或憂蜜。 = = = = = 5 
是一個g掌管大局、做事有_:SL^z：場堅定的人9 = = = = = 6 
人交往時，我常常害怕犯一些愚蟲的錯誤。 = = = = _|7 
？：^以一SL悠閑的態度面對工作和娛樂。 8 
？極少過分沉溺於ffl^情。 = = = = = 9 
常常渴望尋找刺激。 = = = = = 10 
經常感到無助’並希望有人能解決我的問題。 11 
從沒有因爲開心而。 = = = = = 1 2 
很容易受驚嚇。 = = = = = 1 3 
別人聊談不能使我得到很多樂趣。 = = = = = 1 4 
^是一個心平氣和的人。 _ _ _ _ = = = = = 1 5 
喜歡很多人在我周圍。 = = = = = 1 6 
^^ijfmmmm自己完全一文不値。 = = = = = I 7 
^^：^有時沒有盡•能地去維護我的權利。 = = = = = 1 8 
^？：^^ ^^ 土交場合中時，我很少覺得不自然。 19 
p r v ^ ^ ~ ~ j , , I I 
做事情時，f l^充滿精力地• ° ^ 20 
^！：^良難抗拒自己的愁望。 = = = 21 
^i^mmm \我不會覺得快樂。 = = = = = 2 2 
得我有能力應付我大部份的問題。 ^ 2 3 
^Ijgg候我會感到非常的快樂和興奮。 “ 24 • 
^：^^ 艮少感到恐懼及焦慮。 = = = = = 25 
視爲一個熱情和友善的人。 = = = = = 2 6 
容易激動及性情急躁見稱。 = = = = = 2 7 
向麵單獨工作。 = = = = = 28 




不 不 無 分 
同 同 意 同 同 
意 意 見 意 意 
0 1 2 3 4 
30.很多時候，我是所屬團體的領袖。 30 
^有時翰識得想躲起來 ° ‘ ： 丨 3 1 
我 可 紅 作 得 慢 , m m m ^ ° 32 
我對於抵gj：^惑，並沒有困難� _ _ _ _ 33 
£有時候’我^^只因爲要尋求冒_剌激。 i I i :34 
^當我處於_墼力下’有時候我會感到好像精神崩潰似的。 |35 




^當我獨處一時間後，我真的感到自己需要別人。 = = = = = 4 。 
TL我有時候躲深感到自己罪孽深重或有罪惡感。 1 —41 
^在開會的時候 > 我總是麵人說話� I I 42 
jg^我不會因爲別人議笑和agji^而感到窘迫° = = = = = 4 3 
jl^我常常感到精力旺盛。 = = = = = 秘 
Ig：^當有我餓的餓時’糖大吃—頓。 = = = = = 45 
Ig：^我舰看那些令人震慄或恐怖的驟。 = = = = = 箱 
^我雄急時仍能保持誦織。 = = = = = 47 
有時會覺得充滿快樂。 = = = = = 幼 
我很少爲將來憂慮° = = = = = 49 
gg：^我很胃與別人交談。 = = = = = 50 
我常常討厭那些我不得不與他們交往的人。 = = = = = 5 1 
我翻一些可以讓我單獨而不會棚人干擾的工作。 = = = = = 52 
事情出Mli時’我會責怪自己。 = = = = = 5 3 
g l j l l A M是認爲我應_們拿主意。 = = = = = “ 
經常感到自己不如別人。 ’ = = = = = 55 
不像其他人那樣地臓繊和髓。 = = = = = 5 6 
！!：^很少衝断事。 = = = = = 5 7 
！ 喜 • 臨 • ’置身於事件之中。 = = = = = 5 8 
常常覺litS難作決定� ~ I I I 59 
GG：^不覺得自己是活撥的人。 ~|60 
！常常爲事彳青可能會出_而擔心。 — 61 . 
I’感到對陌生人微笑和交往是一件很容易的事情。 — 62 
不容易動怒。 63 
^喜歡在人多的海灘渡假，而不願在樹林內獨立的小屋中渡假。 = = = = 糾 
對自己_價很低。 = = = = = 6 5 




不 不 無 分 
同 同 意 同 同 
意 意 見 意 意 
0 1 2 3 4 
67.在上司及權威面前，我覺得舒適自在。 67 
^我彷彿總駒匆忙忙的。 P —68 
^我有時會因爲吃得太多而病倒。 一69 
Z^我Sm「雲霄at f J的刺激� 70 





^ rnnmrn ’社交聚會通常是無聊的。 76 
！我有時感到事情總賊離望的。 • I I I I {77 
Ig^在聊天時，大部份時間是我織話。 = = = = = 78 
T如果我對某些Ai^了話或做錯了事’我將不敢W：^面對他們。 79 
gg^我生活的節奏很快。 80 
！!^有時候餘因一時衝動而做-些令我後侮的事情° = = = = = 8 1 
gg：^鮮寵的fe^和俗麗的吸引著我。 一 —82 
g g ^當順利時’我仍能做出頗好的決定。 = = = = = 83 
！！：^我很少用『真妙!』或『棒！』•字眼來形_的體驗。 = = = = = ® ^ 
gg：^^^—些可怕的思想會_我的腦袋中。 = = = 85 
我關心我的同事。 = = = = = 肪 
？！^即臉•]••]、的煩惱’贿使我感受到腫。 = = = = = 87 
喜歡有許多人的聚會。 = = = = = 肪 
多時候’當事情不翻時，赌感到腫及想縫。 = = = = = 89 
而言’負責掌握一個局面是不容易的0 = = = = = 恥 
！!—個我認識的人做傻事時，我##他感到難爲情。 = = = = = 9 1 
是一個十分活躍的人。 . = = = = = 9 2 
時常能控制自己的感覺。 —93 
球赛時’我喜歡成爲群眾中的。 — 一94 
！ ！ ： ^ 的 情 緒 相 當 穩 定 / — 9 5 
很容易笑。“ 丨 I i I I h 
本文'fltB版者美國心理評估資源公司(Psychological Assessment Resource Inc.. 16024 North Florida Avenue, Lutz. Florida 
33549)特別許可複製。資科來源 





Please indicate how well you think the listed sentences describe yourself in most situations by checking the corresponding 
boxes of agreeableness. Please make sure you have answered EVERY question and be sure that you have checked the 
correct box for each question. If you want to change your answer, please cross out the previous one and then 
check the right box. Please be as accurate and honest as you can be and don't worry about being "consistent" in 
your answers. 
I i 
i I 1 t I p « S C P h JS «* M 云 35 Q Z < »5 0 1 2 3 4 
1： I^ am not a worrier. i 
？ : l i k e most people I meet. 2 
^ I often get angry at the way people treat me. - 3 
1：.__I shy away from crowds of people. 4 
^ I rarely feel lonely or blue. 5 
：^^^ am dominant, forceful and assertive. 6 
I：h dealing with other people, I always dread making a social blunder. 7 
^ I have a leisurely style in work and play. 8 
：^^^ rarely overindulge in anything. 9 
i£:^often crave excitement. lo 
J J ^ often feel helpless and want someone else to solve my problems. n 
never literally jumped for joy. n 
easily frightened. i3 
l l l ^ d o n ' t get much pleasure from chatting with people. h 
I s T， 
an even-tempered person. ^ ^ ^ ^ i5 
to have a lot of people around me. i6 
IZl^^metimes I feel completely worthless. 口 
jj:.^Jjometimes fail to assert myself as much as I should. is 
feel self-conscious when Vm around people. i9 
？ I do things，I do them vigorously. 20 
have trouble resisting my cravings. 21 — 
~<-^ Jjyouldn，t enjoy vacationing in Las Vegas. 22 
am capable of coping with most of my problems. | | | | |23 
sometimes experienced intense joy or ecstasy. 24 
feel fearful or anxious. 25 
known as a warm and friendly person. 26 
known as hot-blooded and quick-tempered. 27 
相 — prefer to do things alone. 28 
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.2 M •o < s - >> 1 ^ 2 S ? 
2 I I ^ I cn Q Z < 55 0 1 2 3 4 
^ lam seldom sad or depressed. 29 
30. I have often been a leader of groups I have belonged to. 30 
31. At times I have been so ashamed I just wanted to hide. 31 
My work is likely to be slow but steady. 32 
I have little difficulty resisting temptation. 33 
I have sometimes done things just for “kicks” or "thrills，，. 34 
When I，m under a great deal of stress, sometimes I feel like Fm going to pieces. 35 
I am not a cheerful optimist. 36 
feel tense and j ittery. 37 
j j ^ M a n y people think of me as somewhat cold and distant. 38 
am not considered a touchy or temperamental person. 39 
jO^J really feel the need for other people if I am by myself for long. 40 
I j ^ I have sometimes experienced a deep sense of guilt or sinfulness. 41 
j^^In meetings，I usually let others do the talking. 42 
doesn't embarrass me too much if people ridicule and tease me. 43 
often feel as if Fm bursting with energy. 44 
I am having my favorite foods, I tend to eat too much. 45 
tend to avoid movies that are shocking or scary. 46 
keep a cool head in emergencies. 47 
a cheerful, high-spirited person. 48 
seldom apprehensive about the future. 49 
^2:^really enjoy talking to people. so 
£i:^often get disgusted with people I have to deal with. si 
prefer jobs that let me work alone without being bothered by other people. 52 
c^ 
<:^tend to blame myself when anything goes wrong. 53 
people often look to me to make decisions. 54 
feel inferior to others. 55 
not as quick and lively as other people. 56 — 
-•^^J^eldom give iii to my impulses. 57 
to be where the action is. 58 
J ^ s often hard for 
me to make up my mind. 59 ^ 
^^l^^on't consider myself especially “light-hearted.，， 60 
worry about things that might go wrong. 6i 
^^I^^find it easy to smile and be outgoing with strangers. 62 
^^ .^J^jakes a lot to get me mad. 63 
vacation at a popular beach than an isolated cabin in the woods 64 
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JJ 一 >. I I I ^ 1 
w Q Z < 2 0 1 2 3 4 
65. I have a low opinion of myself. 65 
66. I would rather go my own way than be a leader of others. 66 
67. I feel comfortable in the presence of my bosses or other authorities. 67 
68. I usually seem to be in a hurry. 68 
69. I sometimes eat myself sick. 69 
70. I love the excitement of roller coasters. 70 
I can handle myself pretty well in a crisis. 7i 
I am a cheerful, high-spirited person. n 
I have fewer fears than most people. 73 
I have strong emotional attachments to my friends. 74 
75. At times I have felt bitter and resentful. 75 
Social gatherings are usually boring to me. 76 
77. Sometimes things look pretty bleak and hopeless to me. 77 
^ In conversations, I tend to do most of the talking. 78 
If I have said or done the wrong thing to some，I can hardly bear to face them agaiiL 79 
^ My life is fast-paced. so 
^ Sometimes I do things on impulse that I later regret. 8i 
rm attracted to bright colors and flashy styles. 82 
^ When everything seems to be going wrong, I can still make good decisions. 83 
I rarely use words like “fantastic!” or “sensational!” to describe my experiences. 84 
^ Frightening thoughts sometimes come into my head. 85 
I take a personal interest in the people I work with. 86 
Even minor annoyances can be frustrating to me. 87 
^ I enjoy parties with lots of people. 88 
Too often, when things go wrong, I get discouraged and feel like giving up 89 
^ I don't find it easy to take charge of a situation. 9o 
^ ^ When people I know do foolish things, I get embarrassed for them. 9i 
^ ^ l a m a very acdve person. 92 
^ I .am always able to keep my feelings under control. 93 
^ ^ I like being part of the crowd at sporting events. 94 
Pm pretty stable emotionally. 95 ‘ 
^ ^ I laugh easily. % 
p . . 
copyright by Psychological Assessment Resource, Inc. All rights reserved. May not be reproduced in whole or in part in any form or 
by any means without written permission. Source: Paul Costa and Robert McCrae: Revised NEO Personality Inventory (NEO-PI-R). 











2.每題只能有一個答案。請確保你的答案最填SffiE確的方格內。 工不 ； 
如果你•改變主意’可以•去舊答I，然後再重新選擇。 同 同 同 同 
4.答案並沒有•之分’我們只需要你最真誠的答案。 意 意 意 意 
4 - 3 2 1 
1：^家庭是A^中M要的事。 I 丨 丨 i |i 
即使有些壞事發生在我身上’我極少感到恐懼或焦慮。 = = = = 2 
雜竭•能靜取我想要的東西。 = = _ _ 3 
1_當我能把某些事情腿贿麵艮樂意繼績做下去。 4 
〔我總题意嘗試-些我認爲有趣的新雜。 5 
我很腫個人的衣著。 = = = = 6 
！^當我能獲得一些我想要的東西，•感到興奮及活力充沛。 = = = = 7 
L批評或責罵會繊造成歉的傷害。 ^ = = = 8 
！ : 我 想 要 _ _ ’我通常會竭力地去爭取它。 = = = = 9 
常會—些事只因爲它們有趣。 = = = = 1 0 
我抽一點時間來做•事情（例如：剪頭髮）是很難的。 = = = = ” 
我見到有一個機會可讓我'得到我想要的東西,我會tzjp行動。‘ 
我認爲或知_人在生我的氣，我會感到非常擔憂或苦惱o = = = = 1 3 
^我遇到一個機會可以讓我得到我_的東西，卩興奮起來。 = = = = 1 4 
Jlj^ 經常因一時衝動而傲事。 = = = 二 15 
•Ig：^我認爲—些不愉快的事將要發生的時候’我通常會粒不安。 = = = = 1 6 
經常想知道爲何人們會有這樣的舉動。 ^ = = = 1 7 
^有好事發生在我的身上’ •裤深深動感。 = = = = 1 8 
我認爲我弄拷了某••事情時’ ^ #感到擔憂。 
？渴求得到刺激或新感覺》 ： |20 
會以排除_的態度去追求某些我想要的東西。 — 21 
比起我的朋考’我只有很少恐懼° 二22 
？^比賽中取勝可以令我興奮。 23 






Each item of this questionnaire is a statement that a person may either agree with or disagree with. For each item, indicate 
how much you agree or disagree with that the items says. Please respond to all the items; do not leave any blank. Choose 
only one response to each statement. Please be as accurate and honest as you can be. Respond to each item as if it were 
the only item. That is, don't worry about being "consistent" in your responses. 
w 
Si y o < 
2 2 & 2 Q •< Cfl 
4 3 2 1 
1. A person's family is the most important thing in life. i 
^ ^ Even if something bad is about to happen to me, I rarely experience fear or nervousness. 2 
j ^ I go out of my way to get things I want. 3 
3^When I’m doing well at something I love to keep at it. 4 
rm always wiling to try something new if I think it will be fun. 5 
^ ^ H o w I dress is important to me. 6 
Zl^When I get something I want, I feel excited and energized. 7 
^___Criticism or scolding hurts me quite a bit. 8 
Ci^When I want something I usually go all-out to get it. 9 
will often do things for no other reason than that they might be fun. lo 
JJ^ t，s hard for me to find the time to do things such as get a haircut. 11 
J j ^ f I see a chance to get something I want I move on it right away. 12 
feel pretty worried or upset when I think or know somebody is angry at me. i3 
Jj^^yhen I see an opportunity for something I like I get excited right away. i4 
J j ^ often act on the spur of the moment is 
i ^ ^ f I think something unpleasant is going to happen I usually get pretty “worked up.” 16 
cZ：^  often wonder shy people act the way they do. n 
good things happen to me, it affects me strongly. is 
•^^^feel worried when I think I have done poorly at something important. i9 
crave excitement and new sensations. 20 
go after something I use a “no holds barred” approach. 21 
><:^have very few fears compared to my friends. 22 
would excite me to win a contest. 23 












- I I 
1. 口 a.我喜歡狂野、不受限制的派對。 
_ • b.我比較•安靜的聚會’好讓大家可以好好聊聊。 
a . 有些會看上兩至三遍。 “ 
、口 b.我不倉認受再看以前看過的電影。 
^ D a.我經常渴望可以成爲攀山者» 
• b . 我 不 能 _ 那 些 冒 著 性 山 的 人 。 
• a .我討腿有: t M ^ i ^ � 
^ g b.我額一些肉體的氣味。 
• a.老是看見那些舊面孔使我感到沉悶。 
� P b.我享受曰常朋友帶給我的親切感。 
口 a .即使有機會,我亦會獨自去探索H i陌生的城地方》 
^ b.在一個我不太熟悉的地方’我希望有一個導遊。 




9. • a .我體繩或願意去嘗試駄麻。 
^ b.我永遠不#1試食大麻。 
10. • a.我不試那些能產生奇異或危險鄉的藥物。 
b.我希望嘗試一下那些能產生幻覺的藥物。 
11 •口 a.—個明智的人會避免做危險的活動。 
^ b.我有時喜歡有少許危險的活動。 















Z n a.我不想學習駕駛飛機» 
^ • b. 望能夠學習駕駛飛機。 
^ • a.我比較喜歡徘徊於水面多於•處。 
一 .口 b.我想到深海潛水。 
^ • a.我想認識一些同性戀者（不論男或女）。 
一 • b.我會避開那些我懷疑是同性戀的人。 
f • a.我想嘗試跳降落傘。 
b.不論有沒有身穿降落傘’我永遠不想嘗試跳出飛稱。 
a.我比較喜歡那些難以預測、給人帶來刺激的朋友。 
• 口 b.我比較喜_些能«預測及可靠的朋友。 
一 I .,11 . .1. 
2 5 • a.我沒有興趣爲,•而參與某些事情。 
b.我喜歡追求新的和刺激的經歷和感覺’即使它們有點危險、反傳統或違法 。 
^ D a.好藝術的精髓®^其畫面的清晰、對稱及色彩的和諧。 
.口 b.我常在撞色和構圖不規則的現代縛畫中找到美感。 
2 7 • a-我享受在家這樣熟悉的環境中渡過空閒時間。 
b.要我留絲裏，無論時間有多長，我總覺得煩躁不安。 
a.我_上高台跑Wc� 
^ D b.我不喜歡站在高台的感覺（或者我甚至不會^IgS)� 
29 口 a.我im與身材吸引的A^會。 
^ D b.我_與和我思想價値相約的Al^會。 
3 0 • a-豪邁的飮酒行爲通常會破壞一個聚會，因爲有些人會變得很瘋狂和吵鬧。 
b.豪情暢飲是一個好派對不能缺少的 。 
31 • a.無禮是社交的大忌。 
� P b.沉悶的社交的大忌。 
3 2 口 a . —個AM該•前有一定的性經驗。 
b,兩個人與對方結婚後才與對方發生性關係比,。 
3 3 • a-即使我有錢’我亦不屑與那些富家子弟交往。 
^ ^ b.我相信自己會與富家子弟—起尋歡。 
34 • a.我喜歡那些聰明機智的人’ gp使有時他們會侮辱別的人。 
� g b.我討厭那些將自己的快樂建築於別人痛苦上的人。 
35 • a.總括而言’電影賁在有太多描寫性的畫面。 
^ b.我欣賞m中很多的性感場面。 
36 • a.當我喝了幾杯酒，我感覺得最棒。 
^ b.我覺得那些要靠酒精來獲得快樂的人有點問題0 
37 • a.人In的衣著應該依照大眾的品味、整潔和風格爲標準。 
� G B.人們的衣著應該有個人風格，即使有時效果有點怪異。 
38 • a.以小船來去一個很遠的地方是件很愚蟲的事。 • 
� G B.我想用一隻雖然小但纟I得起風浪的船去一個很遠的地方。 
39 • a.我對平凡或沉悶的人缺乏耐性》 
� G B.我總能從每一個與我交談的人中發掘出有趣的地方。 
40 • a.從山坡上滑下來必定會重傷° b . 我想我會享受高又斜的山 M l ^ 地滑下所感覺。 ； L 175 
APPENDIX 3A 
s_ss-v 
Each of the items below contains two choices (a) and (b). Please indicate which the one better describes your likes and the 
Way you feel by checking the corresponding box. Please be as accurate and honest as you can be. 
一 11 _ _ . 一 • 丨 • • 丨 • • ,,,,, 
1. • a. I like "wild" uninhibited parties. 
• b. I prefer quiet parties with good conversadoiL 
^ 
• 2L There are some movies I enjoy seeing a second or even third time. 
• b. I can't stand watching a movie that I've seen before. 
- • I • I 
3. • a. I often wish I could be a mountain climber. 
• b. I can't understand people who risk their necks climbing mountains. 
• a. I dislike all body odors. 
• b. I like some of the earthy body smells. 
' D a. I get bored seeing the same old faces. 
Q b. I like the comfortable familiarity of everyday friends. 
• D a. I like to explore a strange city or section of town by myself, even if it means getting lost 
n b. I prefer a guide when l a m i n a place I don't know well. 
' n a. I dislike people who do or say things just to shock or upset others. 
n b. When you can predict almost everything a person will do and say he or she must be a bore. 
• D a. I usually don't enjoy a movie or play where I can predict what will happen in advance. 口 b. I don't mind watching a movie or play where I can predict what will happen in advance. 
• n a. I have tried marijuana or would like to. 
b. I would never smoke marijuana. 
n a. I would not like to try any drug which might produce strange and dangerous effects on me. 
• b. I would like to try some of the drugs that produce hallucinations. 
n a. A sensible person avoids activities that are dangerous, 
b. I sometimes like to do things that are a little frightening. 
D a. I dislike "swingers"(people who are uninhibited and free about sex). 
� D b. I enjoy the company of real “swingers.” 
� 
. D a. I find that stimulants make me uncomfortable. 
^ D b. I often like to get high (drinking liquor or smoking marijuana). D a. I like to try new foods that I have never tasted before. 
b. I order the dishes with which I am familiar so as to avoid disappointment and unpleasantness. 
D a. I enjoy looking at home movies, videos, or travel slides. 
Looking'at someone's home movies, videos, or travel slides bores me tremendously. Jg 5 — • Q a. I would like to take up the sport of water skiing. 
^^ ^^ ^D b. I would not like to take up water skiing. 
- . 
• D a. I would like to try surfboard riding. 
^^^^D b. I would not like to try surfboard riding. jg ‘ — 
' D a, I would like to take off on a trip with no preplanned or definite routes, or timetable, 
b. When I go on a trip I like to plan my route and timetable fairly carefully. 
D a. I prefer the "down to earth，，kinds of people as friends. 
b. I would like to make Mends in some of the "far-out" groups like artists or "punks." 
L 176 
2Q • a. I would not like to learn to fly an airplane. 
' • b. I would like to learn to fly an airplane. 
21 n a. I prefer the surface of the water to depths. • • b. I would like to go scuba diving. 
22 D a. I would like to meet some persons who are homosexual (men or women). 
. • b. I stay away from anyone I suspect of "gay" or "lesbian." 
22 • a. I would like to try parachute jumping. 
• • b. I would never want to try jumping out of a plane, with or without a parachute. 
• a, I prefer friends who are excitingly unpredictable. 
• • b. I prefer friends who are reliable and predictable. 
25 D a. I am not interested in experience for its own sake. 
• • iHketohavenewandexdtingexpoiencesandsensationsevaiiftiieyareaHldefii^ itening^ unconvenlkiial^ oriDegaL 
D a. The essence of good art is in its clarity, symmetry of form, and harmony of colors. 
' O b. I often find beauty in the "clashing" colors and irregular forms of modem paintings. 
27 • a. I enjoy spending time in the familiar surroundings of home. 
• • b. I get very restless if I have to stay around home for any length of time. 
2g D a. I like to dive off the high board. 
• • b. I don't like the feeling I get standing on the high board (or I don't go near it at all). 
29 • a. I like to date persons who are physically exciting. 
^^ ^^  • b. I like to date persons who share my values. 
3q Q a. Heavy drinking usually ruins a party because some people get loud and boisterous. 
‘ Q b. Keeping the drinks full is the key to a good party. 
3j D a. The worst social sin is to be rude. 
n b. The worst social sin is to be a bore. 
32 • a. A person should have considerable sexual experience before marriage. 
‘ • b. It's better if two married persons begin their sexual experience with each other. 
33 D a. Even if I had the money, I would not care to associate with flighty rich persons in the "jet set.，， 
• b. I could conceive of myself seeking pleasures around the world with the “jet set.” 
34 n a. I like people v^o are sharp and witty even if they do sometimes insult others. 
^ • b. I dislike people who have their fun at the expense of hurting the feelings of others. 
35 D a. There is altogether too much portrayal of sex in movies. 
�^^^^p b. I enjoy watching many of the “sexy，’ scenes in movies. 
36 • a. I feel best after taking a couple of drinks. 
\^^^^• b. Something is wrong with people who need liquor to feel good. 
37 D a. People should dress according to some standard of taste, neatness, and style. 
b. People should dress in individual ways even if the effects are sometimes strange. 
D a. Sailing long distances in small sailing crafts is foolhardy. • 
b. I would like to sail a long distance in a small but seaworthy sailing craft. 
39. D a. I have no patience with dull or boring persons. 
b. I find something interesting in almost every person I talk to. 
40. D a. Skiing down a high mountain slope is a good way to end up on crutches. 
b. I think I would enjoy the sensations of skiing very fast down a high mountain slope. 
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